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Introduction | 1
Respiratory and enteric diseases comprise a substantial proportion of the burdenof morbidity and mortality in the developing world; acute respiratory infectionand diarrheal illness are the top two killers of children less than five years of
age worldwide. Reproductive tract pathogens cause uncomplicated infections of
the mucosal membranes; however, if left untreated, infections with these pathogens
can also lead to pelvic inflammatory disease, ectopic pregnancies and infertility, and
may facilitate the transmission of HIV. Public health interventions such as access to
safe water, improved sanitation, hygiene, immunizations, education, health
communication, and access to acute medical care with appropriate case
management have contributed to on-going improvements in health, and in social
and economic development. One outcome of the increased availability of
antimicrobial agents for symptomatic treatment of illness in hospitals and
community environments, however, has been the emergence of antimicrobial
resistance in pathogens of public health concern.
Antimicrobial resistance is an issue of great significance for public health at the
global level. However, it is of particular concern in the developing world because
fewer affordable and appropriate treatment options are readily available. It has
become increasingly important to monitor patterns of resistance as the
antimicrobial susceptibility of bacterial pathogens which contribute significantly
to the burden of respiratory, febrile, reproductive tract, and diarrheal illness has
declined. Because antimicrobial susceptibility testing is resource-intensive, the
World Health Organization (WHO) recommends that only one or two reference
laboratories in a country perform these tests. Until now, however, there has not
been a technically appropriate source of standardized information for laboratory
detection of antimicrobial resistance that is practical for use in regions with
limited resources.
This laboratory manual focuses on seven bacterial pathogens of public health
importance in the developing world: Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Neisseria gonorrhoeae, Salmonella serotype
Typhi, Shigella, and Vibrio cholerae. Methods for the isolation and identification of
each of these bacterial agents from clinical specimens are presented, and
Introduction
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standardized antimicrobial susceptibility testing techniques and criteria for
interpretation are described. To benefit from the information presented in this
manual, laboratorians must have received training in proper basic microbiological
techniques and be comfortable with such tasks as sterilization of instruments and
media preparation. Flow charts of procedures and color figures of bacterial
colonies and typical reactions have been provided as supplements to the text for
ease of comparative identification. Procedural accuracy and methodological
standardization are critical to the performance of antimicrobial susceptibility
testing, and adherence to protocols of quality control is also vital to ensure that test
results are valid and meaningful.
In order for a laboratory to successfully undertake isolation, identification, and
antimicrobial susceptibility testing responsibilities, it must participate in on-going
investments in materials, supplies, media, reagents, and quality control, along with
periodic training of personnel and quality assessment or proficiency testing. Any
deviations from antimicrobial susceptibility testing methods as described in the
following pages may invalidate the test results. Antimicrobial susceptibility test
methods must be performed as described according to internationally recognized
clinical guidelines such as those provided by NCCLS (an international,
interdisciplinary, nonprofit, educational organization that develops updated
consensus standards and guidelines for the healthcare community on an annual
basis) in order to provide meaningful results for clinical and epidemiological
interpretation. Laboratory staff must be afforded the appropriate time and
resources to carry out the procedures described in this manual if the results are to
be meaningful and applicable to clinical and policy decisions.
As resistance to antimicrobial agents in the pathogens causing these diseases grows
and changes, strategies of response also must evolve. Resistant pathogens can
translate to fewer treatable infections and thus higher morbidity and mortality, a
drain on resources, and an obstacle to social, economic, and health development
overall. Timely communication between the laboratory and public health officials
is essential to the shaping of locally treatment appropriate policies; the data
collected in the laboratory are crucial components of the decision-making process
for clinical and public health policies.
Mindy J. Perilla, MPH
Division of Bacterial and Mycotic Diseases
National Center for Infectious Diseases
Centers for Disease Control and Prevention
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Areference laboratory differs from a clinical laboratory in that microbiologistsare able to dedicate their time to confirmation and investigation of isolatessent in from other laboratories or hospitals and (for the purposes of this
manual) then perform standardized antimicrobial susceptibility testing. This
manual is written and intended for use in a reference laboratory or national central
laboratory setting, where material resources are consistently quality controlled and
available in sufficient quantities for regular testing of isolates. Reference
laboratories must participate in a quality assurance program at least once per year
and should also administer quality assurance programs for laboratories in their
jurisdiction; the World Health Organization (WHO) encourages central public
health laboratories in countries with limited resources to establish national quality
assessment schemes and to participate in at least three surveys per year. Time,
supplies, and personnel can be costly; as a result, it is anticipated that not every
country will be able to support a reference laboratory meeting these requirements.
A country that can not establish a reference laboratory should consult a regional or
sub-regional reference laboratory for further guidance and for advice on where to
send isolates requiring further investigation.
In order to carry out the standardized procedures referred to in this laboratory
manual (and many others), the laboratory must be able to make ongoing
investments in equipment, supplies, and human resources (i.e., trained
laboratorians). The Ministry of Health (or similar appropriate agency) should
therefore ensure that its central public health laboratory has the following items of
great importance:
Requirements of a 
Reference Laboratory 
FOR THE PERFORMANCE OF STANDARDIZED 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
CHAPTER II
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• Laboratory space
• Trained laboratory technologists
• Water (purified either by filter system or distillation apparatus)








– Labels and/or permanent marking pens
– Materials for record-keeping (e.g., laboratory log-books, and a computer
with printer and Internet / e-mail access)
– Antimicrobial disks and / or antimicrobial gradient agar diffusion tests
(Etests®) (depending on the organisms to be tested)
• Standard laboratory supplies (e.g., plates, tubes, pipettes, flasks, inoculating
loops, other glassware or plasticware, rulers, bunsen burners or alcohol burners,
pH meter, bleach, alcohol), media and reagents
It is also of considerable importance that the reference laboratory have an open
line of communication with public health authorities, including ministries of
health, professionals in the medical field, and policymakers. If the laboratory is
responding to an epidemic that extends across borders, an outside public health
agency (e.g., the WHO) may become involved; in such situations, it is significant
that data from the laboratory will enable better decision-making for clinical







Bacterial Agents of Pneum
onia and M
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Haemophilus influenzae | 5
H aemophilus influenzae is a common etiologic agent of diseases such aspneumonia, meningitis, otitis media, and conjunctivitis. Meningitis caused byH. influenzae occurs almost exclusively in children less than five years of age,
and most invasive H. influenzae disease is caused by organisms with the type b
polysaccharide capsule (H. influenzae type b, commonly abbreviated as Hib).
There are conjugate vaccines to prevent H. influenzae infections caused by serotype
b, though they are not widely available in some parts of the world. No vaccines for
the other serotypes or for unencapsulated strains have been developed. Although
meningitis is the most severe presentation of disease, H. influenzae pneumonia
causes more morbidity than H. influenzae meningitis.
Confirmatory identification of H. influenzae
H. influenzae are characterized as small, gram-negative bacilli or coccobacilli 
that require X and V growth factors, grow on chocolate agar (but not on sheep
blood agar), and have a pungent indol smell. Methods for the isolation and
presumptive identification of H. influenzae are included in Appendix 4. Figure 1
presents a schematic flowchart of confirmatory identification of H. influenzae.
Identification of the H. influenzae serotype 
Laboratory identification of H. influenzae includes testing for X and V factor
requirements and then performing serotyping; this sequence of testing is an
efficient way to save costly antisera. However, when the laboratory results must be
obtained rapidly for clinical decision-making, serotyping should be performed first
the prompt presumptive identification of H. influenzae. Isolates identified as H.
influenzae with typing antisera should still be confirmed by testing for X and V
factor requirements.
Haemophilus influenzae
CONFIRMATORY IDENTIFICATION AND 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
CHAPTER III
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FIGURE 1: Flowchart for laboratory identification of Haemophilus influenzae
Sterile site specimen 









Examination of growth on supplemented
chocolate agar shows non-hemolytic,
opaque cream-to-gray colonies.
(Sheep blood agar shows no growth.)




Perform Gram stain on CSF for
clinical decision-making
Inoculate chocolate agar and
blood agar plates
Serotyping by slide agglutination
Test growth factor requirements
and/or serotype identification
Does not require both 
X and V Factors to grow 
= not H. influenzae
No agglutination reaction
in polyvalent antiserum
or saline control; test 
for growth factor 
requirements
Requires both 





If agglutination occurs in the saline
control, the isolate is non-typeable.
Confirm identification as 
H. influenzae with growth factor 
requirements.Isolate may be non-typeable (NT)
or it may not be H. influenzae
Test for growth factor requirements




Antimicrobial susceptibility testing on
Haemophilus Test Medium (HTM)
Serotype-specific 
H. influenzae antisera a,b
a Test for serotype b if rates of Hib
vaccination in the region are low.
b Test with remaining antisera to
identify other serotypes.
H. influenzae is currently recognized to have six serotypes: a, b, c, d, e, and f.
H. influenzae type b (Hib) is the major cause of both H. influenzae meningitis 
and of meningitis overall in unvaccinated children in many parts of the world.
Suspected Hib isolates should be tested with Hib antiserum, an antiserum to one
of the other groups, and saline. A strongly positive (3+ or 4+) agglutination
reaction with type b antiserum and no agglutination with antiserum to the
other serotypes and saline is rapid evidence of Hib.1
Antisera should be stored in the refrigerator at 4˚C when not in immediate use.
Screening an isolate first with polyvalent antiserum (which contains antisera to all
six recognized serotypes) and a saline control is convenient and saves resources
(i.e., type-specific antisera).
• If an isolate is positive in polyvalent antiserum and negative in the saline
control, proceed by testing the isolate with type b antiserum if Hib vaccination
is uncommon in the patient’s geographic region. If the serotype b reaction is
negative, test with the remaining type-specific antisera (i.e., a, c, d, e, and f).
– If Hib disease is unlikely because of widespread vaccination, the culture
should be tested with all the type-specific antisera (i.e., a through f).
• If an isolate is non-agglutinating in the polyvalent antiserum, it is either 
non-typeable or is not H. influenzae. Therefore, growth factor requirements
must be determined to confirm the identity of the isolate as H. influenzae or
another species of Haemophilus.
Slide agglutination test for serotyping suspected H. influenzae isolates
a) Clean a glass slide with alcohol (optional if slides are pre-cleaned). Divide the
slide into equal sections (e.g., three 25-mm [1-inch] sections for a 25-mm x 
75-mm [1-inch x 3-inch] slide) with a wax pencil or other marker.
b) Collect a small portion of growth from the surface of an overnight culture on
chocolate agar (without bacitracin), a Haemophilus ID plate, or Haemophilus
test medium (HTM) plate with a sterile inoculating loop. Make a moderately
milky suspension of the test culture in a small vial with 250 µl (0.25 ml) of
formalinized physiological saline. Vortex the suspension, if possible.
• If only working with several isolates, another option is to make the
suspension directly on the slide in 10 µl of formalinized physiological saline
per droplet.
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1 Laboratorians are often tempted to test suspect H. influenzae isolates only with type b antiserum since
because serotype b (Hib) is vaccine preventable; however, it is of great importance to screen the isolate with a
saline control and at least one other antiserum in addition to type b. Observing agglutination reactions with
several antisera in different portions of the same slide permits comparisons and provides evidence that any
agglutination in type b antiserum is not just a mild cross-reaction with a different serotype, providing the 
laboratorian and clinician with a more informed definition of a ‘positive’ reaction.
• It is not necessary to make a standard suspension for slide serology; however,
it should be noted that a “moderately milky suspension” is roughly
comparable to a 6 McFarland turbidity standard.
c) For the agglutination reaction, use a micropipettor or a bacteriologic loop to
transfer a drop (5–10 µl) of the cell suspension to the lower portion of two
sections of the slide prepared in step a, above. Use enough suspension in the
droplet so that it does not dry on the slide before testing with the antisera.
d) Add 5–10 µl of polyvalent antiserum above the drop of suspension in one of the
test sections on the slide.2 In an adjacent section of the slide, use the same
method to add a (5–10 µl) drop of saline above the final drop of suspension.
• The loop used in the antiserum must not touch either the cell suspension
or the other antisera being tested; if it does, it must not be placed back into
the source bottle of antiserum. If the source antiserum is contaminated, a
new bottle must be used.
e) Using a separate toothpick (or sterile loop) for each section, mix the
antiserum (and control saline) with the corresponding drop of cell suspension.
Avoid contamination across the sections of the slide.
f) Gently rock the slide with a back and forth motion for up to 1 minute. Do not
use a circular motion while rocking, because it can cause the mixtures to run
together and contaminate each other. After one minute of rocking, observe the
mixed drops and read the slide agglutination reactions under bright light and
over a black background, as shown in Figure 2.
g) Only strong agglutination reactions (3+ or 4+) are read as positive. In a
strong reaction, all the bacterial cells will clump and the suspension fluid will
appear clear (see Figures 11 and 42). When a strain reacts with more than one
antiserum, or agglutinates in saline, the result is recorded as non-typeable.
• If strong agglutination occurs in the polyvalent antiserum: Using the methods
described in steps a through f (above), continue testing the isolate with type
b antiserum and other type-specific antisera to identify the serotype.
• If agglutination does not occur in the polyvalent antiserum: The isolate is
either non-typeable or not H. influenzae. Continue by testing the isolate for
X and V growth factor requirements to confirm identification as H.
influenzae.
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2 This laboratory manual suggests using a micropipettor or a loop to transfer antiserum from the bottle to the
slide (rather than the dropper provided with the bottle of antiserum) because they conserve costly antiserum
resources. (Micropipettors permit the precise measurement of antiserum, and the loop method collects only
approximately 5–10 µl of antiserum on average; in contrast, the dropper transfers several times this amount 
in each drop.)  Because only 5–10 µl of antisera are required for agglutination reactions to occur using the
methods presented here, using a micropipettor or a loop to transfer antiserum from the bottle to the slide 
is more cost-effective.
• If agglutination occurs in the saline control: The isolate is recorded as 
non-typeable. Continue by testing the isolate for X and V growth factor
requirements to confirm identification as H. influenzae.
Record results and report to attending clinicians, as appropriate.
Growth factor (X and V) requirements
H. influenzae is a fastidious organism requiring media containing haemin (X
factor) and nicotinamide adenine dinucleotide (NAD, V factor) for growth. The
standard medium is chocolate agar, which is often prepared with horse blood, a
good source of both X and V factors (Appendix 2). Heating the blood is necessary
to make both factors available to the organism. Chocolate agar with added
supplements (e.g., IsoVitaleX, Supplement B, or Vitox) is available commercially or
can be prepared in the laboratory. Supplemented chocolate agar is superior to
unsupplemented medium for growth of H. influenzae and is the medium of
choice. Although some strains of H. influenzae may grow on unsupplemented
chocolate agar, supplements must be added to reliably support the growth of
most strains.
H. influenzae is identified on the basis of its growth requirements for X and V
factors (Table 1). H. influenzae can be differentiated from most other species 
of Haemophilus by its requirement for both X and V factors for growth.
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FIGURE 2: Techniques to properly mix antiserum and suspension for slide agglutination
antiserum
suspension
Gently rock the slide back and forth for slide agglutination reactions.
H. haemolyticus is the only other species requiring X and V factors but this species
differs from H. influenzae by producing hemolysis on horse- or rabbit blood agar.
Tests to identify X and V growth factor requirements: paper disks and strips or
Quad ID plates
Growth factor requirements can be identified with paper disks or strips (using the
principles of agar diffusion) or by using Quad ID plates (which contain four types
of media with and without X and V factors).
• Growth factor test using X, V, and XV factor paper disks or strips
A medium completely without X and V factors, such as tryptone-based 
soy agar (TSA) or heart infusion agar (HIA), must be used for this test.
Methods
a) Prepare a heavy suspension of cells (1 McFarland turbidity standard, see
Appendix 2) from a primary isolation plate in a suitable broth (e.g.,
tryptone-based soy broth (TSB) or heart infusion broth). If the primary
isolation plate contains insufficient growth or is contaminated, make a
subculture on a chocolate agar plate. When preparing the broth avoid
transfer of agar medium to the broth; even the smallest sample of agar will
affect the test and may lead to misidentification of the bacteria because the
agar contains X and V factors.
b) Inoculate a HIA or TSA plate. A sterile swab or sterile loop of the suspension
should be streaked over one-half of the plate (with streaking in at least two
directions to ensure confluent growth). Two strains can be tested on one
100-mm plate, but care must be taken to ensure the isolates do not overlap.
Paper strips or disks containing X, V, and XV factors are placed on the
inoculated plate after the inoculum has dried. When two bacterial strains
are tested on the same plate, as shown in Figure 3, the disks should 
be placed in the exact manner shown.
c) Carefully invert the plate and place it in a CO2-incubator or candle-
extinction jar. Incubate it for 18–24 hours at 35˚C. H. influenzae will grow
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TABLE 1: Identification of Haemophilus species by their growth requirements
X- and V-Factor Requirements ß-hemolysis on
Species X V rabbit blood agar
H. influenzae + + –
H. parainfluenzae * – + –
H. haemolyticus + + +
H. parahaemolyticus – + +
H. aphrophilus + – –
H. paraphrophilus * – + –
* H. paraphrophilus is ornithine negative, whereas H. parainfluenzae is ornithine positive.
only around the XV disk (i.e., the disk containing both X and V factors),
as shown on the upper half of the plate in Figure 3.
• Growth factor test using Haemophilus Quad ID Plates
Quad ID plates are another, although more expensive, method for
determining growth factor requirements of Haemophilus isolates (Figure 4).
Available commercially, the Quad ID plate is divided into four agar
quadrants: one quadrant includes medium containing haemin (X factor);
one quadrant includes medium containing NAD (V factor); another
quadrant contains medium that includes both X and V factors; and, the final
quadrant contains heart infusion agar or blood agar base with 5% horse
blood for differentiating H. haemolyticus, an oral species requiring X and V
factors, from H. influenzae. Quadrant location of the growth factors may
vary with commercial brand of the Quad ID plate.
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FIGURE 3: Growth factor requirements: X and V factors on paper disks
The top strain is only growing around the disk containing both X and V factors  and can therefore be considered
presumptive H. influenzae.
Methods
a) Inoculate the Quad ID plate by suspending the growth from a young, pure
culture of suspected Haemophilus in tryptone soy broth (TSB) or distilled
water to a light, milky suspension (equivalent to a 0.5 McFarland turbidity
standard). Using a bacteriological loop, streak one loopful of this suspension
on each quadrant of the plate, beginning with the V quadrant and ending
with the blood quadrant. Streak the entire quadrant, starting at the
periphery and streaking toward the center of the plate. Stab into the blood
agar for detection of weak hemolysis.
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FIGURE 4: Growth factor requirements: Haemophilus Quad ID plate
X Factor Only X and V Factors
V Factor Only HIA with horse blood (shows hemolytic reactions)
The Quad ID plate is divided into four compartments. One quadrant (upper left) includes medium containing
haemin (X factor). One quadrant (lower left) includes medium containing nicotinamide dinucleotide (NAD, or 
V factor). Another quadrant (upper right) contains medium that includes both X and V factors. The fourth 
quadrant (lower right) contains heart infusion agar (HIA) with 5% horse blood to detect hemolytic reactions 
of Haemophilus species.
b) Invert the plate and incubate under a CO2-enhanced atmosphere 
(in a candle-jar or CO2-incubator) for 18–24 hours at 35˚C.
c) After incubation, examine the blood section for hemolysis and the other
sections for growth. H. influenzae typically shows growth in the XV quadrant
and in the (horse-) blood quadrant with no hemolysis. If strong growth
occurs in either one of the X or V quadrants besides XV, the organism is
probably another species of Haemophilus. If growth occurs in every
quadrant, the culture is probably not a species of Haemophilus. (Note:
Occasionally, H. influenzae may show slight growth in the V-factor
quadrant.) Read and record results.
Hemolytic reactions of Haemophilus species
Although most laboratories will not need to determine the hemolytic reaction of
each Haemophilus spp. (because too few Haemophilus strains will be isolated),
some laboratories may want to determine the hemolytic reaction to definitively
identify both H. influenzae and H. haemolyticus.
• If X, V, and XV factor disks or strips were used to test growth factor
requirements, a separate test to detect hemolytic reactions must be performed
by inoculating a broth suspension of the strain on HIA + 5% rabbit blood (or
agar infusion base containing horse blood); the hemolytic reaction permits
determination the species.
• If a Quad ID plate was used to test for growth factor requirements, the
hemolytic reaction of the organism is tested in the (horse-) blood agar
quadrant of the plate; thus no separate test is required.
H. influenzae should be α-hemolytic (i.e., causing a greening in the agar around
the colony) or γ-hemolytic (non-hemolytic) on the HIA plate containing 5%
rabbit blood, while H. haemolyticus will exhibit ß-hemolysis (i.e., a clearing of the
blood cells in the agar surrounding the colonies on the plate). A summary of test
results used in the identification of H. influenzae and most closely related
Haemophilus species is shown in Table 1. Proper determination of the hemolytic
reaction is the only way to differentiate H. influenzae from H. haemolyticus.
Antimicrobial susceptibility testing of H. influenzae
The results of antimicrobial susceptibility tests will be used to select the most
effective antimicrobial agent to use for treating patients. This laboratory manual
describes susceptibility testing of Haemophilus influenzae by the disk diffusion
method and by the antibiotic gradient strip (Etest®) testing method. Although disk
diffusion will provide information as to whether a strain is susceptible,
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intermediate, or resistant, the Etest® provides more detailed information about the
minimal inhibitory concentration (MIC) of an antimicrobial agent. The accuracy
and reproducibility of these tests are dependent on following a standard set of
procedures and conditions in laboratories on an on-going basis. A sample
worksheet for recording antimicrobial susceptibility test results for H. influenzae is
included in Figure 5.
Media and disks for antimicrobial susceptibility testing
Antimicrobial susceptibility can be determined using the disk diffusion method.
The disk diffusion method presented in this chapter is a modification of the Kirby-
Bauer technique that has been carefully standardized by NCCLS;3 if performed
precisely according to the following protocol, this method will provide data that
can reliably predict the in vivo effectiveness of the drug in question. The accuracy
and reproducibility of this test are dependent on the consistent use of a standard
set of procedures in laboratories. This section describes the optimal media,
inoculum, antimicrobial agents to test, incubation conditions, and interpretation
of results.
The recommended medium for antimicrobial susceptibility testing for 
H. influenzae is Haemophilus test medium (HTM) (Appendix 2). The Mueller-
Hinton agar used for this test should be thymidine-free to obtain consistent results
with trimethoprim-sulfamethoxazole (also referred to as cotrimoxazole). All 
media used for antimicrobial susceptibility testing should be freshly prepared.
Recommended antimicrobial agents for testing are ampicillin, chloramphenicol
and trimethoprim-sulfamethoxazole.
The 10-µg ampicillin disk predicts both intrinsic (i.e., penicillin-binding protein-
mediated, or “PBP”) and ß-lactamase (beta-lactamase) mediated penicillin and
ampicillin resistance and should be used when testing H. influenzae. (Methods 
for ß-lactamase testing of H. influenzae are listed after the direct antimicrobial
susceptibility testing methods in this section.) For H. influenzae, a 30-µg
chloramphenicol disk is used for predicting resistance to chloramphenicol, and a
1.25/23.75-µg trimethoprim-sulfamethoxazole disk is used for predicting
trimethoprim-sulfamethoxazole resistance. The zone diameter sizes can only 
be properly interpreted when HTM is used, as per NCCLS standards.
Quality control of antimicrobial susceptibility testing of H. influenzae
Quality control tests must be performed as part of the normal laboratory routine.
To verify that antimicrobial susceptibility test results are accurate, at least one
control organism should be included with each test. H. influenzae ATCC 49247 is
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3 Formerly known as the National Committee on Clinical Laboratory Standards (and now known solely by 
the acronym), NCCLS is an international, interdisciplinary, nonprofit educational organization that develops
updated consensus standards and guidelines for the healthcare community on an annual basis.
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the control strain used when testing H. influenzae for most antimicrobial agents
(e.g., ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole), although
ATCC 49766 is appropriate for some others. (Consult NCCLS document M100-
S12 [2002] for more complete information.) Inhibition zone diameters obtained
for the control strain should be compared with NCCLS published limits, which
are included in Table 2. If zones produced by the control strain are out of the
expected ranges, the laboratorian should consider possible sources of error.
• Antimicrobial susceptibility tests are affected by variations in media,
inoculum size, incubation time, temperature, and other environmental
factors. The medium used may be a source of error if it fails to conform to
NCCLS recommended guidelines. For example, agar containing excessive
amounts of thymidine or thymine can reverse the inhibitory effects of
sulfonamides and trimethoprim, causing the zones of growth inhibition to be
smaller or less distinct. Organisms may appear to be resistant to these drugs
when in fact they are not.
• If the depth of the agar in the plate is not uniformly 3–4 mm, the rate of
diffusion of the antimicrobial agents or the activity of the drugs may be
affected.
• If the pH of the test medium is not between 7.2 and 7.4, the rate of diffusion
of the antimicrobial agents or the activity of the drugs may be affected.
• If the inoculum is not a pure culture or does not contain a concentration of
bacteria that approximates the 0.5 McFarland turbidity standard, the
antimicrobial susceptibility test results will be affected. For instance, a
resistant organism could appear to be susceptible if the inoculum is too light.
Also, even if the isolates are susceptible, when colonies from blood agar
medium are used to prepare a suspension by the direct inoculum method,
trimethoprim or sulfonamide antagonists may be carried over and produce a
haze of growth inside the zones of inhibition surrounding trimethoprim-
sulfamethoxazole disks.
Quality control tests should be performed once per week if antimicrobial
susceptibility tests are performed daily (after 30 days of in-control results), or with
every group of tests when testing is done less frequently. They should also be done
with each new batch of test medium and every time a new lot of disks is used.
Antimicrobial susceptibility testing of H. influenzae by the disk diffusion method
Prepare the inoculum for seeding the antimicrobial susceptibility media with 
H. influenzae from fresh, pure cultures of H. influenzae (i.e., from isolates grown
overnight on supplemented chocolate agar). Prepare cell suspensions of the
bacteria to be tested in broth or sterile physiological saline; use a suspension equal
to a density of a 0.5 McFarland turbidity standard for the inoculum. (Preparation
of a McFarland turbidity standard is described in Appendix 2.)
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a) Suspend viable colonies from an overnight chocolate agar plate in a tube of
broth to achieve a bacterial suspension equivalent to a 0.5 McFarland
turbidity standard; be careful not to form froth or bubbles in the suspension
when mixing the cells with the broth. This suspension should be used
within 15 minutes.
b) Compare the suspension to the 0.5 McFarland turbidity standard by holding
the suspension and the McFarland turbidity standard in front of a light
against a white background with contrasting black lines and compare the
density (see Figures 51 and 52). If the density of the suspension is too heavy,
the suspension should be diluted with additional broth. If the density of the
suspension is too light, additional bacteria should be added to the
suspension.
c) When the proper density is achieved, dip a cotton swab into the bacterial
suspension. Press the swab on the side of the tube to drain excess fluid.
d) Use the swab to inoculate the entire surface of the HTM plate three times,
rotating the plate 60 degrees between each inoculation (see Figure 34). Use
the same swab with each rotated streak, but do not re-dip the swab in the
inoculum (i.e., the bacterial cell suspension).
e) Allow the inoculum to dry before the disks are placed on the HTM plates.
Drying usually takes only a few minutes, and should take no longer than 15
minutes. (If drying takes longer than 15 minutes, use a smaller volume of
inoculum in the future.)
f) After the plate is dry, antimicrobial disks should be placed on the HTM plate
as shown in Figure 6. The disks should be placed on the agar with sterile
forceps and tapped gently to insure adherence to the agar. Diffusion of the
drug in the disk begins immediately; therefore, once a disk contacts the agar
surface, the disk should not be moved.
g) Invert the plate and incubate it in a CO2-enriched atmosphere (5% CO2-
incubator or candle-extinction jar) for 16–18 hours at 35˚C.
• Note: If this is a new batch of HTM, the antimicrobial disks are new, or it is an
otherwise appropriate time to perform quality control, follow steps a through 
g- above and run parallel tests on the reference strain(s). Appropriate disk
diffusion zone sizes for the reference quality control strain (for the
antimicrobial agents included in this chapter) are presented in Table 2.
h) After overnight incubation, measure the diameter of each zone of inhibition.
The zones of inhibition on the media containing blood are measured from
the top surface of the plate with the top removed. Use either calipers or a
ruler with a handle attached for these measurements, holding the ruler over
the center of the surface of the disk when measuring the inhibition zone
(Figure 6).
• Care should be taken not to touch the disk or surface of the agar. Sterilize
the ruler occasionally to prevent transmission of the bacteria. In all
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measurements, the zones of inhibition are measured as the diameter from
the edges of the last visible colony. Record the results in millimeters
(mm). Figure 5 provides a sample form for recording results.
i) Interpretation of the antimicrobial susceptibility is obtained by comparing
the results obtained and recorded (in the manner described in this protocol)
to the NCCLS standard inhibition zone diameter sizes presented in Table 2.
Minimal inhibitory concentration testing of H. influenzae isolates
Laboratorians determining the minimal inhibitory concentration (MIC) for
resistant isolates must be highly skilled in performing these tests and committed to
obtaining accurate and reproducible results. In addition, a national (or regional)
reference laboratory must have the ability and resources to store isolates either by
lyophilization or by freezing at -70˚C.
Antimicrobial susceptibility testing by disk diffusion indicates whether an
organism is susceptible or resistant to an antimicrobial agent. For surveillance
purposes, a laboratory may want to quantify “intermediate” antimicrobial
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FIGURE 6: The antimicrobial susceptibility disk diffusion test: disk placement and measurement of inhibition
zone diameters
A ruler on a stick can be used to measure zone inibition diameters if calipers are not available.
TABLE 2: Antimicrobial susceptibility test breakpoints and quality control (QC) ranges for 
Haemophilus influenzae
susceptibility test results to trimethoprim-sulfamethoxazole detected by disk
diffusion testing with MIC testing.
MIC testing by dilution can be expensive and challenging; because of the technical
complexity required for these tests, countries that do not currently do MIC testing
by dilution should utilize the international reference laboratory rather than
developing the assay in-country. In countries where MIC testing is done at more
than one laboratory, standardization and quality control should be conducted as
described earlier in this chapter.
With increasing antimicrobial resistance testing being performed outside of
international reference laboratories, the Etest® serves as a test method that is both
convenient and reliable.4 The Etest® requires less technical expertise than MIC
testing by dilution methods, but it gives comparable results. Etest® strips must be
consistently stored in a freezer at -20˚C.
The Etest® is an antimicrobial susceptibility testing method that is as technically
simple to perform as disk diffusion and produces semi-quantitative results that are
measured in micrograms per milliliter (µg/ml). It is drug-specific, consists of a thin
plastic antibiotic gradient strip that is applied to an inoculated agar plate, and is
convenient in that it applies the principles of agar diffusion to perform semi-
quantitative testing.5
The continuous concentration gradient of stabilized, dried antibiotic is equivalent
to 15 log2 dilutions by a conventional reference MIC procedure as suggested by the
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Diameter of zone of inhibition (mm) and NCCLS QC strain
Antimicrobial equivalent MIC breakpoint (µg/ml) a H. influenzae
agent Disk potency Susceptible Intermediate Resistant ATCC 49247 b
Chloramphenicol 30 µg > 29 mm 26– 28 mm < 25 mm 31 – 40 mm
(< 2 µg/ml) (4 µg/ml) (>8 µg/ml) (0.25 – 1 µg/ml)
Trimethoprim- 1.25/ 23.75 µg ≥ 16 mm 11 mm – 15 mm ≤ 10 mm 24 – 32 mm
sulfamethoxazole (< 0.5/9.5 µg/ml) (1/18 – 2/36 µg/ml) (> 4/76µg/ml) (0.03/0.59 – 
(cotrimoxazole) 0.25/4.75 µg/ml)
Ampicillin 10 µg ≥ 22 mm 19 mm – 21 mm ≤ 18 mm 13 – 21 mm
(< 1 µg/ml) (2 µg/ml) (> 4 µg/ml) (2 – 8 µg/ml)
a Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. NCCLS document 
M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087-1898 USA.
b The quality control strain H. influenzae ATCC 49247 is appropriate for the testing of the antimicrobial agents included in this table and this 
laboratory manual overall; however, for testing of some other antimicrobial agents, NCCLS recommends that a different QC strain be used.
Laboratories testing the susceptibility of H. influenzae to antimicrobial agents other than those listed should therefore refer to the NCCLS 
document M100-S12 (or subsequent updates) for appropriate methods.
4 The Etest® can be expensive; contact the manufacturer (AB BIODISK) to inquire about discounts available
for laboratories in resource-poor regions (see Appendix 13).
NCCLS. The Etest® has been compared with and evaluated beside both the agar
and broth dilution susceptibility testing methods recommended by the NCCLS.
Authoritative reports indicate that an (approximately) 85% – 100% correlation
exists between the accepted conventional MIC determinations and the MIC
determined by the Etest® procedure for a variety of organism-drug combinations
(see, e.g, Jorgensen et al. [1994] and Barry et al. [1996] in Appendix 15). Some
studies have cited Etest® MICs as approximately one dilution higher than MICs
determined by standard dilution methods.
Although this manual serves as a general guide to use of the Etest® antimicrobial
gradient strip, always follow the manufacturer’s directions for use of the Etest®,
as certain antibiotic-bacteria (“drug-bug”) combinations have special testing
requirements.
Methods for antimicrobial susceptibility testing with the Etest®
For H. influenzae, HTM is used when performing antimicrobial susceptibility
testing. Follow the directions on the package insert included with the Etest® strips.
Either 150-mm or 100-mm plates can be used, depending on the number of
antimicrobial agents to be tested per isolate. Two different Etest® antimicrobial
strips can be placed in opposite gradient directions on a 100-mm plate, and
although the manufacturer states that up to six Etest® strips can be used on a 150-
mm plate, this laboratory manual suggests that in order to avoid overlapping zones
of inhibition of growth, not more than five Etest® strips be used on a 150-mm
plate (see Figure 7).
a) Suspend viable colonies from an overnight chocolate agar plate into a broth
tube to achieve a bacterial suspension equivalent to a 0.5 McFarland turbidity
standard; be careful not to form froth or bubbles in the suspension when
mixing the cells. This suspension should be used within 15 minutes.
b) Dip a cotton swab into the bacterial suspension. Press the swab on the side of
the tube to drain excess fluid. Inoculate the entire surface of the agar plate three
times with the same swab of inoculum, rotating the plate 60 degrees after each
inoculation to ensure confluent growth of the bacteria (see Figure 34). Use a
single swab of inoculum, and do not return the swab to the broth after each
rotation.
c) Allow the plate to dry for up to 15 minutes. Be sure the plate is entirely dry
before proceeding. While the plate is drying, remove the Etest® strips from the
-20˚C freezer and allow the strips that will be used in the batch of testing to
warm to room temperature. Return the strips that will not be used in this batch
of testing to the -20˚C freezer.
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5 Antimicrobial susceptibility testing with an antimicrobial gradient strip such as the Etest® can be considered
to be a semi-quantitative method (because although the suspension used to inoculate a plate for Etest® is 
standardized, the inoculum itself is not standardized). However, results are generally comparable to 
quantitative results of standard broth microdilution or agar dilution MIC tests.
d) Place the Etest® strips onto the dried, inoculated agar plate with an Etest®
applicator or sterile forceps, oriented as shown in Figure 7. (Make sure that the
printed MIC values are facing upward, [i.e., that the bottom surface of the strip
containing the antimicrobial gradient is in contact with the agar].) Once
applied, do not move the antimicrobial gradient strips.
e) Incubate the plates in an inverted position in a CO2-enriched atmosphere (2%
– 5% CO2) for 16–18 hours at 35˚C. A candle-extinction jar may be used if a
CO2-incubator is not available.
f) After incubation, an ellipse of bacterial growth will have formed on the plate
around the strip and the Etest® can be read. Quality control results must be
reviewed before reading and interpreting the Etest® MIC.
MICs are read from the intersection of the ellipse-formed zone of inhibition with
the value printed on the Etest® strip. Use oblique light to carefully examine the end
point. A magnifying glass may be used if needed. Read the MIC at the point of
complete inhibition of all growth including hazes and isolated colonies. Figure 8
presents a reading guide for the Etest®,6 and shows drug-related effects, technical
and handling effects, organism-related effects and resistance-mechanism-related
effects.
• The graduation marks on the Etest® strip correspond to the standard
concentrations for the agar dilution method, but also include increments
between those standard values. The standard values (see Table 27 in Appendix
7) are used for interpretation and reporting of antimicrobial susceptibility test
results. It is advised that both the actual reading of the value from the strip and
the next-higher standard value (i.e., the value to be used for interpretation) be
included in the laboratory records for testing of the strain. For example, if
testing susceptibility of a H. influenzae isolate to ampicillin, an MIC recorded
from the graduations on the Etest® strip might be 0.75 mg/ml; however, the
reported MIC would be 1.0 µg/ml.
Breakpoints for interpretation of MICs follow the NCCLS guidelines, unless
exceptions made by the manufacturer are provided in the package insert. NCCLS
breakpoints for antimicrobial agents used for H. influenzae are included in Table 2.
Surveillance for emerging antimicrobial resistance in H. influenzae
Laboratories may wish to help detect the emergence of new strains of Haemophilus
by testing isolates against a panel of drugs in which reduced susceptibility is not
expected to be found. A laboratory might look at specific drugs or characteristic
groupings (such as, for example, ß-lactamase negative, ampicillin resistant
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6 AB Biodisk also maintains a website with an Etest® reading guide: http://www.abbiodisk.com.
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FIGURE 7: Proper placement of Etest® strips on dry, inoculated plates
Up to two Etest® strips can be placed on a 100 mm plate, as shown.
Up to five Etest® strips can be placed on a 150 mm plate, as shown.
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FIGURE 8a: Guidance for reading Etest® results
Etest® images and figure legends reprinted from the “Etest® Reading Guide” with the permission of AB BIODISK,
Dalvägen 10, S-169 56 Solna, Sweden. Internet: http://www.abbiodisk.com. Email: etest@biodisk.se.
Intersection in between markings.
Read the next higher value. MIC 0.19 µg/ml.
If the strip is backwards,
MIC = INVALID! 
Retest and position the strip with the MIC scale 
facing the opening of the plate.
Ignore a thin line of growth at the edge of the strip
caused by organisms growing in a tunnel of water.
MIC 0.25 µg/ml.
Different intersections on either side of the strip.
Read the higher value; if the difference is >1 
dilution, repeat the test. MIC 0.5 µg/ml.
The way in which the strip is placed on the medium can affect growth of the organisms and
interpretation of the minimal inhibitory concentration (MIC).
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FIGURE 8b: Guidance for reading Etest® results
Etest® images and figure legends reprinted from the “Etest® Reading Guide” with the permission of AB BIODISK,
Dalvägen 10, S-169 56 Solna, Sweden. Internet: http://www.abbiodisk.com. Email: etest@biodisk.se.
Isolated resistant colonies due to low-level 
mutation. MIC >256 µg/ml.
Bacteriostatic drugs such as trimethoprim and
sulphonamides can give diffuse edges. Read at 
80% inhibition. MIC 3 µg/ml.
Induction of ß-lactamase production by clavulanic
acid at the higher MIC range. MIC 96 µg/ml.
Paradoxical effect showing partial regrowth after
an initial inhibition. MIC 8 µg/ml.
The way in which the strip is placed on the medium can affect growth of the organisms and
interpretation of the minimal inhibitory concentration (MIC).
Haemophilus influenzae | 25
FIGURE 8c: Guidance for reading Etest® results
Scrutinize pneumococcal end-points carefully
to pick up all microcolonies.Tilt the plate
and/or use a magnifying glass.
MIC 2 µg/ml.
Tilt the plate to visualize pin-point colonies 
and hazes.This is particularly important for 
pneumococci. MIC 1 µg/ml.
A highly resistant subpopulation in pneumococci.
MIC >32 µg/ml.
Etest® images and figure legends reprinted from the “Etest® Reading Guide” with the permission of AB BIODISK,
Dalvägen 10, S-169 56 Solna, Sweden. Internet: http://www.abbiodisk.com. Email: etest@biodisk.se.
The way in which the strip is placed on the medium can affect growth of the organisms and
interpretation of the minimal inhibitory concentration (MIC).
Encapsulated strains may not give a confluent
intersection. MIC 1 µg/ml.
[BLNAR] H. influenzae). These strains are believed to be rare at present, but are of
great interest to public health policy and clinicians because although they may
exhibit in vitro susceptibility to certain drugs (e.g., amoxicillin + clavulanic acid,
cefprozil, cefuroxime, and others), they should still be considered resistant in vivo
[NCCLS 2002].
Testing for emerging resistance should not be done with each batch of antimicrobial
susceptibility tests, nor with each new batch of media. Instead such testing could be
done periodically (e.g., on an annual basis), for example on a sampling of preserved
isolates in storage on an annual basis. Methods for preservation and long-term
storage of isolates can be found in Appendix 11. Antimicrobials of interest could
include (but are not necessarily limited to) ceftriaxone and fluoroquinolones.
Appropriate zone diameter sizes can be found in NCCLS documents, which are
updated regularly. If any of these rare strains with reduced susceptibility are
found in the course of this surveillance, notify an international reference
laboratory and submit the isolate for further investigation. A list of international
reference laboratories is included in Appendix 14.
Testing H. influenzae for ß-lactamase production
Testing the H. influenzae isolates for the presence of ß-lactamase will identify most
of ampicillin-resistant strains, because most (but not all) ampicillin resistance
among H. influenzae is caused by the presence of ß-lactamase. Several techniques
are available for the detection of ß-lactamases. All the tests are based on
determination of breakdown products and use either a natural substrate (e.g.,
penicillin) or a chromogenic substance (e.g., nitrocefin). Two methods for
detection of ß-lactamase are presented in this manual: the nitrocefin test and the
acidometric agar plate method.
• Nitrocefin can be used to screen for ß-lactamase either as a reagent dropped
onto colonies or in the form of a treated disk onto which colonies are rubbed.
(This manual suggests using the disk method unless a laboratory is screening
large numbers of isolates because the materials for the reagent tend to be
available in bulk and costs can be high; methods for testing with the liquid
nitrocefin reagent are included in the N. gonorrhoeae chapter [Chapter VI].) 
a) Using sterile forceps or tweezers, place a nitrocefin disk on a clean slide; add
a drop of distilled water.
b) Touch a sterile swab or loop to a characteristic colony from fresh, pure
culture.
c) Rub the swab onto the moistened disk.
d) Observe the disk for five minutes; if the reaction is positive (ß-lactamase
producing strain), the areas of the disk containing growth will turn a
characteristic red/pink color.
• A modified acidometric agar plate method is a differential agar method for
testing H. influenzae isolates for the presence of ß-lactamase activity [Park et al.
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1978; Lucas 1979]. Penicillin and phenol red are combined in a non-nutrient
plate; the pH indicator detects increased acidity resulting from the cleavage of
the ß-lactam ring of penicillin that yields penicilloic acid, and leads to a color
change in the agar.
a) Place a clump of isolated colonies in a discrete spot on the ß-lactamase agar
plate. Many strains can be tested on one plate; be certain to note their
specific positions with proper labels.
b) Apply known ß-lactamase-positive and ß-lactamase-negative control strains
to the plate; label their positions.
c) Incubate the plate in ambient air at 35˚C for 15 minutes.
d) Observe the plate for color change in the agar surrounding each discretely
spaced colony. The agar surrounding positive-control strain should be
yellow, whereas the agar surrounding the negative-control strain should not
exhibit any change in color.
Data for decision-making
Once the laboratory has assessed the serotype and antimicrobial susceptibility
patterns of H. influenzae isolates, the information should be reported back to
public health officials promptly. Factors to consider in the development of
treatment policy include:
• Childhood immunizations should be considered if H. influenzae type b is a
major local cause of invasive disease.
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be available locally (or able to be
obtained quickly).
Consideration of such factors when making data-based decisions will help public
health officials meet needs in a manner appropriate to the local situation and the
specific antimicrobial susceptibility profile. National recommendations for empiric
antibiotic utilization should be developed after considering antimicrobial
susceptibility data, cost, availability, convenience, and other factors.
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N eisseria meningitidis is the etiologic agent of meningococcal disease, mostcommonly meningococcal bacteremia and meningitis. These two clinicallyoverlapping syndromes may occur simultaneously, but meningitis alone
occurs most frequently. N. meningitidis is an encapsulated bacterium and is
classified into serogroups based on the immunological reactivity of the capsule’s
polysaccharide. The most common serogroups causing disease are A, B, C, Y, and
W135. During the past 20 years, serogroups B and C have been responsible for
most meningococcal disease in the Americas and Europe; serogroup A accounts for
most meningococcal disease cases in Africa and some parts of Asia.
Meningococcal disease differs from the other leading causes of bacterial meningitis
because of its potential to cause large-scale epidemics. Historically, these epidemics
have been typically caused by serogroup A and, to a lesser extent, serogroup C. In
Africa, the highest incidence rates of serogroup A meningococcal disease occur in a
region of Sub-Saharan Africa extending from Sudan in the east to The Gambia in
the west; this region consists of 15 countries comprised of more than 260 million
people and has been referred to as the “meningitis belt.” During epidemics,
children and young adults are most commonly affected, with attack rates as high as
1,000/100,000 population, or 100 times the rate of sporadic disease. The highest
rates of endemic or sporadic disease occur in children less than 2 years of age. In
recent years, two major epidemics of meningitis caused by N. meningitidis
serogroup W135 have also been reported. In 2000, an outbreak of meningococcal
disease in Saudi Arabia (which resulted in 253 cases and 70 deaths) was caused by
a virulent clone of serogroup W135; this outbreak occurred simultaneously with
the annual pilgrimage to Mecca and returning pilgrims disseminated this clone
throughout the world, resulting in secondary cases. As of the time of writing of
this laboratory manual in mid-2002, a serogroup W135 meningitis epidemic has
been reported in Burkina Faso with more than 12,000 cases and 1400 deaths to
date.
Neisseria meningitidis
CONFIRMATORY IDENTIFICATION AND 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
CHAPTER IV
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A quadrivalent polysaccharide vaccine that includes serogroups A, C, Y, and W135
is produced and used in the United States; however, bivalent A and C
polysaccharide vaccines are being used in other parts of the world. New
meningococcal conjugate vaccines are under development.
Laboratory personnel at risk for exposure to aerosolized N. meningitidis should
ensure their protective vaccination status remains current and, if possible, work in
a biological safety cabinet. Laboratory scientists who manipulate invasive N.
meningitidis isolates in a manner that could induce aerosolization or droplet
formation (including plating, subculturing, and serogrouping) on an open bench
top and in the absence of effective protection from droplets or aerosols should
consider antimicrobial chemoprophylaxis.
Confirmatory identification of N. meningitidis
The following steps are recommended to confirm the identity of cultures that
morphologically appear to be N. meningitidis (Figure 9). The best results are
obtained with day-old cultures. Always check for purity of the growth by
performing a Gram stain: N. meningitidis is a gram-negative, kidney-bean- or
coffee-bean-shaped diplococcus (see Figure 72). When necessary, make subcultures
to ensure purity. From growth on a blood agar plate, perform Kovac’s oxidase test,
and then identify the serogroup with a slide agglutination test. Finally, confirm the
results with carbohydrate (i.e., sugar) reactions.
Some laboratorians may be interested in the OMP (i.e., outer membrane protein)
subtyping of N. meningitidis isolates; these tests may be performed by international
reference laboratories.
Kovac’s oxidase test for the identification of N. meningitidis
The oxidase test determines the presence of cytochrome oxidase. The Kovac’s
oxidase reagent (1% tetramethyl-ρ-phenylenediamine hydrochloride)7 is turned
into a purple compound by organisms containing cytochrome c as part of their
respiratory chain; therefore, an oxidase-positive test will yield a purple reaction.
(Instructions for making oxidase reagent are found in Appendix 2.)
7 Some laboratories may use a different reagent, Gordon and MacLeod’s reagent, (1% [wt/vol] dimethyl-ρ-
phenylenediamene dihydrocholoride; “dimethyl reagent”) to perform the oxidase test. The dimethyl reagent is
more stable than the tetramethyl reagent (Kovac’s reagent), but the reaction with the dimethyl reagent is slow-
er than that with the tetramethyl reagent. If the laboratory is using the dimethyl- reagent, a positive reaction
will be indicated by a color change to blue on the filter paper (not purple, as with the tetramethyl reagent), and
with the dimethyl reagent it will take 10 – 30 minutes for a positive reaction to develop.
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FIGURE 9: Flowchart for laboratory identification of Neisseria meningitidis
Sterile site specimen




= not N. meningitidis
Growth on blood or chocolate agar is 
grayish, non-hemolytic, round, convex,





Perform Gram stain on CSF for
clinical decision-making
Inoculate blood agar 













= not N. meningitidis




Antimicrobial susceptibility testing 
(do not use disk diffusion)
If no bacteria are detected in the Gram stain of CSF 
but growth is observed on blood or chocolate agar,
laboratories may want to repeat the Gram stain with 
growth from the primary plate.
Oxidase-negative 
= not N. meningitidis
Oxidase-positive
(purple reaction)
* If agglutination occurs in the
saline control, and/or with more
than one antiserum, the isolate is
“non-groupable.”
a) Using a platinum inoculating loop, a disposable plastic loop, or a wooden
applicator stick, pick a portion of the colony to be tested and rub it onto a
treated strip of filter paper (Figure 10). Do not use a Nichrome loop because it
may produce a false-positive reaction.
b) Positive reactions will develop within 10 seconds in the form of a purple color.
Delayed reactions are unlikely with N. meningitidis.
The oxidase test aids in the recognition of N. meningitidis and other members of
the genus Neisseria; other, unrelated, bacterial species with cytochrome c in the
respiratory chain (e.g., Pseudomonas aeruginosa and H. influenzae) are also oxidase
positive.
Identification of the N. meningitidis serogroup
Twelve serogroups based on capsular polysaccharides are currently recognized:
A, B, C, H, I, K, L, W135, X, Y, Z, and Z’ (29E). (Note: serogroup D is no longer
recognized.) Groups A and C are the common causes of meningitis outbreaks in
Africa, but recently outbreaks caused by groups W135 and X have been reported;
group B is a cause of endemic meningitis and may also cause outbreaks in some
regions of the world (e.g., in Brazil). Grouping antisera are available commercially.
Serogrouping can be expensive, but it is valuable. Serogroup data provides
laboratories and public health authorities with the tools to:
• identify outbreaks controllable by a vaccination campaign
• recognize the presence of serogroups causing sporadic disease
• detect the emergence of new outbreak strains (e.g., X or W135).
It is therefore essential that high-level reference laboratories have the capacity to
isolate, identify and confirm the serogroup of N. meningitidis isolates causing
sporadic disease as well as those they receive during the course of an outbreak.
Slide agglutination test for serogrouping suspected N. meningitidis isolates
The following methods require both formalinized physiological saline to make the
meningococcal suspension and unformalinized physiological saline (or phosphate
buffered saline [PBS]) to mix with the antisera. Store antisera in the refrigerator at
4˚C when not in immediate use.
a) Clean a glass slide with alcohol (optional if slides are pre-cleaned). Divide the
slides into equal sections (e.g., three 25-mm [1-inch] sections for a 25-mm x
75-mm [1-inch x 3-inch] slide) with a wax pencil or other marker.
b) Collect a small portion of growth from the surface of an overnight culture on
non-selective blood or chocolate agar plate using a sterile inoculating loop.
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STEP 1: Place filter paper treated with
Kovac’s oxidase in a Petri dish.
STEP 2: Prepare inoculum
and touch filter paper
with loop
STEP 3: A positive reaction with Kovac’s oxidase is
detected within 10 seconds by a color change to 
purple on the area of the filter paper where growth
was rubbed (in step 2).
FIGURE 10: Kovac’s oxidase test: a positive reaction on filter paper
Make a moderately milky suspension of the test culture in 250 µl (0.25 ml) of
formalinized physiological saline. Vortex the suspension, if possible. If working
with only several isolates, it may be more convenient to make the suspension
directly on the slide in 10 µl of formalinized physiological saline per droplet.
• Note: For safety reasons, it is recommended that formalin-killed
meningococcal suspensions rather than saline suspensions of living
organisms be used; however, formalin is a carcinogen and must be stored
and handled with great care. (Alternatively, if formalin is not used to kill the
meningococci, laboratorians can work under a safety hood.)
• It is not necessary to make a standard suspension for slide serology; however,
it should be noted that a “moderately milky suspension” is roughly
comparable to a 6 McFarland turbidity standard.
c) Use a micropipettor or a bacteriologic loop to transfer a drop (5–10 µl) of the
cell suspension to the lower portion of each section of the slide prepared in step
a of this procedure.8
d) Add a drop of group A antiserum above the drop of suspension in one of the
test sections on the slide. In one of the other sections of the slide, add a drop of
W135 antiserum below the drop of suspension in that section. For the third
section of the slide, use the same method to add a drop of saline below the final
drop of suspension.
• The loop used in the antiserum must not touch either the cell suspension
or the other antisera being tested; if it does, it must not be placed back into
the source bottle of antiserum. If the source antiserum is contaminated, a
new bottle must be used.
• Note: In Africa, testing with A and W135 antisera (with a saline control to
detect nonspecific autoagglutination) should be adequate for serologic
characterization of most N. meningitidis isolates. Strains reacting negatively
with A and W135 antisera should then be tested with other available
antisera, particularly C, Y, B, and X.
e) Using a separate toothpick (or sterile loop) for each section, mix each
antiserum (and control saline) with its corresponding drop of cell suspension.
Avoid contamination across the sections of the slide.
f) Gently rock the slide with a back and forth motion for up to 1 minute.
Do not use a circular motion while rocking, as it can cause the mixtures to run
together and contaminate each other. After one minute of rocking, observe the
three mixed drops and read the slide agglutination reactions under bright light
and over a black background (see Figure 2).
g) Only strong agglutination reactions (3+ or 4+) are read as positive. In a
strong reaction, all the bacterial cells will clump and the suspension fluid will
appear clear (see Figure 11 and Figure 42). When a strain reacts only in one
grouping antiserum, it should be recorded as belonging to that serogroup.
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8 This laboratory manual suggests using a micropipettor or a loop to transfer antiserum from the bottle to the
slide (rather than the dropper provided with the bottle of antiserum) because they conserve costly antiserum
resources. (Micropipettors permit the precise measurement of antiserum, and the loop method collects only
5–10µl of antiserum on average; in contrast, the dropper transfers several times this amount in each drop.)
Because only 5–10 µl of antisera are required for agglutination reactions to occur using the methods presented
in this manual, using a micropipettor or a loop to transfer antiserum from the bottle to the slide is more
cost-effective.
(For example, an isolate exhibiting a strong agglutination reaction only in
group A antiserum would be recorded as ‘N. meningitidis, serogroup A.’) 
• If a strong agglutination reaction does not occur with the antisera tested:
– If the isolate is negative in the first two antisera tested (groups A and
W135 in Africa) and the saline control, repeat the test with different 
antisera to identify the serogroup, following steps a through f of this 
procedure.
• When a strain reacts with more than one antiserum or agglutinates in saline,
the strain is categorized as non-groupable. (These results occur rarely with
fresh isolates, but they do happen occasionally.) Non-groupable results are
characterized by:
1) Autoagglutination in the saline control (“autoagglutinable”).
2) Cross-agglutination with reactions in more than one antiserum
(“rough”).
3) No agglutination with either any of the antisera or with the saline control
(“non-reactive”).
Report results of N. meningitidis serogroup testing back to attending clinicians, as
appropriate.
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FIGURE 11: Positive and negative agglutination reactions on a slide: grouping antisera and saline control with Neisseria
meningitidis
When a suspension is mixed with its homologous antiserum, agglutination occurs (left). In a negative reaction, as shown with
a heterologous antiserum (center) or control saline (right), the suspension remains smooth and cloudy in appearance.
Carbohydrate utilization by N. meningitidis: cystine trypticase agar method
Carbohydrate utilization tests are used to further validate the identification of a
strain as N. meningitidis. Various carbohydrates are added to the cystine trypticase
agar (CTA) base to a final concentration of 1%. To confirm a culture as N.
meningitidis, a set of four tubes, each containing a sugar (i.e., glucose [dextrose],
maltose, lactose, and sucrose) is used. Members of Neisseria species produce acid
from carbohydrates by oxidation, not fermentation. N. meningitidis oxidizes
glucose and maltose, but not lactose and sucrose. A phenol red indicator is
included in the medium; it is a sensitive indicator that develops a yellow color in
the presence of acid, at a pH of 6.8 or less. (Methods for the preparation and
quality control of CTA medium are included in Appendix 2.)
a) With an inoculating needle, collect a small amount of growth from an
overnight culture of N. meningitidis on blood agar or chocolate agar.
b) Stab the inoculum several times into the upper 10 mm of medium. Use another
sterile needle, or flame the same needle, before inoculating each of the four
carbohydrates to be tested.
c) Fasten caps of tubes tightly and place in a 35°C incubator (without CO2).
Incubate for at least 72 hours (and up to 5 days) before discarding as negative.
d) Development of visible turbidity and a yellow color in the upper portion of the
medium indicates growth and the production of acid and is interpreted as a
positive test (Figure 12). Although reactions may occur as early as 24 hours after
inoculation, some reactions are delayed. If only glucose or maltose or none of
the sugars react, continue incubation for up to 5 days before discarding.
Occasionally, strains of N. meningitidis are encountered that utilize only dex-
trose or maltose but not both (Table 3).
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TABLE 3: Carbohydrate utilization by some species of Neisseria and Moraxella
Produces acid from a
Species Glucose b Maltose Lactose Sucrose
N. meningitidis + + – –
N. gonorrhoeae (+) c – – –
N. sicca + + – +
N. lactamica + + + –
M. catarrhalis – – – –
a Negative results should not be interpreted prior to 72 hours of incubation in order to avoid false-negative results for delayed acid 
production reactions.
b Glucose may be also be referred to as “dextrose”.
C Strains of N. gonorrhoeae that are weak acid producers may appear to be glucose-negative in cystine trypticase agar (CTA) medium.
Commercial identification kits for Neisseria
Several commercial identification systems that use biochemical or enzymatic
substrates are available for identification of Neisseria species. These systems may
occasionally require supplemental tests, and other characteristics, such as
microscopic and colony morphology, must be considered; additionally,
antimicrobial susceptibility testing cannot be conducted without a confirmed 
N. meningitidis isolate. Generally, each system is self-contained, but addition of one
or more reagents to complete certain reactions may be necessary. Follow the
manufacturer’s instructions precisely when using these kits. For detailed
instructions and use of appropriate control strains, also consult the Clinical
Microbiology Procedures Handbook (see Appendix 15). Rapid sugar utilization test
kits may also be used toward the identification of N. meningitidis.
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FIGURE 12: Cystine trypticase agar sugar reactions for acid production from carbohydrates by Neisseria meningitidis
Acid is produced by utilization of sugar and causes the CTA medium to turn yellow at or just below the agar surface.
For N. meningitidis, there is utilization of dextrose and maltose (two tubes on left with yellow color just below the 
surface) and no utilization of lactose nor sucrose (two tubes on right with solid red color of medium).
Antimicrobial susceptibility testing of N. meningitidis
N. meningitidis does not commonly show resistance to many antimicrobial agents.
Low-level resistance to penicillin is common in some areas of the world, though
the clinical significance of this resistance has not yet been established.
Meningococcal resistance to sulfonamides, rifampicin (also referred to as
rifampin), and chloramphenicol has also been described. Chloramphenicol tends
to be the empiric drug of choice for treating patients with meningitis caused by 
N. meningitidis; rifampicin and sulfonamides are often used for prophylaxis.
Antimicrobial susceptibility testing of N. meningitidis should not be performed
by disk diffusion, even though it is the least expensive screen, because results are
very difficult to interpret and will not provide data useful for making informed
treatment decisions. Two appropriate methods for testing include (1) minimal
inhibitory concentration (MIC) determination by broth microdilution, and (2) 
use of the Etest® strip. The broth microdilution methodology provides
laboratorians with quantitative MIC results based on the inhibition of growth of a
standard inoculum in standard concentrations (dilutions) of antimicrobial. The
Etest® antimicrobial susceptibility test methodology provides laboratorians with
semi-quantitative MIC results, because although a standard suspension is used to
inoculate a plate, the inoculum is not precisely standardized. Results of the 
Etest® and conventional MIC testing by broth microdilution are generally
comparable.
The broth microdilution procedure can be expensive and challenging to perform
and, because of the technical complexity required, countries that do not currently
do MIC testing by dilution should utilize the international reference laboratory
rather than developing the assay in-country. For laboratories that do not perform
MIC testing by dilution methods but still want to perform antimicrobial
susceptibility tests on N. meningitidis isolates, the Etest® may be a convenient
alternative.9 The Etest® is easier to quality control and is the focus of this section 
of the manual, but broth microdilution methodology is included in Appendix 7.
Figure 13 shows a sample worksheet for recording antimicrobial susceptibility 
test results for N. meningitidis.
Either 150-mm or 100-mm plates can be used for the Etest®, depending on the
number of antimicrobial agents to be tested per isolate. Two different Etest®
antimicrobial strips can be placed in opposite gradient directions on a 100-mm
plate, and although the manufacturer states that up to six Etest® strips can be 
used on a 150-mm plate, this laboratory manual suggests that in order to avoid
overlapping zones of inhibition of growth, not more than five Etest® strips be 
used on a 150-mm plate (see Figure 7).
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9 The Etest® can be expensive; contact the manufacturer (AB BIODISK) to inquire about discounts available
for laboratories in resource-poor regions (see Appendix 13).
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FIGURE 13:Sam
ple form
 for recording antim
icrobial susceptibility test results for Neisseria
m
eningitidis
Note:After 18 – 22 hours of incubation,check the results for the quality control (QC) strain against the standard acceptable ranges;if they are in control,continue reading results for the test isolate.Record M
IC
results in µg/m
l.(Breakpoints for interpretation of results m
ay be found in Table 4.)
Minimal inhibitory concentration testing of N. meningitidis by Etest® antimicrobial 
gradient strip
Mueller-Hinton + 5% sheep blood agar is used when testing N. meningitidis
isolates with the Etest®. Follow the directions on the package insert included with
the Etest® strips.
a) Using a sterile cotton-tip applicator, touch the surface of one to four
morphologically similar, isolated colonies grown on a chocolate agar plate
incubated in CO2-enhanced atmosphere (5% CO2 in a CO2-incubator or
candle-extinction jar) at 35˚C for 18–22 hours. Immerse the applicator into a
tube containing sterile broth (e.g., Muller-Hinton broth). Rub the applicator
against the wall of the tube slightly to release a small amount of growth into the
liquid. Cap the tube and mix the cells to form a suspension, being careful not to
form froth or bubbles in the suspension when mixing the cells. This suspension
should be used within 15 minutes.
b) Adjust the turbidity of the inoculum to that of a 0.5 McFarland turbidity
standard. If the turbidity of the inoculum is greater than the standard, dilute it
with broth to equal the turbidity of the standard. (Figures 51 and 52 in
Appendix 2 show how to compare the turbidity of the suspension with the
standard and also provide black and white lines as a reading background.)
c) Immerse a sterile cotton-tipped swab into the adjusted inoculum (prepared in
step b of this procedure). Remove excess liquid by pressing the swab tip against
the inside of the tube. Inoculate the entire surface of a 15x150-mm Mueller-
Hinton + 5% sheep blood agar plate three times with the same swab of
inoculum, rotating the plate 60 degrees after each inoculation to ensure even
distribution of the inoculum and confluent growth of the bacteria (see Figure
34). Use a single swab of inoculum, and do not return the swab to the broth
after each rotation.
d) Allow the inoculum to dry on the surface of the plate (which should take
approximately 10 minutes). Be sure the plate is entirely dry before proceeding.
While the plate is drying, remove the Etest® strips from the -20˚C freezer, and
allow the strips that will be used in the batch of testing to warm to room
temperature. Return the antimicrobial gradient strips that will not be used in
this batch of testing to the -20˚C freezer.
e) When the surface of the inoculated plate is dry and the Etest® strips are at room
temperature, place the antimicrobial gradient strips onto the agar with an
Etest® applicator or sterile forceps, as illustrated in Figure 7. Make sure that the
printed MIC values are facing upward (i.e., that the bottom surface of the strip
containing the antimicrobial gradient is in contact with the agar.) Once
applied, it is important to not move the antimicrobial gradient strips.
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f) Incubate the plates in an inverted position in a 5% CO2 atmosphere for 18–22
hours at 35˚C. A candle-extinction jar may be used if a CO2-incubator is not
available. Because N. meningitidis grows well in a humid atmosphere,
laboratorians may choose to add a shallow pan of water to the bottom of the
incubator or add a dampened paper towel to the candle-extinction jar.
After incubation, an ellipse of bacterial growth will have formed on the plate
around the strip and the Etest® can be read. Quality control results must be
reviewed before reading and interpreting the Etest® MIC. MICs are read from
the intersection of the ellipse-formed zone of inhibition with the value printed on
the Etest® strip. Use oblique light to carefully examine the end point. A magnifying
glass may be used if needed. Read at the point of complete inhibition of all growth
including hazes and isolated colonies. Figure 8 presents a reading guide for the
Etest®,10 and shows drug-related effects, technical and handling effects, organism-
related effects, and resistance mechanism-related effects.
• The graduation marks on the Etest® strip correspond to the standard
concentrations for the agar dilution method, but also include increments
between those standard values. The standard values (see Table 27 in Appendix
7) are used for interpretation and reporting of antimicrobial susceptibility test
results. It is advised that both the actual reading of the value from the strip and
the next-higher standard value (i.e., the value to be used for interpretation) be
included in the laboratory records for testing of the strain. For example, if
testing susceptibility of an isolate to penicillin, an MIC recorded from the
graduations on the Etest® strip might be 0.094 µg/ml; however, the reported
MIC would be 0.125µg/ml.
Quality control for antimicrobial susceptibility testing of N. meningitidis
To verify that antimicrobial susceptibility test results are accurate, it is important to
include at least one control organism. It is of note here that NCCLS11 does not
publish MIC ranges specific to N. meningitidis; however, the Centers for Disease
Control and Prevention (CDC, United States of America) recommends that if
antimicrobial susceptibility testing of N. meningitidis is going to be performed,
then a banked control strain for fastidious organisms (S. pneumoniae ATCC 49619)
should be used for quality control. The NCCLS MIC ranges for quality control
testing of S. pneumoniae ATCC 49619 with the antimicrobial agents penicillin,
rifampicin, and sulfonamides are included in Table 4. If zones produced by the
control strain are out of the expected ranges, the laboratorian should consider
possible sources of error.
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10 AB Biodisk also maintains a website with an Etest® reading guide: http://www.abbiodisk.com.
11 Formerly known as the National Committee on Clinical Laboratory Standards (and now known solely by
the acronym), NCCLS is an international, interdisciplinary, nonprofit educational organization that develops
updated consensus standards and guidelines for the healthcare community on an annual basis.
Resistance to antimicrobials other than penicillins and rifampicin is not commonly
detected in N. meningitidis; however, laboratories, clinicians, and other public
health practitioners may be interested in performing annual screens of isolates in
storage. (Appendix 11 provides methods for how to preserve and store
meningococcal isolates.) Periodic, non-routine surveillance for characteristics such
as ß-lactamase production, and ceftriaxone, chloramphenicol and fluoroquinolone
resistance will help provide information to public health agencies and international
reference laboratories regarding the emergence of new N. meningitidis strains of
clinical and public health concern.
Antimicrobial susceptibility tests are affected by variations in media, inoculum
size, incubation time, temperature, and other factors. The medium used may be a
source of error if it fails to conform to NCCLS recommended guidelines. For
example, agar containing excessive amounts of thymidine or thymine can reverse
the inhibitory effects of sulfonamides and trimethoprim, causing the zones of
growth inhibition to be smaller or less distinct for trimethoprim-sulfamethoxazole
(cotrimoxazole); organisms may then appear to be resistant to these drugs when in
fact they are not. If the depth of the agar in the plate is not 3–4 mm or the pH is
not between 7.2 and 7.4, the rate of diffusion of the antimicrobial agents or the
activity of the drugs may be affected. (Do not attempt to adjust the pH of this
Mueller-Hinton agar even if it is out of range; see Appendix 2) 
If the inoculum is not a pure culture or does not contain a concentration of
bacteria that approximates the 0.5 McFarland turbidity standard, the antimicrobial
susceptibility test results will be affected. For instance, a resistant organism could
appear to be susceptible if the inoculum is too light. Also, if colonies from blood
agar medium are used to prepare a suspension by the direct inoculum method,
trimethoprim or sulfonamide antagonists may be carried over and produce a 
haze of growth inside the zones of inhibition surrounding trimethoprim-
sulfamethoxazole disks even when the isolates being tested are susceptible.
Reading and interpreting the Etests® 
Read the MIC at the point where the zone of inhibition intersects the MIC scale on
the strip, as illustrated in Figure 8. Record the quality control results first. If zones
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TABLE 4: Minimal inhibitory concentration (MIC) ranges for quality control of Neisseria meningitidis antimicrobial 
susceptibility testing
Trimethoprim-
QC strain for Penicillin Rifampicin (Rifampin) sulfamethoxazole Chloramphenicol
N. meningitidis a MIC Range b MIC Range b MIC Range b MIC Range b
S. pneumoniae 0.25 – 1 µg/ml 0.015 – 0.06 µg/ml 0.12/2.4 – 1/19 µg/ml 2 – 8 µg/ml
ATCC 49619
a Source: Dr. F.Tenover, Centers for Disease Control and Prevention, Atlanta, Georgia, USA: 2002.
b Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement.
NCCLS document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087 USA.
produced by the control strain are out of the expected ranges (Table 4), the
laboratorian should consider possible sources of error. If all antimicrobial agents
are in control, read the test MICs. Note any trailing endpoints.
Because antimicrobial susceptibility test results can be affected by many factors not
necessarily associated with the actual susceptibility of the organism (e.g., inoculum
size, agar depth, storage, time, and others), quality control practices must be
followed carefully.
Although NCCLS has not defined standardized breakpoints for the interpretation
of an N. meningitidis isolate as susceptible or not, the MICs obtained by
antimicrobial susceptibility testing methods as described in this document can 
still be used. Just as a laboratory might assess antimicrobial susceptibility for the
very many other organisms for which no NCCLS breakpoints have been defined,
laboratorians and clinicians should consider the site of infection in conjunction
with the dose and pharmacokinetics of the antimicrobial agent to determine 
how much drug reaches the site of the infection. This information should then
compared to the MIC value to determine if the concentration of drug available is
at least four times greater than the MIC. If the concentration of drug available is
≥4 times the MIC, the organism may be considered susceptible; if not, it is
resistant.
Data for decision-making
Once the laboratory has confirmed the identification and serogroup (and
antimicrobial susceptibility patterns, if appropriate) of N. meningitidis isolates, the
information should be reported promptly to public health officials. Factors to
consider in the development of a treatment policy include:
• Immunization should be considered if a N. meningitidis vaccine serotype is a
major cause of local invasive disease.
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be available locally (or be able to be
obtained quickly).
Consideration of such factors when making data-based decisions will help public
health officials meet needs in a manner appropriate to the local situation and the
specific antimicrobial susceptibility profile. National recommendations for empiric
antibiotic utilization should be developed after considering antimicrobial
susceptibility data, cost, availability, convenience, and other factors.
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S treptococcus pneumoniae is a common agent of lower and upper respiratorydiseases, such as pneumonia, meningitis and acute otitis media (middle earinfections), affecting children and adults worldwide. This bacterial pathogen is
the cause of approximately 40% of acute otitis media. Although acute otitis media
and other upper respiratory tract infections do not commonly progress to invasive
disease they do contribute significantly to the burden and cost of pneumococcal
disease. Meningitis in infants, young children and the elderly is often caused by 
S. pneumoniae. Persons who have sickle cell disease, anatomic asplenia, or are
immunocompromised also have increased susceptibility to S. pneumoniae
infection. Pneumococcal meningitis is the most severe presentation of disease, but
most illnesses and deaths result from pneumococcal pneumonia. Pneumococcal
polysaccharide vaccine has been available for preventing invasive disease in the
elderly and in persons with chronic illnesses that may impair their natural
immunity to pneumococcal disease; however, this vaccine is not effective in
children <2 years of age. In contrast to polysaccharide vaccines, conjugate vaccines
are effective in young children. A pneumococcal conjugate vaccine covering seven
serotypes that most commonly cause bacteremia in children in the United States
(and some other industrialized nations) was approved for clinical use in 2000;
research on vaccine formulations containing serotypes more common in
developing countries is underway.
S. pneumoniae is frequently carried in the throat without causing disease.
On occasion, public health investigations call for studies on the prevalence of
S. pneumoniae carriage. For this research, samples may be collected using
nasopharyngeal (NP) swabs; methodology for collection and isolation with NP
swabs is included in Appendix 5. Antimicrobial susceptibility testing on isolates
should be performed as presented in this chapter.
Streptococcus pneumoniae
CONFIRMATORY IDENTIFICATION AND 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
CHAPTER V
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Confirmatory identification of S. pneumoniae
S. pneumoniae are gram-positive diplococci or chains of cocci (see Figure 73). On
blood agar and chocolate agar plates, S. pneumoniae colonies appear small, greyish
and mucoid (i.e., watery), and are surrounded by a greenish zone of alpha-
hemolysis (α-hemolysis).
Colonies of pneumococci and α-hemolytic viridans streptococci each appear 
raised when young; however, after 24–48 hours, the center of pneumococcal
colonies becomes depressed, whereas viridans streptococcal colonies retain their
raised appearance (Figure 14). A 3x hand-lens or a microscope (30x–50x) can
therefore be a useful aid in differentiating pneumococci from α-hemolytic viridans
streptococci. Laboratory differentiation between S. pneumoniae and viridans
streptococci is accomplished by optochin and bile solubility testing: pneumococci
are susceptible to optochin and bile-soluble, while viridans streptococci are not.
Commercially available slide agglutination tests can also be used for identification
of pneumococci. For optimal results plates for pneumococcal identification assays
should be incubated in a 5% CO2 atmosphere.
A flowchart diagram of the laboratory identification of S. pneumoniae is included
in Figure 15. Presumptive identification of S. pneumoniae is made by determining
the susceptibility of the strain to optochin (i.e., ethylhydrocupreine). The bile
solubility test is also used for identification of S. pneumoniae, particularly when
results of the optochin susceptibility test are ambiguous.
Optochin susceptibility test
The optochin susceptibility test is performed with a 6-mm, 5-µg optochin disk,12
and is used to differentiate between S. pneumoniae and viridans streptococci.
Optochin-susceptible strains can be identified as S. pneumoniae.
Performance of the optochin susceptibility test
a) Touch the suspect α-hemolytic colony with a sterile bacteriological loop and
streak for isolation onto a blood agar plate in a straight line. Several strains can
be tested on the same plate at once, streaked in parallel lines and properly labeled.
b) Aseptically place an optochin or “P” disk with a diameter of 6 mm (and
containing 5 µg of ethylhydrocupreine) on the streak of inoculum, near the end
where the wire loop was first placed. Because the inoculum is streaked in a
straight line, three to four colonies may be tested on the same plate (Figure 16).
12  The results and interpretation of the optochin susceptibility test presented in this document are 
appropriate for the 6-mm, 5-µg optochin disk (“P”-disk), although-different size disks (and possibly
optochin concentrations) are available for purchase. When using optochin disks with different size and/or
concentration parameters, follow the manufacturer’s instructions for interpretation.
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FIGURE 14: A properly streaked blood agar plate with pneumococci and viridans streptococci
Note how growth is heavy where streaking began on the left and then thins to individual colonies.
The S. pneumoniae has a depressed center (yellow arrows) at 24 – 48 hours incubation,
whereas the viridans streptococci retain a raised center (black arrows).
S. pneumoniae
viridans streptococci
c) Incubate the plates in a CO2-incubator or candle-jar at 35˚C for 18–24 hours.
d) Read, record, and interpret the results.
Reading and interpreting the optochin susceptibility test results 
In Figure 16, the strain in the top streak is resistant to optochin and, therefore, is
not a pneumococcus. The strains in the center and lower streaks are susceptible to
optochin and appear to be pneumococci.
α-hemolytic  strain
with zone of inhibition     
9 mm – 13 mm* 
in diameter
α-hemolytic strain
with zone of 
inhibition 
≥ 14 mm in diameter
* =  S. pneumoniae
48 | Manual for Identification and Antimicrobial Susceptibility Testing
FIGURE 15: Flowchart for laboratory identification of Streptococcus pneumoniae
Sterile site specimen




= not S. pneumoniae
Examination of growth on blood (or
chocolate) agar shows small, grayish,
moist, watery colonies, surrounded by a
greenish zone of α-hemolysis
Gram-positive 
diplococci or gram-
positive cocci in chains
Perform Gram stain for 
clinical decision-making
Inoculate blood agar 
(and/or chocolate agar) plates
Bile-soluble strain
= S. pneumoniae
Not bile soluble        
(= not S. pneumoniae)
* with a 6-mm, 5-µg disk
Antimicrobial susceptibility testing on
Mueller-Hinton agar              
plus 5% sheep (or horse) blood
Optochin susceptibility test
(6-mm, 5-µg optochin disk)
(If testing with a 10-mm disk, a zone of inhibition 
≥16 mm= S. pneumoniae, and strains with zones of 
inhibition <16 mm should be tested for bile solubility;
Follow manufacturers’ instructions for disks of 
other sizes or concentrations.)
α-hemolytic strain
with zone of inhibition
≤ 8 mm* 
( = viridans 
streptococci)
Isolate not susceptible 
to optochin             
( = not 
S. pneumoniae)
* with a 6-mm, 5-µg disk
* with a 6-mm, 5-µg disk
Bile solubility test
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• α-hemolytic strains with a zone of inhibition of growth greater than 14 mm in
diameter are pneumococci.
(If using a 10-mm, 5-µg disk, α-hemolytic isolates with a zone of inhibition
of growth >16 mm in diameter are considered susceptible to optochin and,
therefore, are pneumococci.)
• α-hemolytic strains with no zones of inhibition are viridans streptococci.
• α-hemolytic strains with zones of inhibition ranging between 9 mm and 
13 mm should be tested for bile solubility for further characterization and
identification.
(If using a 10-mm disk, α-hemolytic isolates with a zone of inhibition of
growth <16 mm should be tested for bile solubility.)
FIGURE 16: Optochin susceptibility test for identification of Streptococcus pneumoniae
The optochin susceptibility test for S. pneumoniae uses P-disks (optochin disks); this 
laboratory manual presents guidelines for interpretation of the optochin susceptibility
test based on a 6-mm, 5-µg optochin disk. The strain in the top streak grew up to the
disk: it is resistant to optochin and therefore is not a pneumococcus. The strains in the
center and lower streaks are susceptible to optochin and appear to be pneumococci.
Bile solubility test
The bile solubility test is performed on isolates with small zones of inhibition in
the optochin susceptibility test. It can be performed using either the “tube
method” or the “plate method.”
Tube method for the performance of the bile solubility test
Two tubes are required for bile solubility testing of each suspect strain of
S. pneumoniae.
a) Take a loop of the suspect strain from fresh growth on a blood agar plate and
prepare a bacterial cell suspension in 0.5 ml of sterile saline. The suspension of
bacterial cells should be cloudy, similar to that of a 0.5 or 1.0 McFarland
turbidity standard. (Preparation of a McFarland turbidity standard is described
in Appendix 2.)
• If growth on the optochin test plate is sufficient, the suspension can be 
made with the bacterial cells collected from the specific streak of suspect 
S. pneumoniae.
• When there is insufficient growth to make a suspension of the proper
density in 0.5 ml of sterile saline, inoculate a blood agar plate with the
suspect growth and incubate overnight (i.e., for 18 – 24 hours at 35˚C in a
CO2-enriched atmosphere) to prepare a fresh culture.
b) Divide the suspension into two equal amounts (i.e., 0.25 ml per tube). Add 
0.25 ml of saline to one tube and 0.25 ml of 2% sodium desoxycholate (bile
salts) to the other.
• To make a 2% concentration of bile salts, add 0.2 g of sodium desoxycholate
to 10 ml of saline.
c) Shake the tubes gently and incubate them at 35˚– 37˚C for up to 2 hours.
d) Examine the tubes periodically for lysis of cells in the tube containing the bile
salts. A clearing of the tube, or a loss in turbidity, is a positive result (Figure 17).
• Strains that yield clearing of the suspension in tube in the bile solubility test
should be reported as “bile soluble.”
• Strains for which the turbidity in the tube remains the same as that in the
saline control tube is reported as negative for bile solubility (or “bile
insoluble” or “bile resistant”).
Plate method for the performance of the bile solubility test
In place of the tube test for bile insolubility, a laboratorian may perform the bile
solubility test using the plate method. A freshly prepared culture of the suspect
organism must be used for this test.
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a) Place a drop of 10% sodium desoxycholate solution directly on a colony of the
suspect pneumococcal strain to be tested.
• (To prepare the 10% solution of bile salts, add 1 g of sodium desoxycholate
bile salts to 10 ml of sterile saline.)
b) Keep the plate at room temperature (i.e., 72˚–75˚C) or place it face up (i.e.,
agar-side up) and on a level surface in an ambient air incubator (i.e., not a
CO2-incubator) at 35˚C for approximately 15 minutes (or until the 10% bile
salt reagent dries).
• Optional: instead of leaving the plate out at room temperature, laboratorians
may choose to put the plate top-side (i.e., agar-side) up on a level surface in
an ambient air incubator (i.e., not a CO2-incubator) at 35˚C until the
reagent dries (approximately 10–15 minutes).
c) When the reagent dropped on the suspect colony is dry, read, record, and
interpret the results.
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FIGURE 17: Positive and negative results of the bile solubility test 
Results of the bile solubility test are shown for two different strains of bacteria. A slight decrease in turbidity is observed in
the tube containing bile salts for strain 1 (2nd tube from left), but the contents are almost as turbid as the control tube (far
left); therefore, strain 1 is not Streptococcus pneumoniae. Strain 2 is S. pneumoniae: all turbidity in the tube on the far right
has disappeared, the clearness indicating that the cells have lysed; in contrast, the control tube (2nd from right) is still turbid








Bile Salts  (+)
Pneumococcal colonies are bile-soluble and will disappear or appear as flattened
colonies; in contrast, bile-resistant streptococcal colonies will be unaffected.
Interpretation of the combined optochin and bile solubility tests for 
pneumococcal identification 
The following summary of results of the optochin and bile-solubility tests is
commonly used to accurately and conveniently identify S. pneumoniae (i.e.,
pneumococcus).
• A strain exhibiting a zone of inhibition by optochin ≥14 mm (with a 6-mm,
5-µg disk) is a pneumococcus.
• A strain exhibiting a smaller but definite zone of inhibition by optochin (9–13
mm with a 6-mm, 5-mg disk) and that is also bile soluble is a pneumococcus.
The following summary of results of the optochin and bile-solubility tests should
be interpreted as negative for S. pneumoniae (and positive for viridans
streptococci).
• A strain with a small zone of inhibition by optochin (≤8 mm with a 6-mm,
5-µg disk) that is not bile soluble is not a pneumococcus. (The colonies can 
be identified as viridans streptococci.)
• Strains with no zones of inhibition by optochin are not pneumococci.
(The colonies can be identified as viridans streptococci.)
Commercial test kits for identification (slide agglutination test)
Commercially available slide agglutination tests (e.g., Slidex Pneumo-kit® and the
Pneumoslide™) can also help identify colony growth from blood agar plates as S.
pneumoniae. Follow the manufacturer’s instructions precisely when using these
and any other commercial tests.
If a colony appears to be S. pneumoniae on the basis of morphology and
susceptibility to optochin, but it has a negative bile solubility test, slide
agglutination tests can assist with identification of the isolate. A positive slide
agglutination test should be interpreted as a possible S. pneumoniae isolate, whereas
a negative slide agglutination reaction in conjunction with the positive optochin
and negative bile solubility would indicate the isolate is not S. pneumoniae.
Identification of the S. pneumoniae serotype
Serotyping of pneumococci is not usually necessary for a clinical response.
However, in some situations or settings (e.g., studies focusing on evaluation 
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of vaccine efficacy), it will be appropriate to type these isolates. Methods for
serotyping and Quellung typing are included in Appendix 6.
Antimicrobial susceptibility testing of S. pneumoniae
The results of antimicrobial susceptibility tests will be used to help make
recommendations for clinical treatment. There are a variety of methods by 
which one can determine the antimicrobial susceptibility of a bacterial 
pathogen, commonly including disk diffusion, testing by agar dilution or broth
microdilution, and testing by antimicrobial gradient agar diffusion (e.g., with the
Etest® strip). The disk diffusion method presented in this chapter is a modification
of the Kirby-Bauer technique that has been carefully standardized by NCCLS;13
if performed precisely according to the following protocol, this method will yield
data that can reliably predict the in vivo effectiveness of the drug in question. This
section describes the optimal media, inoculum, antimicrobial agents to test,
incubation conditions, and interpretation of results for S. pneumoniae.
The disk diffusion method gives valid data for only certain antibiotics, so this
laboratory manual recommends use of the Etest® to gather data about the 
minimal inhibitory concentration (MIC) of antimicrobial agents.14 MIC testing 
can also be done by dilution; however because agar dilution and broth
microdilution are expensive and technically complex, this manual recommends
that countries that do not currently do MIC testing by dilution should utilize the
international reference laboratory rather than developing the assay in-country.
(Alternatively, if resources are available, laboratories may purchase commercially-
available, frozen MIC panels and follow the manufacturer’s instructions to carry
out the MIC test.)
This laboratory manual describes antimicrobial susceptibility testing of S.
pneumoniae by the disk diffusion method and by the Etest® antimicrobial gradient
strip method. (Figure 18 is a sample worksheet for recording results of the
antimicrobial susceptibility tests.) Although disk diffusion will provide
information for most antimicrobial agents regarding interpretation of a strain as
susceptible, intermediate, or resistant, the Etest® provides general information
about the MIC of antibiotic. The accuracy and reproducibility of this test are
dependent on following a standard set of procedures and conditions in
laboratories on an on-going basis.
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13 Formerly known as the National Committee on Clinical Laboratory Standards (and now known solely by
the acronym), NCCLS is an international, interdisciplinary, nonprofit educational organization that develops
updated consensus standards and guidelines for the healthcare community on an annual basis.
14 The Etest® can be expensive; contact the manufacturer (AB BIODISK) to inquire about discounts available
for laboratories in resource-poor regions (see Appendix 13).
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Quality control of antimicrobial susceptibility testing of S. pneumoniae
Quality control tests must be performed as part of the normal laboratory routine.
To verify that antimicrobial susceptibility test results are accurate, at least one
control organism should be included with each test or new set of testing
conditions. S. pneumoniae ATCC 49619 is the NCCLS control strain to use when
performing antimicrobial susceptibility testing on S. pneumoniae isolates.
Inhibition zone diameters obtained for the control strain should be compared
with NCCLS published limits, which are included in Table 5. If zones produced
by the control strain are out of the expected ranges, the laboratorian should
consider possible sources of error.
• Antimicrobial susceptibility tests are affected by variations in media,
inoculum size, incubation time, temperature, and other environmental
factors. The medium used may be a source of error if it fails to conform to
NCCLS recommended guidelines. For example, agar containing excessive
amounts of thymidine or thymine can reverse the inhibitory effects of
sulfonamides and trimethoprim, causing the zones of growth inhibition to be
smaller or less distinct. Organisms may appear to be resistant to these drugs
when in fact they are not.
• If the depth of the agar in the plate is not uniformly 3–4 mm, the rate of
diffusion of the antimicrobial agents or the activity of the drugs may be
affected.
• If the pH of the test medium is not between 7.2 and 7.4, the rate of diffusion
of the antimicrobial agents or the activity of the drugs may be affected. (Note:
Do not attempt to adjust the pH of the Mueller-Hinton agar test medium if it 
is outside the range; see Appendix 2.)
• If the inoculum is not a pure culture or does not contain a concentration 
of bacteria that approximates the 0.5 McFarland turbidity standard, the
antimicrobial susceptibility test results will be affected. For instance, a
resistant organism could appear to be susceptible if the inoculum is too light.
Also, even if the isolates are susceptible, when colonies from blood agar
medium are used to prepare a suspension by the direct inoculum method,
trimethoprim or sulfonamide antagonists may be carried over and produce 
a haze of growth inside the zones of inhibition surrounding trimethoprim-
sulfamethoxazole disks.
Quality control (“QC”) tests should be performed once per week if antimicrobial
susceptibility tests are performed daily after 30 days of in-control results, or with
every group of tests when testing is done less frequently. They should also be done
with each new batch of antimicrobial susceptibility test medium and every time a
new lot of disks is used.
Antimicrobial susceptibility testing by disk diffusion
Antimicrobial susceptibility can be determined using the disk diffusion method;
however, disk diffusion antimicrobial susceptibility testing is generally not
performed on meningitis isolates. This laboratory manual describes the optimal
media, inoculum, antimicrobial agents to be tested, incubation conditions, and
interpretation of results.
• Mueller-Hinton agar medium supplemented with 5% sheep blood is
recommended for determining the antimicrobial susceptibility of S. pneumoniae
specimens by disk diffusion. The agar plates should have a uniform depth of
3–4 mm.
• The l-µg oxacillin disk is recommended for predicting the susceptibility of S.
pneumoniae to penicillin because penicillin disks do not provide reproducible
results. Interpretations of the oxacillin disk diffusion test are generalizable
across the ß-lactam drugs for S. pneumoniae.
– It is only possible to conclude if a strain is susceptible to penicillin based
on the oxacillin screen, and not if it is resistant to penicillin. If the zone of
inhibition around the oxacillin disk is less than 20 mm, additional MIC
testing (e.g., by Etest®) must be performed to assess whether the isolate is
resistant or susceptible to penicillin.
• A 30-µg chloramphenicol disk is used for detecting resistance to
chloramphenicol.
• A 25-µg trimethoprim-sulfamethoxazole (cotrimoxazole) disk (i.e., a disk
comprised of 1.25 mg trimethoprim plus 23.75 mg sulfamethoxazole) is used
for detecting trimethoprim-sulfamethoxazole resistance in S. pneumoniae.
The Mueller-Hinton agar used for this test should be thymidine free to 
obtain accurate results with trimethoprim-sulfamethoxazole.
Methods for antimicrobial susceptibility testing by disk diffusion
Prepare the inoculum for antimicrobial susceptibility testing of S. pneumoniae
from fresh pure cultures of S. pneumoniae (grown overnight on blood or chocolate
agar). Prepare cell suspensions of the bacteria to be tested in sterile physiological
saline or Mueller-Hinton broth. A cell suspension equal to a density of a 0.5
McFarland turbidity standard is used for the inoculum. (Preparation of a
McFarland turbidity standard and plate count methods are described in 
Appendix 2.)
a) Suspend viable colonies from an overnight sheep blood or chocolate agar plate
in a tube of broth to achieve a bacterial suspension equivalent to a 0.5
McFarland turbidity standard; be careful not to form froth or bubbles in the
suspension when mixing the cells with the broth. This suspension should be
used within 15 minutes.
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b) Compare the density of the suspension to the 0.5 McFarland turbidity standard
by holding the suspension and McFarland turbidity standard in front of a light
against a white background with contrasting black lines (see Figures 51 and 52,
Appendix 2). If the density is too heavy, the suspension should be diluted with
additional suspending medium (i.e., saline or broth). If the density is too light,
additional bacteria should be added to the suspension.
c) When the proper density is achieved, dip a cotton or dacron swab into the
bacterial suspension. Lift it out of the broth and remove excess fluid by pressing
and rotating the swab against the wall of the tube.
d) Use the swab to inoculate the entire surface of the supplemented Mueller-
Hinton agar plate three times, rotating the plate 60 degrees between each
inoculation (see Figure 34). Use the same swab with each rotated streak, but do
not re-dip the swab in the inoculum (i.e., the bacterial cell suspension).
e) Allow the inoculum to dry before placing the disks on the plates. Drying usually
takes only a few minutes, and should take no longer than 15 minutes. (If drying
takes longer than 15 minutes, use a smaller volume of inoculum in the future.)
f) After the plate is dry, place the antimicrobial disks on the plates (as shown in
Figure 6). Use sterile forceps to place the disks on the Mueller Hinton agar and
tap them gently to ensure they adhere to the agar. Diffusion of the drug in the
disk begins immediately; therefore, once a disk contacts the agar surface, the
disk should not be moved.
g) Incubate the plates in an inverted position in a 5% CO2 atmosphere for 20–24
hours at 35˚C. A candle-extinction jar may be used if a CO2-incubator is not
available.
• If this is a new batch of Mueller-Hinton agar, the antimicrobial disks are
new, or it is an otherwise appropriate time to perform quality control, follow
steps a through g above and run parallel tests on the reference strain(s).
Appropriate disk diffusion zone sizes for the reference QC strains are
included in Table 5.
h) After overnight incubation, measure the diameter of each zone of inhibition
with a ruler or calipers. The zones of inhibition on the media containing blood
are measured from the top surface of the plate with the top removed. Use either
calipers or a ruler with a handle attached for these measurements, holding the
ruler over the center of the surface of the disk when measuring the inhibition
zone (see Figure 6).
• Care should be taken not to touch the disk or surface of the agar. Sterilize
the ruler occasionally to prevent transmission of the bacteria. In all
measurements, the zones of inhibition are measured as the diameter from
the edges of the last visible colony. Record the results in millimeters (mm).
Figure 5 provides a sample form for recording results.
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i) Interpret the antimicrobial susceptibility of the test strain (and check that
results for the QC strain S. pneumoniae ATCC 49619 are within the acceptable
control range) by comparing the results to the NCCLS standard zone sizes
(Table 5).
The Etest® for minimal inhibitory concentration testing of S. pneumoniae
For S. pneumoniae, disk diffusion testing indicates whether an organism is
susceptible or resistant to an antimicrobial for most agents. However, disk
diffusion testing for pneumococcal isolates and oxacillin (a penicillin agent) is not
sufficient to distinguish between complete and intermediate resistance. For
surveillance purposes, a laboratory may want to quantify the results of the oxacillin
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TABLE 5: Antimicrobial susceptibility test breakpoints and quality control ranges for Streptococcus pneumoniae
Diameter of zone of inhibition (mm) and NCCLS QC strain
Antimicrobial Disk equivalent MIC breakpoint (µg/ml) a S. pneumoniae 
agent potency Susceptible Intermediate Resistant ATCC 49619
Chloramphenicol 30 µg ≥ 21 mm ~ ≤ 20 mm 23 – 27 mm
(≤ 4 µg/ml) ~ (≥ 8 µg/ml) (2 – 8 µg/ml)
Trimethoprim- 1.25 / ≥ 19 mm 16 – 18 mm ≤ 15 mm 20 – 28 mm
sulfamethoxazole 23.75 µg (≤ 0.5 – 9.5 (1/19 – 2/38 (≥4/76 (0.12/2.4 – 1/19
(cotrimoxazole) µg/ml) µg/ml) µg/ml) µg/ml)
Oxacillin b 1 µg ≥ 20 mm b ** b ** b ≤ 12mm c
Disk diffusion ONLY
Penicillin b MIC ONLY (≤ 0.06 µg/ml) (0.12 – 1 µg/ml) (≥ 2 µg/ml) (0.25 – 1 µg/ml)
Ceftriaxone d, e MIC ONLY
Non-meningitis (≤ 1 µg/ml) (2 µg/ml) (≥ 4 µg/ml) (0.03 – 0.12 µg/ml)
isolate MIC
Meningitis isolate MIC (≤ 0.5 µg/ml) (1 µg/ml) (≥ 2 µg/ml)
Cefotaxime d, e MIC ONLY
Non-meningitis (≤ 1 µg/ml) (2 µg/ml) (≥ 4 µg/ml) (0.03 – 0.12 µg/ml)
isolate MIC
Meningitis isolate MIC (≤ 0.5 µg/ml) (1 µg/ml) (≥ 2 µg/ml)
a Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. NCCLS 
document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087-1898 USA.
b Oxacillin should only be tested by disk diffusion. If the zone is <20 mm, an isolate cannot be reported as susceptible,
intermediate or resistant, and MIC testing must be conducted for an appropriate penicillin (or other ß-lactam) drug.
c “Deterioration in oxacillin disk content is best assessed with QC organism Staphylococcus aureus ATCC 25923, with an acceptable
zone diameter of 18 to 24 mm” [NCCLS 2002].
d Penicillin, ceftriaxone, and cefotaxime should only be tested by a method that will provide an MIC; it is presented in this table 
as a follow-up for an equivocal oxacillin disk diffusion test (i.e., oxacillin zone of inhibition <20 mm). Perform MIC testing on 
the specific penicillin (or other ß-lactam) drug that would be used to treat.
e Ceftriaxone and cefotaxime have separate interpretive MIC breakpoints for meningitis and non-meningitis isolates.
disk diffusion test by performing minimal inhibitory concentration (MIC) testing
of penicillin or any other beta-lactam antibiotic that would be used for treatment.
As mentioned earlier in this manual, MIC testing by dilution can be expensive and
challenging, and because of the technical complexity required for these tests,
countries that do not currently do MIC testing by dilution should utilize the
international reference laboratory rather than developing the assay in-country. The
World Health Organization (WHO) recommends that only one laboratory in a
resource-limited region perform antimicrobial susceptibility testing; however, in
countries where MIC testing is done at more than one laboratory, standardization
and quality control should be conducted at each laboratory in accordance with the
standardized guidelines presented in this manual.
Laboratorians determining the minimal inhibitory concentration (MIC) for
resistant isolates must be highly skilled in performing these tests and committed to
obtaining accurate and reproducible results. In addition, a national (or regional)
reference laboratory must have the ability and resources to store isolates either by
lyophilization or by freezing at -70˚C. Methods for preservation and storage of
isolates are presented in Appendix 11, and detailed methods for transport of
isolates according to international regulations are presented in Appendix 12.
With increasing antimicrobial resistance testing being performed outside of
international reference laboratories, the Etest® serves as a test method that is both
convenient and reliable.15 The Etest® requires less technical expertise than MIC
testing by dilution methods, but it gives comparable results. Etest® strips must be
consistently stored in a freezer at -20˚C.
The Etest® is an antimicrobial susceptibility testing method that is as technically
simple to perform as disk diffusion and produces semi-quantitative results that are
measured in micrograms per milliliter (µg/ml). It is drug-specific, consists of a thin
plastic antibiotic gradient strip that is applied to an inoculated agar plate, and is
convenient in that it applies the principles of agar diffusion to perform semi-
quantitative testing.16
The continuous concentration gradient of stabilized, dried antibiotic is equivalent
to 15 log2 dilutions by a conventional reference MIC procedure as suggested by the
NCCLS. The Etest® has been compared and evaluated beside both the agar and
broth dilution susceptibility testing methods recommended by the NCCLS.
Authoritative reports indicate that an (approximately) 85% – 100% correlation
exists between the accepted conventional MIC determinations and the MIC
determined by the Etest® procedure for a variety of organism-drug combinations
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15 The Etest® can be expensive; contact the manufacturer (AB BIODISK) to inquire about discounts available
for laboratories in resource-poor regions (see Appendix 13).
16 Antimicrobial susceptibility testing with an antimicrobial gradient strip such as the Etest® can be considered
to be a semi-quantitative method (because although the suspension used to inoculate a plate for Etest® is 
standardized, the inoculum itself is not standardized). However, results are generally comparable to 
quantitative results of standard broth microdilution or agar dilution MIC tests.
(see, e.g., Jorgensen et al. [1994] and Barry et al. [1996] in Appendix 15). Some
studies have cited Etest® MICs as approximately one dilution higher than MICs
determined by standard dilution methods.
Although this manual serves as a general guide to use of the Etest® antimicrobial
gradient strip, always follow the manufacturer’s directions for use of the Etest®,
as certain antibiotic-bacteria (“drug-bug”) combinations have special testing
requirements. For example, macrolides (e.g., azithromycin, erythromycin) should
be tested in a normal atmosphere, not with CO2.
Methods for performing antimicrobial susceptibility testing of S. pneumoniae
with the Etest®
The manufacturer of the Etest® indicates that when testing S. pneumoniae, the
Mueller-Hinton agar test medium can be supplemented with either sheep or horse
blood; however, it may be easier to interpret results on medium prepared with
sheep blood (except when testing susceptibility to trimethoprim-sulfamethoxazole,
in which case sheep blood should not be used as a supplement) [CDC,
unpublished data]. This laboratory manual therefore suggests that Mueller Hinton
agar with 5% sheep blood should be used when performing antimicrobial
susceptibility testing of S. pneumoniae with the Etest® (except when testing for
susceptibility to trimethoprim-sulfamethoxazole, in which case horse blood
should be used in place of sheep blood). Either 150-mm or 100-mm plates can be
used, depending on the number of Etests® used per sample (Figure 7). Two
different Etest® antimicrobial strips can be placed in opposite gradient directions
on a 100-mm plate, and note that although the manufacturer states that up to six
Etest® strips can be used on a 150-mm plate, this laboratory manual suggests that
in order to avoid overlapping zones of inhibition of growth, not more than five
Etest® strips be used on a 150-mm plate.
a) Suspend viable colonies from an overnight blood agar plate into a broth tube to
achieve a bacterial suspension equivalent to a 0.5 McFarland turbidity standard;
be careful not to form froth or bubbles in the suspension when mixing the cells.
This suspension should be used within 15 minutes.
b) Dip a cotton swab into the bacterial suspension. Press the swab on the side of
the tube to drain excess fluid. Inoculate the entire surface of the agar plate three
times with the same swab of inoculum, rotating the plate 60 degrees after each
inoculation to ensure confluent growth of the bacteria (Figure 34). Use a single
swab of inoculum, and do not return the swab to the broth after each rotation.
c) Allow the plate to dry for up to 15 minutes. Be sure the plate is entirely dry
before proceeding. While the plate is drying, remove the Etest® strips from the
-20˚C freezer, and allow the strips that will be used in the batch of testing to
warm to room temperature. Return the strips that will not be used in this batch
of testing to the -20˚C freezer.
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d) Place the Etest® strips onto the dried, inoculated agar plate with an Etest®
applicator or sterile forceps (Figure 7.) Make sure that the printed MIC values
are facing upward (i.e., that the bottom surface of the strip containing the
antimicrobial gradient is in contact with the agar.) Once applied, do not move
the antimicrobial gradient strips.
e) Incubate the plates in an inverted position in a CO2-enriched atmosphere
(2%–5% CO2) for 20–24 hours at 35˚C. A candle-extinction jar may be used if
a CO2 incubator is not available.
• Always follow the manufacturer’s instructions included with each package of
strips, because incubation conditions may vary by organism-antimicrobial
(or “drug-bug”) combination.
f) After incubation, there will be an ellipse of bacterial growth will have formed
on the plate around the strip and the Etest® can be read. It is important to
review quality control results before reading and interpreting the Etest® MIC.
MICs are read from the intersection of the ellipse-formed zone of inhibition with
the value printed on the Etest® strip. Use oblique light to carefully examine the end-
point. A magnifying glass may be used if needed. Read at the point of complete
inhibition of all growth including hazes and isolated colonies. Figure 8 presents a
reading guide for the Etest®,17 and shows drug-related effects, technical and
handling effects, organism-related effects and resistance-mechanism-related effects.
• The graduation marks on the Etest® strip correspond to the standard
concentrations for the agar dilution method, but the marks also represent
increments between those standard values. The standard values (Table 27 in
Appendix 7) are used for interpretation and reporting of antimicrobial
susceptibility test results. It is advised that if the MIC appears to be an inter-
dilutional value, both the actual reading of the value from the strip and the
next-higher standard value (i.e., the value to be used for interpretation) be
included in the laboratory records for testing of the strain. For example, if
testing susceptibility of a S. pneumoniae isolate to penicillin, an MIC recorded
from the graduations on the Etest® strip might be 0.094 µg/ml; however, the
reported MIC would be 0.125µg/ml, and the organism would be interpreted as
being intermediate to penicillin.
Breakpoints follow the NCCLS guidelines, unless exceptions made by the
manufacturer are provided in the package insert. NCCLS breakpoints for 
S. pneumoniae–antimicrobial combinations are included in Table 5.
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17 AB Biodisk also maintains a website with an Etest® reading guide: http://www.abbiodisk.com.
Surveillance for emerging pneumococcal resistance
Laboratories may wish to help detect the emergence of new strains of pathogens by
testing isolates against a panel of drugs in which reduced susceptibility is not
expected to be found. This could be done, for example, on a sampling of preserved
isolates in storage on an annual basis. Methods for preservation and long-term
storage of isolates can be found in Appendix 11.
Antimicrobials of interest could include (but are not necessarily limited to):
tetracycline, erythromycin, clindamycin, rifampin, ceftriaxone, amoxicillin,
ciprofloxacin and vancomycin. Appropriate zone sizes can be found in NCCLS
documents, which are updated regularly. Laboratorians should notify a reference
laboratory of any isolates observed to have rare characteristics of non-
susceptibility; for example, as of early 2002, no pneumococcus has exhibited
decreased susceptibility to vancomycin [NCCLS 2002]. A list of international
reference laboratories is included in Appendix 14.
Data for decision-making
Once the laboratory has antimicrobial susceptibility patterns of S. pneumoniae
isolates, the information should be reported promptly to public health officials.
Factors to consider in the development of a treatment policy include:
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be available locally (or be able to be
obtained quickly).
Consideration of such factors when making data-based decisions will help public
health officials meet needs in a manner appropriate to the local situation and 
the specific antimicrobial susceptibility profile. National recommendations for
empiric antibiotic utilization should be developed after considering antimicrobial
susceptibility data, cost, availability, convenience, and other factors. Information 
on pneumococcal antimicrobial resistance, together with data on the major
pneumococcal serotypes responsible for disease, may become increasingly valuable
to public health officials in the future, as new formulations of multivalent
pneumococcal conjugate vaccines become available for global use.18
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N eisseria gonorrhoeae, also commonly referred to as “gonococcus” or “GC”,causes an estimated 62 million cases of gonorrhea worldwide each year[Gerbase et al., 1998]. Spread by sexual intercourse, N. gonorrhoeae may
infect the mucosal surfaces of urogenital sites (cervix, urethra, rectum) and the
oro- and nasopharynx (throat), causing symptomatic or asymptomatic infections.
GC is always pathogenic and, if untreated, gonorrhea is a major cause of pelvic
inflammatory disease (PID), tubal infertility, ectopic pregnancy, chronic pelvic
pain and/or disseminated gonococcal infection (DGI). The probability of co-
infection with other sexually transmitted infections (STIs) may be high in some
patient populations. Neonates may acquire gonococcal infection of the conjunctiva
during birth. The diagnosis of gonorrhea in older infants and young children is
often associated with allegations of sexual abuse; transmission through neither
nonsexual human nor fomite contact has been documented. Epidemiological
studies provide strong evidence that gonococcal infections facilitate HIV
transmission [Fleming and Wasserheit 1999]. Extended-spectrum cephalosporins,
fluoroquinolones and spectinomycin are recognized as the most effective
antibiotics for the treatment of gonorrhea in most areas of the world.
Antimicrobial resistance in N. gonorrhoeae is the most significant challenge to
controlling gonorrhea. Gonococcal strains may be resistant to penicillins,
tetracyclines, spectinomycin, and, recently, resistance to the fluoroquinolones
(ciprofloxacin and ofloxacin) and the macrolide azithromycin has emerged
[Handsfield 1994; Knapp et al. 1997; Young et al. 1997; CDC 1999]. Resistance to
the penicillins and tetracyclines is conferred by chromosomal and/or plasmid-
mediated mechanisms. Resistance to spectinomycin, fluoroquinolones and
azithromycin is chromosomally mediated, and certain types of chromosomal
mutations may contribute to resistance to several classes of antibiotics
simultaneously.
Neisseria gonorrhoeae
CONFIRMATORY IDENTIFICATION AND 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
CHAPTER VI
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Agents used for the treatment of bacterial infections, including co-infecting STIs,
may select for resistance in N. gonorrhoeae. For example, whereas a 1-gram dose 
of azithromycin is sufficient for treatment of infections with C. trachomatis and 
H. ducreyi, this dose is sub-optimal for the treatment of N. gonorrhoeae and may
result in the incidental selection and spread of resistant gonococcal strains.
At the time of writing of this manual (2002), the broad-spectrum cephalosporins
(ceftriaxone, cefixime, etc.) are the only class of antimicrobial agents to which
gonococci have not developed confirmed resistance, although a few isolated strains
have exhibited decreased susceptibility to cefixime [CDC 2000; Wang 2002].
It is of great importance to perform laboratory surveillance of antimicrobial
resistance in N. gonorrhoeae in order to assess the effectiveness of locally
recommended therapies. Only measurement of the in vitro susceptibilities of the
infecting organism will provide objective information to help determine if a post-
treatment isolate is truly resistant to the antimicrobial agent being used to treat the
infection, as opposed to infection which fails to respond to treatment due to
inadequate absorption of the agent, non-compliance with therapy, or re-exposure.
At the population level, surveillance is key for the monitoring of local, regional and
international trends in antimicrobial resistance, which can help inform and shape
public health policy. Comparison between antimicrobial susceptibilities of
gonococci isolated in different geographical areas provides information about 
the distribution and temporal spread of resistant isolates. Thus, changes in
recommended antimicrobial therapies can be anticipated, and surveillance can be
enhanced to guide timely changes in these therapies at the local level.
Presumptive identification of N. gonorrhoeae
After the specimen has been collected from the patient, it should be labeled with a
unique identifier assigned in tandem with the demographic and clinical
information so it can be linked for epidemiological studies. Methods for streaking
for isolation from specimen swabs, primary culture methodology, and isolate
storage and transport are included in Appendices 8, 11 and 12.
Because N. gonorrhoeae is highly susceptible to adverse environmental conditions
(as described in Table 28 of Appendix 8), strains must always be incubated at
35˚–36.5˚C in a humid, CO2-enriched atmosphere. Subculture colonies that appear
to be gonococcal (gram-negative diplococci growing in pinkish-brown colonies 0.5
– 1 mm in diameter, see Appendix 8) from the primary selective medium to a non-
selective medium, such as GC-chocolate agar with 1% defined supplement, to
obtain a pure culture of the isolate. (Specimens from normally sterile sites, such as
the conjunctiva, are cultured on nonselective medium for primary isolation;
subculture for purity if examination of the plate shows evidence of contaminants.)
If the subcultured isolate is not pure, continue to perform serial subcultures of
individual colonies of gram-negative diplococci until a pure culture is obtained.
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A presumptive diagnosis of N. gonorrhoeae originally isolated on selective medium
can be made based upon colonial morphology, the observation of typical (gram-
negative) diplococci in pairs, tetrads or clusters upon Gram stain or simple single
stain with Loeffler’s methylene blue, and a positive oxidase reaction. A presumptive
diagnosis of N. gonorrhoeae originally isolated on nonselective medium can be
made based upon these characteristics plus an appropriate reaction in at least one
supplemental biochemical or enzymatic test (e.g., superoxol 4+ reaction, see
‘Supplemental Tests’). A flowchart of tests required for presumptive identification
of isolates from sites with normal flora (i.e., isolated on selective media such as
MTM, ML, or GC-Lect) and isolates from normally sterile sites (i.e., isolated on
nonselective medium, such as GC-chocolate agar) is presented in Figure 19.
Oxidase test
The oxidase test uses Kovac’s reagent (a 1% (wt/vol) solution of N, N, N’, N’
–tetramethyl-ρ-phenylenediamine dihydrochloride)18 to detect the presence of
cytochrome c in a bacterial organism’s respiratory chain; if the oxidase reagent is
catalyzed, it turns purple. Neisseria species give a positive oxidase reaction, and
gram-negative oxidase-positive diplococci isolated on gonococcal selective media
may be identified presumptively as N. gonorrhoeae. Preparation of oxidase reagent
and appropriate quality control methods are included in Appendix 2.
Perform an oxidase test on growth of representative colonies that stained as (gram-
negative) diplococci. Because the oxidase reagent is toxic for bacteria, it is
recommended to perform the oxidase test on a sterile swab and not directly on the
culture plate, particularly if there are only a few suspect colonies. Alternatively, one
can use filter paper in place of a swab for this test. Do not perform the oxidase
test with a Nichrome loop, as it may produce a false-positive reaction. If a sterile
swab was used to make a smear for the Gram stain (as described in Appendix 4),
the swab can then be used to conduct the oxidase test. The oxidase test should only
be performed on freshly grown (18–24 hour) organisms.
• Swab method for Kovac’s oxidase test
a) Select suspect colonies from the culture plate (selective or nonselective
medium) with the swab.
b) Use a Pasteur pipette to add one drop of oxidase reagent to the swab.
c) If the isolate is N. gonorrhoeae, a positive (purple) reaction should occur
within 10 seconds.18 (See Figure 20).
18 Some laboratories may use a different reagent, Gordon and MacLeod’s reagent, (1% [wt/vol] dimethyl-ρ-
phenylenediamene dihydrocholoride; “dimethyl reagent”) to perform the oxidase test. The dimethyl reagent 
is more stable than the tetramethyl reagent (Kovac’s reagent), but the reaction with the dimethyl reagent is
slower than that with the tetramethyl reagent. If the laboratory is using the dimethyl- reagent, a positive 
reaction will be indicated by a color change to blue on the filter paper (not purple, as with the tetramethyl
reagent), and with the dimethyl reagent it will take 10 – 30 minutes for a positive reaction to develop.
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oxidase-positive
= suspect N. gonorrhoeae
FIGURE 19: Flowchart for isolation and presumptive identification of Neisseria gonorrhoeae
Colonies on selective media (e.g., Martin-Lewis
[ML] or Modified Thayer-Martin [MTM]) are 
pinkish-brown and translucent, with smooth 
consistency and defined margins, and are typically
0.5 – 1.0 mm in diameter.*
Colonies on GC-chocolate agar are 
pinkish-brown and translucent, exhibit
smooth consistency and defined margins,





(e.g., urethra, cervix, vagina, rectum, and pharynx)
* If a presumptive isolate exhibits unusual characteristics 
upon antimicrobial susceptibility testing, confirm the 
identification with biochemical and enzymatic tests.
Antimicrobial susceptibility testing on 
GC-susceptibility test medium
* Fastidious strains of N. gonorrhoeae may produce





* Fastidious strains of N. gonorrhoeae may produce





= suspect N. gonorrhoeae
oxidase negative 
= negative
• An isolate from selective medium (MTM, ML) 
is considered ‘presumptive GC’ when it is an 
oxidase-positive, (gram-negative) diplococcus.
• An isolate from nonselective medium can be
considered presumptive GC when it is an 
oxidase-positive, (gram-negative) diplococcus
and gives an appropriate reaction in at least one
supplemental test (e.g., superoxol 4+ reaction).
Note: it is acceptable practice to perform 
antimicrobial susceptibility testing on presumptive
isolates of N. gonorrhoeae (GC) for treatment 
purposes.*  
Oxidase test
Reactions typical of N. gonorrhoeae
in supplemental tests:
Superoxol/Catalase: positive








Gram stain or simple single stain
(e.g., Loeffler’s methylene blue stain)
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• Moistened filter paper method for Kovac’s oxidase test
a) Place a piece of filter paper in a petri dish.
b) Just prior to performing the test, add one to two drops of oxidase reagent to
the filter paper and allow it to absorb; the filter paper should be moist, but
not wet, after the reagent has been absorbed.
c) Using a platinum loop, a plastic loop, a sterile swab or a wooden applicator
stick, pick a portion of the colony to be tested and rub it onto the moistened
filter paper. (Do not use a Nichrome loop.) If the isolate is N. gonorrhoeae, a
positive (purple) reaction should occur within 10 seconds.18 (See Figure 10.)
Confirmatory identification of N. gonorrhoeae
If a laboratory is reporting results back to the clinical setting for treatment
purposes, a presumptive diagnosis based on Gram stain and oxidase reaction is
sufficient for colonies isolated on GC-selective media, and the laboratorian can
continue with antimicrobial susceptibility testing of a pure culture of the isolate
(presented later in this chapter). If, however, the diagnosis must be confirmed or 
a presumptive isolate exhibits unusual characteristics upon antimicrobial
susceptibility testing (e.g, for ceftriaxone, a minimal inhibitory concentration
(MIC) >0.25µg/ml, or equivalent inhibition zone diameter <35mm), the
laboratorian should perform biochemical and enzymatic tests of pure culture to
confirm the identification of the isolate. It is worth noting, for example, that
FIGURE 20: Kovac’s oxidase test: a positive reaction on a swab
The right-hand picture shows a positive reaction on a swab that was used to harvest suspect growth and was then 
moistened with Kovac’s oxidase reagent. The left-hand picture shows a positive oxidase direct-plate test result with 
Kovac’s oxidase. Note that if growth is sparse, it is suggested that a laboratory not use the direct-plate testing method
because it is toxic to gonococcal growth.
because men who have sex with men (referred to in literature as “MSM”) have
higher rates of non-gonococcal neisserial infections in the urethra than do other
populations, the epidemiology could lead a clinician to request a confirmed
diagnosis. Another example of a situation where the diagnosis requires definitive
confirmation would be a case of suspected sexual abuse; the discussion of the
related social, medical and legal issues with which a laboratory could be involved
goes beyond the scope of this laboratory manual.19
Figure 21 shows one pathway by which diagnosis might be confirmed with
biochemical and enzymatic tests. This laboratory manual will present methods to
perform tests for a reaction to superoxol reagent (or catalase reagent), colistin
resistance, the production of polysaccharide from sucrose, detection of acid
production with a commercial test, detection of enzyme production by a
chromogenic substrate in a commercial test, and nitrate reduction. Table 6
provides a listing of reactions to a variety of tests performed on non-gonococcal
species which may be mistakenly identified as N. gonorrhoeae based on reactions
only with the acid production or enzyme substrate tests. The table includes a blank
row so it may be copied and used as a sample worksheet in which to record results
of confirmatory tests.
Laboratorians wishing to learn more about the concepts behind the biochemical
and enzyme substrate test reactions presented here, or seeking information about
other tests and methodologies in more detail, can refer to the American Society of
Microbiology’s Manual of Clinical Microbiology, or, for example, to the CDC
website for clinical diagnosis of gonorrhea (http://www.cdc.gov/ncidod/dastlr/ 
gcdir/gono.html).
Biochemical and enzyme substrate supplemental tests
Species of three genera—Neisseria, Kingella, and Moraxella (Branhamella)—must
be considered when examining clinical specimens or cultures for N. gonorrhoeae.
Neisseria species (except N. elongata and N. weaveri) and M. catarrhalis are gram-
negative diplococci and, in stained smears, resemble N. gonorrhoeae, exhibiting
kidney bean- or coffee bean-shaped diplococci with adjacent sides flattened. It
should be noted that is not unusual to isolate N. meningitidis from urethral
specimens from men who have sex with men or to isolate N. lactamica from the
throats of young children. Kingella denitrificans and Moraxella species are
coccobacilli, but cells of some strains may occur as pairs and look like diplococci 
in smears. Thus, all of these species must be considered when identifying gram-
negative diplococci in clinical specimens. Characteristics that differentiate among
these genera and species are presented in Appendix 8 and Table 6. A sample listing
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19 The Centers for Disease Control and Prevention (CDC) maintains a website that includes information
regarding social, medical and legal issues surrounding the diagnosis of gonorrhea and with which a public






Gram stain or simple single stain 
(e.g., Loeffler’s methylene blue stain)
Superoxol test
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FIGURE 21: Flowchart exhibiting one algorithm for confirmatory identification of Neisseria gonorrhoeae




Prepare inocula from pure cultures of gram-negative, oxidase-positive diplococci 
isolated from selective medium (e.g., MTM) and grown on non-selective medium
















Colistin resistance Nitrate-reduction test
4+ “explosive” superoxol reaction + colistin-resistance +
nitrate-negative + glucose-positive + maltose-negative
= confirmed N. gonorrhoeae
Colistin-resistant and 
nitrate-negative
Note: if resources are available, several confirmatory tests may be run concurrently, rather than waiting for results from each test
before continuing.














































































































































































































































































































































































































































































































































































































































































































































































































































































































of quality control strains for the supplemental tests described in this manual for
the identification of N. gonorrhoeae is included in Table 7.
In a reference laboratory setting, the tests described below are best performed
concurrently since they all require an inoculum prepared from fresh (18–24 hour)
growth. However, when resources are limited, laboratorians may choose to screen
isolates with a subset of these tests to detect isolates resembling N. gonorrhoeae
prior to further testing. Sequential testing practices can conserve resources by
limiting the use of more costly commercial tests (e.g., acid production or enzyme
substrate) to only those isolates resistant to colistin and exhibiting a strong
superoxol reaction. When choosing the screening approach, it is important to
remember that tests performed on successive days will require a fresh (18–24 hour)
subculture of the isolate.
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Test Positive control Negative control
Superoxol (or Catalase) test N. gonorrhoeae ATCC 49226 [4+] K. denitrificans ATCC 33394
N. cinerea ATCC 14685 [weak, 2+] (no reaction in superoxol)
(positive reaction in superoxol)
Colistin resistance test N. gonorrhoeae ATCC 49226 N. cinerea ATCC 14685
K. denitrificans ATCC 33394 N. mucosa ATCC 19696
(resistant to colistin) (susceptible to colistin)
Polysaccharide N. polysaccharea ATCC 43768 N. gonorrhoeae ATCC 49226
production test N. mucosa ATCC 19696 N. cinerea ATCC 14685
(produce polysaccharide) (do not produce polysaccharide)
Nitrate reduction test K. denitrificans ATCC 33394 N. gonorrhoeae ATCC 49226
N. mucosa ATCC 19696 N. cinerea ATCC 14685
(able to reduce nitrate) (unable to reduce nitrate)
Acid production test Use the QC strains recommended by the test manufacturer* plus N. cinerea.
* If the manufacturer has not designated specific strains for QC:
•  N. gonorrhoeae (ATCC 49226) produces acid from glucose
•  N. meningitidis (ATCC 13077) produces acid from glucose and maltose
•  N. lactamica (ATCC 23970) produces acid from glucose, maltose, and lactose
• N. mucosa (ATCC 19696) produces acid from glucose, maltose, and sucrose
•  N. cinerea (ATCC 14685) glucose negative, but may produce a weak glucose 
reaction; does not produce acid from the other sugars.
Enzyme substrate test Use the QC strains recommended by the test manufacturer.*
* If the manufacturer has not designated specific strains for QC:
•  N. gonorrhoeae (ATCC 49226) produces hydroxyprolylaminopeptidase.
•  N. meningitidis (ATCC 13077) produces γ-glutamylaminopeptidase.
•  N. lactamica (ATCC 23970) produces ß-galactosidase.
•  M. catarrhalis (ATCC 25238) produces none of these enzymes.
Note: Laboratorians should follow QC strain designations provided by manufacturers of (commercial) tests; however, if specific 
strain numbers are not provided, those included in this table can be used for guidance.
TABLE 7: Examples of quality control (QC) strains for supplemental tests used to identify Neisseria gonorrhoeae
Superoxol / Catalase
The superoxol test is a simple test that uses 30% hydrogen peroxide (H2O2) as a
reagent. Reactions of superoxol with N. gonorrhoeae are typically “explosive” (4+,
very strong), compared with weaker (2+) reactions with most non-gonococcal
Neisseria species, and a negative reaction with K. denitrificans. In contrast, the
catalase test is performed with 3% hydrogen peroxide and yields much weaker
results. This laboratory manual suggests performing the superoxol test (30%
H2O2) if the reagent is available. This is because results with the superoxol 
reagent are more differential for N. gonorrhoeae than those obtained with the
catalase reagent.
a) Using a sterile inoculating loop or swab, remove some 18–24 hour growth from
a pure culture on either selective or non-selective medium, and put it on a clean
slide.20
b) Using an eye-dropper or a pipette, place a drop of reagent onto the growth.
c) N. gonorrhoeae typically has a very strong (4+), “explosive” reaction to contact
with superoxol reagent, as pictured in Figure 22. Catalase will give a much
weaker (1+ or 2+) reaction.
d) Follow steps a and b to perform the superoxol/catalase test on positive and
negative QC strains. (Examples of QC strains are included in Table 7.)
It should be noted that some strains of N. meningitidis and M. catarrhalis will 
have a strong superoxol reaction that is not ‘explosive’ upon the addition of the
hydrogen peroxide but can appear as such to an eye unfamiliar with the
characteristic reaction of N. gonorrhoeae. This test, therefore, is not definitive 
for N. gonorrhoeae, although it remains differential.
Colistin resistance
Resistance to colistin can be determined either on a selective medium containing
colistin (e.g., MTM or ML), or on GC-chocolate agar using the principles of disk
diffusion (with a 10 µg colistin disk). A disk diffusion method for qualitative
measurement of colistin resistance is presented here.
a) Turn a plate of medium so that it is lid-down on a table. Use a waterproof
marker to divide the plate into labeled sectors for the test strain(s), the positive
control and the negative control. Examples of QC strains are included in 
Table 7.
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20 The superoxol / catalase tests can be performed directly on a plate. However, it should be noted that 
hydrogen peroxide reacts with red blood cells, although reactions have not been noted on GC-chocolate agar.
If the test is to be performed on an agar plate, place a drop of the reagent on the surface of an uninoculated
plate of the medium (or an area of the test plate that does not contain growth) to ensure that no reaction
occurs with medium and reagent alone; if a reaction does occur, the test must be performed on a slide 
(or in a petri dish).
K. denitrificans
GC chocolate agar Slide
K. denitrificans exhibits
a negative reaction in
superoxol reagent .
(30% H2O2).
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FIGURE 22: Positive and negative reactions in superoxol (30% H2O2) and catalase (3% H2O2) reagents
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N. gonorrhoeae
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GC chocolate agar Slide
Catalase reagent (3% H2O2)
N. gonorrhoeae
exhibits a 4+ reaction 
in catalase reagent
(3% H2O2).
• A 100-mm plate can be divided into four sectors, permitting testing of two
clinical strains alongside the positive and negative controls. If there are
multiple clinical strains requiring the colistin resistance test at once, and the
colistin disks are from the same batch, it is appropriate to run the positive
and negative controls on only one plate.
b) Prepare a suspension of a pure overnight culture (approximately equal to a 0.5
McFarland turbidity standard) in Mueller-Hinton broth or phosphate buffered
saline (PBS).
c) Using a sterile swab or inoculating loop, inoculate the GC-chocolate agar plate
evenly with a swab. Allow the plate to dry so that there is no visible surface
moisture.
d) Apply a colistin disk (10 µg) to the center of the plate, tapping it down to
ensure even contact with the surface. Incubate at 35˚–36.5˚C in 5% CO2 and
increased humidity for 18–24 hours.
After incubation, examine the plate for inhibition of growth around the colistin
disk. N. gonorrhoeae is colistin-resistant, and will grow all the way up to the disk,
as will all strains of N. meningitidis, N. lactamica and K. denitrificans. In contrast,
strains of commensal Neisseria species, most of which are colistin-susceptible, will
exhibit zones of inhibition at least 10 mm in diameter with a non-standardized
inoculum. Some strains of N. subflava biovars, N. cinerea, and M. catarrhalis may
be sufficiently resistant to colistin so as to also grow up to the disk. Thus, the
colistin resistance test is not definitive for N. gonorrhoeae but will aid in
differentiating between this species and many commensal species.
Polysaccharide production test
Some species produce a starch-like polysaccharide when grown on a medium
containing sucrose. Upon addition of a drop of Gram’s iodine to the growth,
this starch will immediately stain dark blue-purple to brown or black. This test is
easy to perform and is a useful differential test to be used in combination with
others (e.g., superoxol, colistin resistance, acid production) in the identification of
N. gonorrhoeae. It is not possible to detect polysaccharide in the sucrose-
containing medium of rapid acid-detection tests. The methods for preparation of
the medium appropriate for this test (tryptone-based soy agar [TSA] containing
1% sucrose) can be found in Appendix 2.
a) Turn a plate of sucrose medium so that it is lid-down on a table. Use a
waterproof marker to divide the plate into labeled sectors for the test strain(s),
the positive control and the negative control. (Examples of QC strains are
included in Table 7.)
• A 100-mm plate can be divided into four sectors, permitting testing of two
clinical strains alongside the positive and negative controls. If there are
multiple clinical strains requiring the polysaccharide test at once, and the
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plates of medium are from the same batch, it is appropriate to run the
positive and negative controls on only one plate.
b) Use a sterile swab or loop to inoculate the polysaccharide test medium with
pure culture.
• Although this test is best performed on isolated colonies, because 
N. gonorrhoeae and strains of some other species do not grow well on 
this medium, the plate should be inoculated heavily for confluent growth 
so that the test can detect starch produced by pre-formed enzyme in the
inoculum itself.
c) Incubate medium at 35˚–36.5˚C in a CO2-enriched, humid atmosphere for
18–24 hours.
• It is important that this test be performed on growth no more than 24
hours old. This is because on prolonged incubation the organisms may
metabolize the polysaccharide, thus resulting in a false-negative reaction.
d) Use a Pasteur pipette, eyedropper, or inoculating loop to add one drop of
Gram’s iodine to growth on the plate. Isolates that produce polysaccharide will
immediately turn a dark color (brown, purple, black), as shown in Figure 23.
• If the growth immediately changes color with the addition of Gram’s 
iodine, the strain is considered “polysaccharide-positive.” Examples of
polysaccharide-positive organisms include N. polysaccharea, N. mucosa,
N. sicca, and N. flavescens.
• If the growth does not change color (other than acquiring the light-brown
color of the iodine reagent), the reaction is negative, and the strain is 
considered “polysaccharide-negative.” N. gonorrhoeae is polysaccharide-
negative, as are, e.g., K. denitrificans, M. catarrhalis, N. cinerea, N. lactamica,
and N. meningitidis.
Quality control should be performed with each new batch of sucrose medium or
reagent. This is particularly important because some commercial preparations
of Gram’s iodine will not react with the starch, yielding false-negative results.
Examples of controls for the polysaccharide-production test are listed in Table 7.
Acid production test
As of the time of writing of this laboratory manual (2002), it is no longer advised
that cystine trypticase agar (CTA) containing glucose, maltose, lactose or sucrose
be used for acid production tests for N. gonorrhoeae. The rationale for this shift
in procedure is because many strains of N. gonorrhoeae produce very little acid
from glucose and the color change is not observed in the CTA-sugar media, thus
yielding incorrect identifications.
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FIGURE 23: Positive and negative results of the polysaccharide-production test on sucrose medium
Organisms able to produce polysaccharide from sucrose turn a brown to blue-black color with the addition of Gram’s iodine
to growth on sucrose medium and are termed “polysaccharide-positive.”
Organisms unable to produce polysaccharide from sucrose do not undergo a color change with the addition of Gram’s iodine
to growth on sucrose medium and are termed “polysaccharide-negative.”
(Note: polysaccharide-negative colonies may acquire the light brown-yellow color of the iodine reagent.)
Polysaccharide negative N. gonorrhoeae
Polysaccharide  postitive N. polysaccharea
Because CTA-sugar media can exhibit misleading results for some strains of N.
gonorrhoeae, as described above, this laboratory manual advises that, if available, a
commercial test be used if it is necessary to detect acid production to confirm the
identification of an isolate as N. gonorrhoeae. Perform the test according to the
manufacturer’s instructions and using the manufacturer’s recommendations for
quality control; note that incubation of the acid production test must occur in an
atmosphere without supplemental CO2 in order to avoid false-positive results. It 
is important that the test chosen to detect acid production be able to differentiate
between N. gonorrhoeae and N. cinerea and M. catarrhalis. Reaction patterns of
various Neisseria species in the acid production test are illustrated in Figure 24.
Many of the commercial acid production tests were developed to differentiate
among species that routinely grow on selective media for the gonococcus,
including N. gonorrhoeae, N. meningitidis, N. lactamica and M. catarrhalis.
However, interpretive criteria provided with the product (package insert) may 
not provide guidance for the identification of K. denitrificans, N. subflava biovars,
and N. cinerea strains, all of which may also grow on gonococcal selective media.
The laboratory will therefore want to ensure that the product can distinguish 
N. gonorrhoeae from these other species, or perform additional tests to allow the
correct identification of N. gonorrhoeae. Table 6 provides information to guide 
the choice of supplemental tests for the differentiation of N. gonorrhoeae from
other species.
It is suggested that a strain of N. cinerea be included among QC strains for the acid
production test (in addition to N. gonorrhoeae and others). Although N. cinerea is
considered to be glucose-negative and will be listed as such in tables of acid
production reactions, it does actually produce acid from glucose and then rapidly
over-oxidize it to produce CO2 and water; as a result, it may either appear negative
or give a weak positive glucose reaction (due to residual acid produced from the
glucose and not over-oxidized, and/or due to residual carbonic acid from the
production of CO2), and it is therefore useful to compare this reaction to that of
the N. gonorrhoeae control strain. In addition to N. cinerea, follow the quality
control instructions provided by the manufacturer of the commercial kit; if the
manufacturer has not provided specific QC strain designations, guidance for the
selection of appropriate QC strains is provided in Table 7.
Enzyme substrate test
The chromogenic enzyme substrate test detects enzymes (ß-galactosidase, γ-
glutamylaminopeptidase, and hydroxyprolylaminopeptidase), and is considered
“chromogenic” because color changes indicate the presence or absence of certain
enzymes in different Neisseria species. The test is commercially available and
should be performed according to the manufacturer’s directions. (Figure 25 in this
laboratory manual shows the Gonochek-II®.) Because most enzyme substrate tests
were developed to differentiate only among the organisms believed to grow on
media selective for N. gonorrhoeae, documentation provided with the product is
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FIGURE 24: Acid production commercial test kit results for Neisseria gonorrhoeae and related organisms
Note: Some strains of N. gonorrhoeae can present as glucose-negative because of weak acid reactions. For this 
reason and confirmatory purposes, it is recommended that the rapid test be supplemented with additional tests.
(Refer to Table 6 for supplementary tests and reactions.)
N. gonorrhoeae
produces acid only from glucose.
N. meningitidis
produces acid from glucose and maltose.
N. lactamica
produces acid from glucose, maltose, and lactose.
N. mucosa
produces acid from glucose, maltose, and sucrose.
N. cinerea
produces no acid.
C G M L S
C G M L S
C G M L S
C G M L S
C G M L S
C = Control G = Glucose M = Maltose L = Lactose S = Sucrose
usually limited to distinguishing between N. gonorrhoeae (which produces only
hydroxyprolylaminopeptidase), N. meningitidis (which produces γ-glutamyl-
aminopeptidase), N. lactamica (which produces ß-galactosidase), and 
M. catarrhalis (which produces none of these three enzymes). It is now known that
strains of several commensal Neisseria species can grow on selective GC media and
also produce only hydroxyprolylaminopeptidase. The chromogenic enzyme
substrate test is therefore not definitive for the identification of N. gonorrhoeae.
Table 6 provides information to guide the choice of supplemental tests for the
differentiation of N. gonorrhoeae from other species. Follow the quality control
instructions provided by the manufacturer of the commercial kit; if the
manufacturer has not provided specific QC strain designations, guidance for the
selection of appropriate QC strains is provided in Table 7.
Nitrate reduction test
The nitrate reduction test is available commercially or can be made easily in the
laboratory. This test distinguishes between species that can reduce nitrate (NO3) to
nitrite (NO2) or nitrogenous gases. In the context of this chapter, the test is useful
for differentiating between strains of N. gonorrhoeae (nitrate-negative) and K.
denitrificans or M. catarrhalis (two nitrate-positive species sometimes misidentified
as N. gonorrhoeae).
The nitrate reduction test uses a medium containing nitrate and three different
reagents: sulfanilic acid (“Nitrate Reagent A”), α-naphthylamine (“Nitrate Reagent
B”), and zinc powder (“Zn+2 dust”). Bacteria able to reduce nitrate from the
medium into either nitrite or into nitrogenous gases are “nitrate-positive,” while
bacteria that lack enzymes to reduce nitrate are “nitrate-negative.”
In practical terms, the nitrate reduction test centers around the colorimetric
detection of nitrite in the test medium. Nitrite forms a compound with sulfanilic
acid, which when reacted with α-naphthylamine gives a pink-to-red color
depending upon the concentration of nitrite in the medium; the addition of
Nitrate Reagents A and B is therefore only able to detect the presence of nitrite in
the medium. If a pink-red color is detected after the addition of Nitrate Reagents 
A and B, the organism is considered to be “nitrate-positive.” However, if there is no
color change in the medium after the addition of these reagents, it is necessary to
determine whether nitrate was ever reduced to nitrite, or whether the nitrite
produced was completely reduced to nitrogenous gases. This is accomplished by
using a small amount of zinc powder, which chemically catalyzes the reduction of
nitrate to nitrite and nitrite to nitrogenous gases. (It is therefore critical to use only
a very small amount of zinc powder so that if nitrate has not been reduced by
enzymes produced by the bacteria, the reaction catalyzed by the zinc powder is not
so strong as to reduce the nitrate completely to nitrogenous gases so rapidly that it
is not possible to detect the nitrite produced in the catalytic reaction in the
medium.) Nitrate-negative strains will exhibit a color change to red after
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incubation with zinc powder (nitrate is reduced to nitrite by the zinc powder, and
the nitrite is detected by Nitrate Reagents A and B already in the medium, yielding
a color change to pink-red). Nitrate-positive strains do not exhibit a color change
after incubation with zinc powder because nitrate in the medium will have already
been reduced beyond nitrite to nitrogenous gases. To summarize:
• Bacteria that reduce nitrate to nitrite may be identified when addition of
Nitrate Reagents A and B causes the medium to change color from clear to
pink-red; no additional testing with zinc powder is required. Results should be
recorded as “nitrate-positive.”
• Bacteria that reduce nitrate to nitrite and then further reduce the nitrite to
nitrogenous gases are identified when there is no color change in the medium
after either the addition of Nitrate Reagents A and B, or after incubation with
zinc powder. Results should be recorded as “nitrate-positive.”
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FIGURE 25: Reactions of Neisseria gonorrhoeae and related organisms in a commercial enzyme substrate test
The enzyme substrate test is a chromogenic test used to identify organisms that produce γ-glutamylaminopeptidase 
(indicated in this example of commercial test kit results as a color change to yellow), ß-galactosidase (indicated in this
example as a color change to blue), hydroxyprolylaminopeptidase (indicated in this example as a color change to red-pink),
and none of these enzymes (indicated by an absence of change of color in the cell suspension in the tube).
Test organism in
suspension
Color change to yellow
prior to exposure to 
substrate in red cap 
No color change
occurs prior to 
exposure to 
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(* Species which do not usually grow on selective media for  N. gonorrhoeae but may do so occasionally and give a positive
hydroxyprolylaminopeptidase reaction in an enzyme substrate test.)
• Bacteria unable to reduce nitrate at all are identified when there is no color
change with the addition of Nitrate Reagents A and B, but there is a color
change in the medium from clear to pink-red after incubation with zinc
powder. Results should be recorded as “nitrate-negative.”
The nitrate test is performed in a standard nitrate broth which is inoculated
heavily to give a dense suspension of organisms because many Neisseria species
may not grow in this medium; the reaction for these species will therefore depend
upon preformed enzymes in the inoculum. The test must be performed exactly as
described; if not performed correctly, the test results may be inaccurate and an
incorrect identification made. A schematic representation of the nitrate reduction
test is shown in Figure 26. Media and reagents required for this test are described
in Appendix 2.
Nitrate reduction occurs only under anaerobic conditions; it is therefore important
to ensure a low surface-area to depth ratio to limit the diffusion of oxygen into the
medium during the test. These conditions will be met by dispensing 5 ml of
medium into a 13 mm diameter screw-cap tube.
It is important to run a medium control and both negative- and positive- controls
as the test is complex and the controls have known outcomes to indicate if the
media and reagents are reacting appropriately. Quality control tests should be
performed each time clinical isolates are tested, using QC strains included in
Table 7.
Methods
a) Using colonies from a fresh, pure culture on GC-chocolate agar, prepare a heavy
suspension in nitrate broth.
b) Remove the screw-cap top from the tube of nitrate test medium and inoculate
the medium to give heavy turbidity. Replace the screw-cap top.
c) Incubate the inoculated tubes and an uninoculated medium control tube at
35˚–36.5˚C (without supplemental CO2) for 48 hours.
d) After incubation for 48 hours, remove the screw-cap top from the tube. Add 5
drops of Nitrate Reagent A to each tube (including the uninoculated control
medium). Shake each tube gently back and forth to mix Reagent A with the
medium, add 5 drops of Nitrate Reagent B to each tube (again including the
uninoculated control medium), and again shake each tube gently back and
forth to mix Reagent B with the medium.
• If the uninoculated control medium turns pink-red, the test is invalid, and
a new batch of media must be prepared.
• If the uninoculated control medium shows no color change, proceed to 
step e.
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e) Examine the test medium and controls for a pink-red color; this color should
develop within a few minutes if the medium is still warm. The reaction may
take a little longer if the medium has cooled before the reagents are added.
• The negative control medium should show no color change.
• The positive control medium may or may not exhibit a color change to 
pink-red, depending upon whether nitrate was reduced to nitrite or further
reduced to nitrogenous gases.
• If the test medium turns pink-red after the addition of Nitrate Reagents A
and B, the reaction is positive and the test is completed. If a pink-red color
develops, do not perform step f and record the reaction as nitrate-positive.
f) If the medium is still colorless after the addition of Nitrate Reagents A and B,
add a very small amount of zinc powder to the medium. (A convenient method
to estimate the amount of zinc powder required for the test is to use the sharp
point of a knife to pick up the powder; the pile of zinc powder should not
exceed 4–5 mg, or 2–3 mm in diameter.) Shake the tube vigorously back and
forth to mix well, and allow it to stand at room temperature for 10–15 minutes.
• If the negative control turns pink-red after the addition of zinc powder,
the amount of zinc added is sufficient for the reaction to occur (and not so
much as to cause rapid over-reduction of nitrate to nitrogenous gases).
Continue by interpreting the reactions in the test media.
• If the medium remains colorless after the addition of zinc powder, the test
result is positive (nitrate has been reduced to nitrite and further reduced to
nitrogenous gases). Record the result for the isolate as “nitrate-positive.”
• If the medium turns pink-red after the addition of zinc powder, the 
result is negative. Record the result for the isolate as “nitrate-negative.”
N. gonorrhoeae is nitrate-negative.
No identification of genus or species can be made on the basis of any of the above
biochemical and enzymatic tests alone, but performing a combination (e.g., as
presented in Figure 21) can lead to a definitive identification of N. gonorrhoeae.
Antimicrobial susceptibility testing of N. gonorrhoeae
The methods presented in this laboratory manual are those recommended by
NCCLS (an international, interdisciplinary, nonprofit, educational organization
that develops updated consensus standards and guidelines for the healthcare
community on an annual basis),21 although a variety of methods are used
internationally to determine antimicrobial susceptibilities of N. gonorrhoeae.
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21 Formerly known as the “National Committee for Clinical Laboratory Standards,” NCCLS is now known 
solely by its acronym.
These methodologies are currently (2002) being reviewed by the International
Collaboration on Gonococci (ICG), and it is possible that some modifications will
be made to the methods described in this document.22
Minimal inhibitory concentration (MIC) determination by the agar dilution
method is the reference method (“gold standard”) for determining the
antimicrobial susceptibilities of N. gonorrhoeae isolates. However, this method is
complex to perform, and so is beyond the scope of this manual.23 Antimicrobial
susceptibilities can also be determined by the disk diffusion test, or MICs can be
obtained with the Etest® (AB Biodisk). This document presents the methods for
antimicrobial susceptibility testing of N. gonorrhoeae with the antimicrobial agents
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FIGURE 26: Schematic representation of the nitrate reduction test
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Note: Each nitrate reduction test must have three controls: one positive, one negative, and one just medium.
As a result, four complete tests will need to be performed to interpret the result for one test isolate. The medium control
and negative control should each always yield a negative reaction; a positive control should always yield a positive reaction.
If these results do not occur, start the test over with a new suspension, new media, and new reagents.
N. gonorrhoeae is “nitrate-negative,” so if the pathway shows a nitrate-positive result and the controls are functioning
properly, the isolate is not a gonococcus.
22 International gonorrhea reference laboratories can provide additional information on ICG activities; contact
information for these laboratories is included in Appendix 14.
23 Laboratorians interested in learning more about agar dilution antimicrobial susceptibility test methods may
contact an ICG reference laboratory (Appendix 14).
Add zinc powder
(Zn Dust)
currently recommended by WHO for the primary therapy of gonorrhea:
ciprofloxacin, azithromycin, ceftriaxone, cefixime, and spectinomycin [WHO 2001].
Factors such as testing medium, inoculum size, incubation atmosphere, and
antimicrobial disk concentrations may affect the antimicrobial susceptibility values
obtained. Thus, quality control is of great importance and, with every test run,
laboratory personnel must include reference strains with known antimicrobial
susceptibilities to ensure that the susceptibility results for test isolates are accurate.
It should be noted that for methods that determine MICs, the MIC will be
accurate plus or minus (±) one dilution. For example, an organism with an MIC of
penicillin of 0.25 µg/ml may exhibit an MIC of 0.125 µg/ml to 0.5 µg/ml, but it
would be found upon repeated testing that most antimicrobial susceptibility values
(i.e., the modal MIC) for this organism and drug would be 0.25 µg/ml. Disk
diffusion results (i.e., inhibition zone diameters, mm) exhibit a similar normal
distribution upon repeated testing of the same isolates. It is important to keep
these variations of measurement in mind as laboratories typically perform only
one complete set of antimicrobial susceptibility tests per isolate, and not repeated
measures for the same antimicrobial agent unless there is a specific reason to do so,
such as confirming an unusual antimicrobial susceptibility result.
WHO has recommended a number of isolates for quality control (QC), although
these do not adequately represent the variety of resistance patterns now known to
exist for N. gonorrhoeae. Consequently, most international laboratories have
included additional QC strains exhibiting resistance and intermediate resistance to
fluoroquinolones and emerging resistance to azithromycin. Only one strain, N.
gonorrhoeae ATCC 49226, is designated by NCCLS for QC of antimicrobial
susceptibility testing of gonococcal isolates. At the Centers for Disease Control and
Prevention (CDC), the NCCLS-recommended QC strain and supplemental QC
strains are routinely made available to investigators (see Appendix 14 for contact
information). Strains of N. gonorrhoeae are currently being tested under ICG
sponsorship to establish an international reference panel for QC of antimicrobial
susceptibility testing that represents the known range of resistances in this species.
Once the susceptibility of a gonococcal strain to an antimicrobial agent has been
measured in vitro, the strain is then classified as susceptible, intermediate, or
resistant to each antimicrobial agent tested to indicate whether the infection may
either respond fail to respond to therapy with that agent. For clinical applications
(i.e., prescribing appropriate therapy for individual patients), antimicrobial
susceptibilities are always interpreted strictly according to standardized guidelines,
such as the NCCLS interpretive criteria. These criteria must be specific for the dose
of the agent used to treat the infection [Knapp et al. 1995]. For example, NCCLS
criteria for the interpretation of susceptibility of N. gonorrhoeae to ciprofloxacin
were developed to correspond to treatment with the recommended 500-mg of
ciprofloxacin in a single oral dose; assessment of treatment efficacy of a single oral
dose of 250-mg of ciprofloxacin would require the development of separate
interpretive criteria.
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Organism-antimicrobial-dose interactions are categorized into one of two levels of
classification based on the clinical efficacy of the antimicrobial agent. One level
applies to antimicrobial agents to which an organism has not yet developed
clinically significant resistance, and uses the categories “susceptible” and “decreased
susceptibility.” The second level is used when the organism has developed clinically
significant resistance resulting in failure of the infection to respond to therapy with
the recommended dose of the antimicrobial agent (“treatment failures”), and uses
the categories “susceptible”, “intermediate,” and “resistant.” For example:
• At the time of writing (2002), gonococcal infections have not been confirmed to
fail to respond to therapy with extended-spectrum cephalosporins, such as
cefixime (400-mg in a single oral dose). The NCCLS has established an
interpretive criterion of “susceptible” as an MIC of ≤ 0.25 mg/ml of cefixime
(corresponding disk diffusion zone of inhibition diameter with a 5-µg cefixime
disk, ≥ 31mm). Organisms with a higher MIC (or smaller inhibition zone
diameter) are classified as exhibiting “decreased susceptibility” to cefixime.
• When infections fail to respond to recommended therapies with specific
antimicrobial agents, a “resistant” category is established for that organism-
antimicrobial-dose combination by NCCLS. Breakpoints are set for in vitro
determination of this category based on testing of a variety of isolates resistant
to the recommended therapeutic treatment. For example, gonococcal infections
caused by organisms for which the ciprofloxacin MICs are ≥ 1.0 mg/ml
(corresponding disk diffusion zone diameter of inhibition with a 5 mg
ciprofloxacin disk, ≤ 27mm) have failed to respond to therapy with the WHO-
recommended single oral ciprofloxacin dose of 500-mg. NCCLS had previously
defined the “susceptible” breakpoint for ciprofloxacin as an MIC of ≤ 0.06
mg/ml (zone inhibition diameter ≥ 41 mm), so the “intermediate” designation
applies to those isolates for which the MICs are in the range between the
susceptible and resistant categories, i.e., 0.125 µg/ml – 0.5 µg/ml (28 mm – 
40 mm). For gonococcal infections, it should be noted that organisms in the
“intermediate” category for an antimicrobial agent have rarely been associated
with confirmed instances of treatment failure with that agent.
NCCLS interpretive criteria are designed to define antimicrobial susceptibility test
result categories when NCCLS methodology is used to perform the tests, as
presented in this laboratory manual.24 The additional QC reference strains
included in this laboratory manual for antimicrobial agents not currently included
in NCCLS guidelines have been validated by the Gonorrhea Research Branch
(Neisseria Reference Laboratory) at the CDC, and may be used alongside NCCLS
criteria with the methods presented here until an ICG-sponsored international QC
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24 NCCLS methods are presented in this document, and are strongly recommended. However, if a laboratory
uses different antimicrobial susceptibility testing methodologies for N. gonorrhoeae, and all quality control 
references are consistently in check with the NCCLS interpretive criteria for QC strain ATCC 49226, the 
laboratory may consider interpreting results for the alternate testing methodology according to the NCCLS
interpretive criteria.
reference panel is designated. Tables 9 and 10 provide summaries of QC ranges
and interpretive criteria for clinical isolates.25
In resource-limited geographic areas or in local clinical laboratories, antimicrobial
susceptibility test results should be determined for current antimicrobial
therapies and also the alternate antimicrobial agent(s) that would be used if
resistance emerged to the current regimen. Not all local laboratories will have the
capacity to perform antimicrobial susceptibility testing on isolates. National or
large regional laboratories acting in the capacity of a reference laboratory should
be able not only to provide assistance to local laboratories and health authorities
(clinical applications), but also to perform the most extensive susceptibility testing
to a broad range of antimicrobial agents in order to compare susceptibilities of
isolates at the regional, national and international levels (surveillance activities).26
In a local laboratory, if it is not feasible to perform prospective surveillance, the
laboratory should at least determine susceptibilities of post-treatment “treatment
failure” isolates which could either be truly resistant treatment failures or else
susceptible isolates acquired by re-infection. If a laboratory is unable to perform
antimicrobial susceptibility testing, isolates should be sent to a laboratory that can
perform such testing. (Methods for preservation and storage of isolates are
included in Appendix 11; transport of isolates is addressed in Appendix 12.) 
In addition to providing immediate assistance to local and regional laboratories
and public health authorities in efforts to control gonorrhea by determining
antimicrobial susceptibilities to the recommended therapies, reference laboratories
may want to conduct more extensive antimicrobial susceptibility testing in order to
develop a global perspective on antimicrobial resistance in N. gonorrhoeae.
Determination of antimicrobial susceptibilities to a wide range of agents—
penicillin, tetracycline, spectinomycin, extended-spectrum cephalosporins (e.g.,
ceftriaxone and cefixime), fluoroquinolones (e.g., ciprofloxacin, ofloxacin, and
levofloxacin), and the macrolide azithromycin—allows for the comparison of
isolates from the population served by the testing laboratory with isolates from
other regions.
Laboratory-based surveillance for antimicrobial resistance may be conducted at
one of two basic levels. When resources are limited, surveillance may be performed
for susceptibilities to antimicrobial agents being used for primary and secondary
therapy of gonorrhea, i.e., the primary agent being used to treat infections and the
alternative therapeutic agent(s) that would be used to treat infections not treated
effectively by the primary regimen. In this instance, antimicrobial susceptibilities
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25 If antimicrobial susceptibility test QC results for a locally developed testing method are consistent but do not
agree with those obtained by NCCLS-recommended methods, the testing laboratory may want to consult with
the ICG for assistance with the development of standard interpretive criteria appropriate to the situation.
26 Laboratorians interested in learning more about the methods used for the surveillance of antimicrobial
resistance in N. gonorrhoeae isolates can find links to various protocols through the following internet address:
http://www.cdc.gov/ncidod/dastlr/gcdir/gono.html 
would be interpreted by the standards used for clinical applications, e.g., by
NCCLS standards.
When investigators wish to compare the antimicrobial susceptibilities of N.
gonorrhoeae strains in their geographic locality with those in other geographic
areas, susceptibilities are usually determined to a larger number of antimicrobial
agents than those used locally for treatment. A typical panel might include the
following: penicillin, tetracycline, spectinomycin, an extended-spectrum
cephalosporin (e.g., ceftriaxone or cefixime), a fluoroquinolone (e.g., ciprofloxacin,
ofloxacin, or levofloxacin), and a macrolide (e.g., azithromycin). For broad
surveillance purposes, gonococcal isolates are described first by their
susceptibilities to penicillin and tetracycline (although these drugs should not be
used treat gonorrhea) and by a simple test to detect the production of ß-lactamase
(described below). This is because, based on the level of resistance to penicillin and
tetracycline and the detection of ß-lactamase, it is possible to predict whether the
mechanisms of resistance to penicillin and tetracycline are chromosomally
mediated or plasmid-mediated.
A specialized classification and terminology with standard acronyms has been
developed to describe patterns of penicillin-tetracycline resistance and designate
penicillin-tetracycline resistance phenotypes, as presented in Table 8. Organisms
that are ß-lactamase-negative and resistant to penicillin but not tetracycline, for
example, use the NCCLS designation “penicillin-resistant,” and are designated
“PenR.” Other acronyms do not use NCCLS designations in their names, although
NCCLS methods are used to identify the resistances. For example, “CMRNG”
(chromosomally mediated resistant N. gonorrhoeae) describes organisms that have
chromosomally mediated resistance to both penicillin (MIC ≥ 2.0 mg/ml, or
equivalent inhibition zone diameter ≤ 26 mm) and tetracycline (MIC ≥ 2.0 mg/ml,
or equivalent inhibition zone diameter ≤ 30 mm) and do not produce ß-lactamase.
It should be noted that while plasmid-mediated resistance to penicillin can be
detected and confirmed with a simple test to detect ß-lactamase, plasmid-mediated
resistance to tetracycline can only be identified presumptively with susceptibility
results and must be confirmed with a complex test demonstrating the presence of
the TetM-conjugative plasmid (e.g., by laboratories performing molecular
epidemiologic testing).
The basic penicillin-tetracycline resistance phenotype acronym characterizes
susceptibilities only of penicillin and tetracycline. For other therapeutic agents,
NCCLS (or equivalent) standardized criteria are used to classify susceptibilities to
these agents, and antimicrobial resistance (including “intermediate” or “decreased
susceptibility” categories) to these additional antimicrobial agents is appended to
the penicillin-tetracycline resistance phenotype. For example, a CMRNG isolate
exhibiting resistance to ciprofloxacin (CipR) would be cited as “CMRNG, CipR.”
Such descriptive designations permit one to rapidly appreciate the fact that
ciprofloxacin resistance is occurring in an organism already resistant to penicillin
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ß-lactamase results and specific MIC values associated 
Phenotype Phenotype definition with phenotype definitions for Neisserea gonorrhoeae a, b
Susceptible Isolates exhibiting either ß-lactamase negative isolate exhibiting:
susceptibility or intermediate • Susceptibility to penicillin [MIC < 2.0 µg/ml (>26 mm)]
resistance to both penicillin • Susceptibility to tetracycline [MIC < 2.0 µg/ml (>30 mm)]
and tetracycline
PPNG Penicillinase-producing ß-lactamase positive isolate. Approximately six ß-lactamase
Neisseria gonorrhoeae plasmids have been identified in N. gonorrhoeae, most 
commonly:
• “Asian” = 4.4 megadaltons (Mda) (7.2 kb)
• “African” = 3.2 Mda (5.3 kb)
• “Toronto” = 3.05 Mda (4.7 kb)
(PPNG is defined only by production of ß-lactamase and 
not by MICs of penicillin.) c
TRNG Tetracycline resistant ß-lactamase negative isolates possessing a TetM-containing
Neisseria gonorrhoeae conjugative plasmid. TRNG isolates will exhibit both:
• Susceptibility to penicillin [MIC < 2.0 µg/ml (>26 mm)]
• Resistance to tetracycline with MIC ≥ 16.0 µg/ml (≤20 mm)
Presumptive identification of this phenotype is based on MICs 
of penicillin and tetracycline. Confirmatory identification of 
TRNG (TetM and subtyping) is by PCR
PP/TR Penicillinase-producing, ß-lactamase positive isolates of N. gonorrhoeae exhibiting:
tetracycline resistant • Resistance to tetracycline with MIC ≥ 16.0 µg/ml (<20 mm)
Neisseria gonorrhoeae
PenR Chromosomally mediated ß-lactamase negative isolates exhibiting both:
resistance to penicillin • Resistance to penicillin with MIC ≥ 2.0 µg/ml (≤26 mm)
• Susceptibility to tetracycline [MIC < 2.0 µg/ml (>30 mm)]
TetR Chromosomally mediated ß-lactamase negative isolates exhibiting both:
resistance to tetracycline • Susceptibility to penicillin [MIC < 2.0 µg/ml (>26 mm)]
• Resistance to tetracycline with an MIC range of 
2.0 µg/ml - 8.0 µg/ml (20 – 30mm)
CMRNG Chromosomally mediated ß-lactamase negative isolates exhibiting both:
resistant Neisseria gonorrhoeae • Resistance to penicillin with MIC ≥ 2.0 µg/ml (≤26 mm)
• Resistance to tetracycline with MIC ≥ 2.0 µg/ml (≤30 mm)
a Note: Some TRNG may exhibit tetracycline MICs <16.0 µg/ml, and some TetR isolates may exhibit tetracycline MICs ≥16.0 µg/ml.
The difference between TRNG and TetR can only be confirmed by a test to determine the presence or absence of the 
TetM plasmid.
b Note: For some research purposes, a breakpoint of 1.0 µg/ml of penicillin and tetracycline is used to differentiate more 
equitably between (penicillin and tetracycline) susceptible isolates and isolates belonging to the CMRNG group of 
organisms [Rice and Knapp 1994].
c Note: For PPNG isolates, MICs for penicillin are typically high  (≥8.0 µg/ml) (≤20 mm); however, it is possible for them to be 
lower and have larger zones of inhibition as well. Some PPNG isolates have MICs as low as 0.25 µg/ml of penicillin but are still 
ß-lactamase positive.
TABLE 8: Phenotypic designations of Neisseria gonorrhoeae
and tetracycline. The use of penicillin-tetracycline resistance phenotypes also has
practical applications for monitoring susceptibilities to the extended-spectrum
cephalosporins: gonococcal isolates exhibiting chromosomally mediated, high
levels of resistance to penicillin (PenR) or penicillin and tetracycline (CMRNG)
exhibit higher—but still susceptible—MICs of ceftriaxone and cefixime.
Aggregation and analysis of phenotypic data permit investigators to monitor
changes in the prevalence of resistant strain populations and their geographic
patterns of spread, and these surveillance tools may be used to help anticipate the
need to revise treatment recommendations before resistance becomes endemic in a
region and undermines the effectiveness of local gonorrhea control measures.
Further characterization of resistant strains
An area of research in which reference laboratories may be interested in
participating is the further subtype characterization27 of isolates exhibiting the
same antimicrobial resistance phenotypes. Subtyping methods are resource-
intensive, however, and so it is not expected that every reference laboratory will be
able to adopt these techniques. Genotypic and phenotypic subtyping characterizes
individual strains and facilitates a refined interpretation of the antimicrobial
resistance data. By assigning strain subtype designations, investigators may be able
to differentiate between the strain types which are sporadically imported and
coincidentally exhibit the same resistance phenotype as a local strain. Strain
subtyping coupled with information about social-sexual networks may facilitate
proactive disease control interventions.
Methods for detecting antimicrobial resistance in N. gonorrhoeae
As detailed above, there are two different approaches taken when defining for what
antimicrobial agents susceptibility tests should be performed. When performing
antimicrobial susceptibility testing for clinical purposes, susceptibilities should be
determined to the antimicrobial agents currently used for treatment of gonorrhea
and the alternate antimicrobial agent(s) that would be prescribed if the primary
course were to be ineffective. When performing antimicrobial susceptibility testing
for surveillance purposes, however, the clinical testing is supplemented with an
expanded panel of antimicrobial agents in conjunction with ß-lactamase testing,
providing the laboratory with phenotypic data appropriate for international
comparisons.
Tests identifying gonococcal strains that produce ß-lactamase are used in
conjunction with MICs as an integral component of surveillance to differentiate
between chromosomally mediated and plasmid-mediated resistance to penicillin for
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27 Examples of phenotypic typing include auxotyping (determination of nutrients required for growth of a
strain), serotyping, ß-lactamase plasmid typing, and TetM plasmid typing. Examples of genotypic typing
include Lip subtyping, RFLP-related typing, and Opa typing.
N. gonorrhoeae, as explained above. The nitrocefin test is a qualitative test used to
detect production of ß-lactamase; it can be performed using the same culture on
GC-chocolate agar used to prepare the inoculum for MIC (or disk diffusion) tests.
Test for ß-lactamase production by N. gonorrhoeae
The most reliable way to detect ß-lactamase-producing strains of N. gonorrhoeae is
to use the nitrocefin test. Reactions are strongest when the test is performed on
cultures recently removed from an incubator and still warm. The nitrocefin test is
performed either with a liquid reagent or with a treated disk. Because the liquid
reagent can be expensive, the disk method is preferable if relatively few isolates are
to be tested. Positive and negative controls should be run each time this test is
performed. Positive and negative control strains may be selected from among those
listed in Table 7.
Nitrocefin disk method
a) Use sterile forceps or tweezers to place a nitrocefin disk on a clean slide.
b) Add a drop of distilled water to the disk and allow it to absorb so the disk is
moistened, but not wet.
c) Touch a sterile swab or loop to a characteristic colony in fresh, pure, 18–24 hour
culture.
d) Rub the swab on the moistened disk so that the growth goes into the filter
paper of the disk.
e) Examine the disk: if the reaction is positive, the areas of the disk containing
growth will turn a characteristic red/pink color. Reactions typically occur within
five minutes.
f) Record results. Strains for which the inoculum on the nitrocefin disk turns red/ 
pink are considered “ß-lactamase positive”. Strains for which the inoculum on
the nitrocefin disk does not change color are considered “ß-lactamase negative.”
Nitrocefin liquid reagent
If it is anticipated that a large number of isolates will be tested, laboratorians
should investigate obtaining nitrocefin powder and preparing the liquid reagent.
The nitrocefin test using liquid reagent is performed either by dropping reagent
directly on colonies growing on selective or nonselective media, or by diluting the
reagent and using it as a suspension medium for bacterial growth in a tube.
Although the former method is easier as it involves fewer steps, the advantage of
the latter method is that it uses lesser amounts of the costly liquid reagent.
(Methods for the different preparations of the nitrocefin reagent as used for each
of these tests are included in Appendix 2.)
To perform the test for ß-lactamase production with liquid nitrocefin reagent
using the plate method, use an eyedropper, Pasteur pipette or inoculating loop to
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place a drop of the undiluted reagent directly onto fresh gonococcal colonies
growing on selective or nonselective culture media. After several minutes, the
colonies will turn pink if the gonococcal strain is producing ß-lactamase, and
should be recorded as “ß-lactamase positive.” If, after ten minutes, no color change
has occurred on the colonies dropped with reagent, the gonococcal strain is
considered “ß-lactamase negative,” and should be recorded as such.
To perform the test for ß-lactamase production with liquid nitrocefin reagent
using the tube method, dispense dilute nitrocefin solution (25 mg/L prepared in
0.1M phosphate buffer) into a test tube, and use it to prepare a heavy suspension
(~ McFarland 2) of the suspect gonococcal colonies from 18–24 hour culture. If
ß-lactamase producing organisms are present, the suspension should change color
from colorless/yellow to pink within 15 seconds; record a strain exhibiting this
color change as ‘ß-lactamase positive.’ If after five minutes no color change has
occurred in the suspension, record the strain as ‘ß-lactamase negative.’
Results of ß-lactamase tests are used in conjunction with results of antimicrobial
susceptibility tests performed according to NCCLS methodologies.
Antimicrobial susceptibility testing of N. gonorrhoeae using NCCLS methodologies
Antimicrobial susceptibility testing by both disk diffusion and the antimicrobial
gradient strip Etest® method are conducted on the same standardized medium.
Because gonococci are fastidious, antimicrobial susceptibility tests for most
antimicrobial agents are performed on a GC agar base medium supplemented with
IsoVitaleX or an equivalent supplement. Mueller-Hinton medium, on which
susceptibilities of most aerobic bacteria are determined, is not suitable for
determining gonococcal susceptibilities; however, Mueller-Hinton broth can be
used to prepare the gonococcal cell suspensions that will be tested. Furthermore,
gonococcal susceptibilities should not be determined on media containing
chocolatized blood or hemoglobin because of the variability of blood products
(which may affect susceptibilities of N. gonorrhoeae to various antimicrobial
agents). Antimicrobial susceptibility test results for N. gonorrhoeae should only be
interpreted when tested on GC-susceptibility test medium, a standard quality
controlled GC agar base medium plus 1% defined supplement.
A sample form for recording the results of antimicrobial susceptibility tests for 
N. gonorrhoeae is included in Figure 27.
Antimicrobial susceptibility testing of N. gonorrhoeae by disk diffusion
Disk diffusion testing should be carried out as defined by the NCCLS performance
standards and with the NCCLS quality control strain N. gonorrhoeae ATCC 49226.
It is recommended that laboratories obtain additional gonococcal reference strains
exhibiting resistance patterns not exhibited by ATCC 49226: supplemental QC
strains, tested routinely by disk diffusion and agar dilution methods with
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consistent results, may be obtained from the Neisseria Reference Laboratory,
Gonorrhea Research Branch, CDC (see Appendix 14). Quality control values for
disk diffusion zone diameter sizes for these strains are presented in Table 9.
Methods
a) Label one plate of GC-chocolate agar for each clinical isolate and QC strain to
be tested.
b) Inoculate plates with each test strain and streak for isolation. Incubate
inoculated plates at 35˚–36.5˚C in a CO2-supplemented atmosphere with
increased humidity for 16–20 hours.
• Note: if isolates are maintained in culture prior to inoculation for
antimicrobial susceptibility testing, they must be subcultured every 24 hours
prior to being tested.
• Note: if isolates are stored frozen prior to inoculation for antimicrobial
susceptibility testing, they must be subcultured at least once after initial
culture from the frozen preparation prior to being tested.
c) Suspend isolated colonies (from the overnight cultures prepared in steps a and
b) in 1.0–2.0 ml of Mueller-Hinton broth (or PBS). Mix the suspension
thoroughly on a vortex mixer to break up clumps of growth as much as
possible.
• It is easier to prepare the suspensions with a swab28 than with an inoculating
loop. The best method to avoid excessive clumping of growth in the
suspension is to roll the swab over the colonies rather than to use a scraping
method to harvest cells.
d) Adjust the turbidity of the cell suspension to the turbidity of a 0.5 McFarland
standard by comparing tubes against black and white lines and adding broth or
culture as needed (see Figures 51and 52 in Appendix 2). The suspension must
be used to inoculate the plate within 15–20 minutes after preparation, or else
it must be discarded and a new suspension prepared.
• Note: The inoculation step must be completed within 15–20 minutes
because the organisms will begin to die within a short time after the
suspension is prepared, and even though the suspension will be visually
comparable to the McFarland standard, the viability of the inoculum
delivered onto the test medium may be too low to produce reliable
antimicrobial susceptibility test results.
• If there are many cultures to test, they should be done in small batches (e.g.,
five or six isolates at a time) to avoid loss of viability.
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28 Notes on the survival of N. gonorrhoeae with different swab materials are included in Table 29, Appendix 8.
e) Pour 60 ml of GC base medium containing 1% defined supplement into a 150-
mm diameter plate to a uniform depth of 3–4 mm (in order to assure proper
conditions for disk diffusion results). The number of plates required for the
testing of each strain will be dependent upon the number and type of
antimicrobial agents to be tested, as some have larger inhibition zone sizes than
others and the zones of inhibition must not overlap. Generally speaking, GC
susceptibility tests have no more than 3 disks on each plate.
Plates to be used for antimicrobial susceptibility testing must have warmed to
room temperature before they are inoculated with the cell suspension. The
surface of the plate must also be dry prior to inoculation; if not, invert the
plates and dry them with lids slightly open either in an incubator at 35˚–36.5˚C,
or in a biohazard hood. There should be no visible drops of moisture on the
surface of the agar when the plates are inoculated.
f) Moisten a sterile applicator swab28 in the standardized cell suspension and
remove any excess moisture by rotating the swab against the glass above the
liquid in the tube. Inoculate the entire surface of each plate three times, rotating
the plate 60˚ each time to ensure confluent growth (Figure 34).
g) Store the inoculated plates at room temperature for 3–5 minutes to allow the
medium to absorb the moisture from the inoculum. It is essential that the
surface of the medium is dry before the antimicrobial disks are applied. Plates
may be dried in an incubator or biohazard hood as described in step e. (If it
takes longer than 15 minutes for the inoculum to dry, use a smaller volume /
express more suspension from the swab in the future.)
h) Using sterile forceps, tweezers or a disk dispenser, apply disks of the selected
antimicrobial agents to the surface of the inoculated medium; tap them to
ensure they are in complete contact with the surface of the agar. Once a disk
has touched the agar surface, diffusion begins and it must not be moved.
All disks should be placed approximately the same distance from the edge of
the plate and from each other (Figure 28).
i) Cover and invert the inoculated plates and incubate them at 35˚–36.5˚C in a
3%–5% CO2 atmosphere (in a CO2-incubator or candle-extinction jar) for
20–24 hours.
j) At 20–24 hours after inoculation and incubation, read the results of the
antimicrobial susceptibility tests.
• Examine the plates from the back, viewed from the top down against a black
background and illuminated with reflected light (so hazy growth is more
easily seen). Measure the diameter of the zone of inhibition with calipers, a
ruler, or a ruler on a stick (see Figure 6).
• Read the results for ATCC 49226 and compare them to the values in Table 9;
if they are in control, continue reading and comparing results for the other
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QC strains tested. If these are also in control, continue to read and record
results for the clinical isolates.
k) Interpret the results. Table 10 presents zone inhibition diameters and equivalent
minimal inhibitory concentrations (MICs) for test strains, along with the
NCCLS standard interpretations of those zones diameters as sensitive,
intermediate, or resistant.
After interpreting results, report them back to the primary laboratory.
Antimicrobial susceptibility testing of N. gonorrhoeae by Etest® antimicrobial
gradient strip
Antimicrobial susceptibility testing with the Etest® antimicrobial gradient strip29 is
technically as simple to perform as the disk diffusion test, but provides semi-
quantitative MIC results. The strip is impregnated with a standard gradient of
antimicrobial agent, and the front of the strip has MIC values that are to be read in
correspondence with inhibition of growth on the plate after incubation. Always
read the insert in the package of Etest® strips, and follow the manufacturer’s
instructions for performance of the test.
Antimicrobial susceptibility testing of N. gonorrhoeae is performed on GC base
medium plus 1% defined growth supplement; methods for the preparation and
QC of this medium are included in Appendix 2 (“Media, Reagents and Quality
Control”). The standardization of the inoculum and methods for the inoculation
of the test plate are the same for the Etest® as they are for the disk diffusion test for
N. gonorrhoeae; follow steps a through g above, and then continue with step h,
below. Strict quality control practices are of extreme importance in order for the
proper performance and appropriate interpretation of the antimicrobial
susceptibility test. If conditions cannot be controlled and standardized, it is better
that the laboratory not perform the antimicrobial susceptibility test at all, because
the results obtained cannot be interpreted according standardized criteria.
Inaccurate results are useless to the clinician, can even cause harm to a case-
patient, and should not be recorded for use in public health policy treatment
decision-making.
Laboratorians should ensure that the Etest® strips used for antimicrobial
susceptibility testing of N. gonorrhoeae strains cover the appropriate range of
antibiotic concentrations for these organisms.30
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29 The Etest® can be expensive; contact the manufacturer (AB BIODISK) to inquire about discounts available
for laboratories in resource-poor settings (see Appendix 13).
30 Please note that for certain antimicrobial agents (particularly some ß-lactams), the Etest® is available in a
high- and low range of concentrations. For testing of N. gonorrhoeae with the ceftriaxone Etest®, for example,
it is recommended that laboratories use the low-range concentration (0.002 µg/ml – 32 µg/ml) rather than the
high-range concentration (0.016 µg/ml – 256 µg/ml). A complete list of strips and ranges of concentrations is
available from AB Biodisk (at http://www.abbiodisk.se/productsservice/product.htm ).
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FIGURE 28: Disk diffusion testing: disk placement for Neisseria gonorrhoeae and measurements of inhibition zone diameters
Top: Photographs of bacterial growth, zones of inhibition, and measurement of the zones. Note that the disk on the left
is surrounded by a resistant strain and the diameter of the zone of inhibition is equivalent to the diameter of the disk 
(6 mm), whereas the figure on the right shows a strain with a zone of inhibition of 17 mm.
Te P
Cip
Bottom: The shaded area represents uniform growth of the strain on the plate;
the white areas surrounding the disks represent zones of inhibition. Zones of
inhibition are measured as indicated by the double-arrow lines.
Note: Calipers or a ruler on a stick (see Figure 6) can be helpful for measuring the diameter of a zone of inhibition.
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Methods
a - g) Methods for the preparation of the standard inoculum and the inoculation
of the test plates are included in steps a through g of ‘disk diffusion methods’,
listed above.
h) Remove the Etest® strips from the freezer, and allow them to reach room
temperature (approximately 30 minutes). It is extremely important to keep the
Etest® strips that are not going to be used in a freezer at -20˚C.
i) When the surface of the plate is dry, place the Etest® strips on the agar surface
with sterile forceps, tweezers or test-dispenser, as illustrated in Figure 7. (Make
sure that the printed MIC values are facing upward, i.e., that the bottom surface
of the strip containing the antimicrobial gradient is in contact with the agar.)
Once the test strip has touched the surface, it should not be moved.
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TABLE 10: Interpretive criteria for antimicrobial susceptibility of Neisseria gonorrhoeae
Breakpoints for zone of inhibition (mm) NCCLS QC strain
Antimicrobial Disk and equivalent MIC (µg/ml) a N. gonorrhoeae
agent potency Susceptible Intermediate Resistant ATCC 49226
Penicillin 10 units ≥ 47 mm 27 – 46 mm ≤ 26 mm 26 – 34 mm
(≤ 0.06 µg/ml) (0.125 – 1.0 µg/ml) (≥ 2.0 µg/ml) (0.25 – 1.0 µg/ml)
Tetracycline 30 µg ≥ 38 mm 31 – 37 mm ≤ 30 mm 30 – 42 mm
(≤0.25 µg/ml) (0.5 – 1.0 µg/ml) (≥ 2.0 µg/ml) (0.25 – 1.0 µg/ml)
Spectinomycin 100 µg ≥ 18 mm 15 – 17 mm ≤ 14 mm 23 – 29 mm
(≤ 32.0 µg/ml) (64.0 µg/ml) (≥ 128.0 µg/ml) (8.0 – 32.0 µg/ml)
Ceftriaxone ** 30 µg ≥ 35 mm ** ** 39 – 51 mm
(≤ 0.25µg/ml) ** ** (0.004 – 0.016 µg/ml)
Cefixime ** 5 µg ≥ 31 mm ** ** 37 – 45 mm
(≤ 0.25 µg/ml) ** ** (0.004 – 0.03 µg/ml)
Ciprofloxacin 5 µg ≥ 41 mm b 28 – 40 mm ≤ 27 mm 48 – 58 mm
(≤ 0.06 µg/ml) (0.125 – 0.5 µg/ml) (≥ 1.0 µg/ml) (0.001 – 0.008 µg/ml)
Ofloxacin 5 µg ≥ 31 mm 25 – 30 mm ≤ 24 mm 43 – 51 mm
(≤ 0.25 µg/ml) (0.5 – 1.0 µg/ml) (≥ 2.0 µg/ml) (0.004 – 0.016 µg/ml)
** Only “susceptible” interpretive criteria are available for zones and MICs for ceftriaxone and cefixime; isolates with ranges outside
the values in this table should be noted as having “decreased susceptibility” and sent to an international reference laboratory for
further testing.
a Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. NCCLS 
document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087-1898 USA.
b Recent experience has shown that some gonococcal isolates with ciprofloxacin zone sizes of 36 mm (and therefore classified as 
“intermediate” by current NCCLS criteria) have MICs of 0.06 mg/ml and are classified as “susceptible” by current NCCLS criteria for
MICs determined by agar dilution susceptibility testing. More research is needed to clarify the relationship between an MIC of 0.06
µg/ml of ciprofloxacin and the corresponding disk diffusion zone inhibition diameters exhibited by such organisms. It is therefore
advised that the antimicrobial susceptibilities of isolates exhibiting inhibition zone diameters of 36–41 mm be confirmed by MIC
testing before they are classified as exhibiting intermediate resistance to ciprofloxacin.
• Although the manufacturer’s insert for the Etest® says that up to two strips
can be used on a 100-mm plate and up to six on a 150-mm plate, because
gonococci can have such wide zones of inhibition, this laboratory manual
advises using only one Etest® strip per 100 mm plate for N. gonorrhoeae.
The number of strips on a 150-mm plate will be determined by the
combination of drugs being tested; zones of inhibition must not overlap.
(Once laboratorians have determined the range of susceptibilities of local
gonococcal isolates to various antimicrobial agents with the Etest® on 100-
mm plates, they can assess which combinations of antimicrobial agents can
be tested on a 150-mm plate without overlapping zones of inhibition,
usually 3 or 4 antimicrobial agents.) 
j) Incubate the inoculated Etest® plate according to the manufacturer’s
instructions (usually 20–24 hours at 35˚–36.5˚C in a 5% CO2 atmosphere).
k) After incubation for 20–24 hours, there will be an ellipse of inhibition of
bacterial growth on the plate around the Etest® strip, and the MIC values can
be read (see Figure 8).
• The graduation marks on the Etest® strip correspond to the standard
concentrations for the agar dilution method, but also include increments
between those standard values. The standard values (see Table 27 in
Appendix 7) are used for interpretation and reporting of antimicrobial
susceptibility test results. It is advised that both the actual reading of the
value from the strip and the next-higher standard value (i.e., the value to be
used for interpretation) be included in the laboratory records for testing of
the strain. For example, if testing susceptibility of a gonococcal isolate to
ciprofloxacin, an MIC recorded from the graduations on the Etest® strip
might be 0.094 µg/ml; however, the reported MIC would be 0.125 µg/ml and
the organism would be interpreted as exhibiting intermediate resistance to
ciprofloxacin.
l) Read the results for ATCC 49226 and compare them to the values in Table 9; if
they are in control, continue reading and comparing results for the other QC
strains tested. If these are also in control, continue to read and record results for
the clinical isolates. It is essential to review the MIC results of the quality
control strains prior to interpreting the MICs of the clinical isolates.
m)Read and interpret the results for the test strains. Table 10 presents the NCCLS
interpretive criteria (susceptible, intermediate, resistant) for different
antimicrobials, including those currently recommended for the primary therapy
of uncomplicated gonorrhea.
A reading guide for interpretation of Etest® antimicrobial susceptibility results and
guidance in reading MICs from the Etest® strip is presented in Figure 8. The guide,
included with the permission of AB Biodisk, shows how growth appears around
the strip and provides guidance for how the test should be interpreted.
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When reading any antimicrobial susceptibility test results for N. gonorrhoeae, the
laboratorian should be aware of critical values that indicate a need for retesting.
Table 11 presents a listing of critical antimicrobial susceptibility test values for the
laboratory to be aware of. If the MIC results for an organism are higher than those
listed for the specific antimicrobial agent, the reference laboratory should re-test
the isolate. If the results are still atypical, confirm the identification of the
organism, ensure the test is being performed properly, and then re-test the isolate
again. If it still produces a high MIC, notify the national and an international
reference laboratory and send the isolate for further investigation. Instructions for
the preservation and storage of isolates are presented in Appendix 11, while
Appendix 12 includes the instructions for regulation-compliant packaging and
shipping of isolates.
When the susceptibility value is confirmed upon re-test, the confirmatory
laboratory should notify the submitting laboratory and then other laboratories in
the regional and international network. If the isolate represents a new
antimicrobial resistance phenotype, it is important that the confirming reference
laboratory disseminate preserved cultures of the isolate to other reference
laboratories for inclusion among susceptibility quality control strains. Isolates
showing a previously undescribed resistance pattern should not be used for
scientific research (such as the determination of the resistance mechanisms)
without permission from the originating clinician and/or laboratory.
Data for decision-making
Antimicrobial susceptibility testing can be performed on an isolate presumptively
identified as N. gonorrhoeae, although confirmatory testing should be completed
before antimicrobial susceptibility test results exceeding the critical MIC values are
reported. (For example, before reporting results, laboratories should confirm the
identification of an organism showing an unexpectedly high MIC to, e.g.,
ceftriaxone.) Once the laboratory has determined the antimicrobial susceptibilities,
the information should be reported back to public health officials in a timely
manner. Factors to consider in the development of a treatment policy include:
• Laboratories should screen and report values for antimicrobial agents currently
in use for primary therapy of gonorrhea in the region and, ideally, also for the
second line drugs.
• MIC “critical values” can be useful tools to initiate (enhanced) surveillance and
epidemiological investigations to determine if there is an association between
the in vitro susceptibility of a strain and the clinical outcome.
• Extended-spectrum cephalosporins, fluoroquinolones, and spectinomycin are
recognized as the most effective antimicrobial agents for the treatment of
gonorrhea in most geographic areas of the world.
• The antimicrobial agent and dose chosen should be effective against at least
95% of local gonococcal strains.
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be readily available.
• It should be possible to store the chosen antimicrobial agent under conditions
(e.g., refrigeration) that will maintain the activity of the drug.
It is important to consider the above factors when making decisions relating to
treatment of gonorrhea. Determination of antimicrobial susceptibilities to
therapeutic agents will help public health officials review the appropriateness of
treatment recommendations for local populations, and surveillance of
antimicrobial susceptibilities will promote effective disease control.
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S almonella serotype Typhi (S. Typhi), the etiologic agent of typhoid fever,causes an estimated 16.6 million cases and 600,000 deaths worldwide eachyear. A syndrome similar to typhoid fever is caused by “paratyphoidal”
serotypes of Salmonella. The paratyphoid serotypes (i.e., S. Paratyphi A, S.
Paratyphi B, and S. Paratyphi C) are isolated much less frequently than S. Typhi.
Rarely, other serotypes of Salmonella, such as S. Enteritidis, can also cause “enteric
fever.” Like other enteric pathogens, S. Typhi is transmitted through food or water
that has been contaminated with feces from either acutely infected persons,
persistent excretors, or from chronic asymptomatic carriers. Humans are the only
host for S. Typhi; there are no environmental reservoirs.
Effective antimicrobial therapy reduces morbidity and mortality from typhoid
fever. Without therapy, the illness may last for 3–4 weeks and case-fatality rates
may exceed 10%. With appropriate treatment, clinical symptoms subside within a
few days, fever recedes within 5 days, and mortality is reduced to approximately
1%. Relapses, characterized by a less severe but otherwise typical illness, occur in
10%–20% of patients with typhoid fever, usually after an afebrile period of 1–2
weeks. Relapses may still occur despite antimicrobial therapy.
S. Typhi is most frequently isolated from blood during the first week of illness, but
it can also be present during the second and third weeks of illness, during the first
week of antimicrobial therapy, and during clinical relapse. Fecal cultures are
positive in approximately half the cases during the first week of fever, but the
largest number of positive cultures occurs during the second and third weeks of
disease. Bone marrow cultures are frequently positive (90% of cases) and are more
likely to yield S. Typhi than are cultures from any other site, especially when the
patient has already received antimicrobial therapy. Organisms can also be isolated
from duodenal aspirates, rose spots, and infrequently (i.e., in approximately 25%
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In typhoid fever, serologic responses to O, H, and Vi antigens usually occur by the
end of the first week of illness. The Widal test, which measures antibody responses 
to H and O antigens, can suggest the diagnosis, but the results are not definitive and
must be interpreted with care because titers also may be elevated in response to a
number of other infections. High-titer, single serum specimens from adults living in
areas of endemic disease have little diagnostic value. Even when paired sera are 
used, the results must be interpreted in light of the patient’s history of typhoid
immunization and previous illness, the stage of the illness when the first serum
specimen was obtained, the use of early antimicrobial therapy, and the reagents used.
There are currently (2002) at least two effective vaccines available for typhoid,
both of which were recently licensed for use in the United States. The oral live
attenuated vaccine (for use in children aged 6 years and older) and the parenteral
(i.e., injectable) capsular polysaccharide vaccine (for use in children aged 2 years
and older) each have efficacy of 50%–80% and fewer adverse events associated 
with their use than earlier typhoid vaccines. A team doing research in Vietnam
reported promising preliminary success of a new conjugate vaccine in early 2001.
The two U.S.-licensed vaccines have been widely and effectively used by travelers 
to typhoid-endemic regions, though the expense and limited experience with their
use as a public health intervention in countries with high endemic rates of typhoid
fever precludes the widespread use of these vaccines in countries with limited
resources. Nonetheless, it is good policy for laboratory technicians who may be
working with this organism to supplement their laboratory safety practices and
ensure that their vaccination status against typhoid fever remains current.
In developing countries, typhoid fever is frequently diagnosed solely on clinical
grounds; however, isolation of the causative organism is necessary for a definitive
diagnosis. Isolation of the agent is also a necessity for the performance of
antimicrobial susceptibility testing.
Resistance to the antimicrobial agents amoxicillin, trimethoprim-sulfamethoxazole,
and chloramphenicol is being increasingly reported among S. Typhi isolates;
quinolone resistance has been reported from the Indian subcontinent and
Southeast Asia. Determining antimicrobial resistance patterns is essential in
recommending treatment. In areas where resistance to these agents is common
among circulating S. Typhi strains, fluoroquinolones and parenteral third-
generation cephalosporins are probably the best choice for empiric treatment of
typhoid fever. Cefixime may be recommended in some cases as a less expensive,
oral alternative to parenteral ceftriaxone.
Identification of S. Typhi 
A preliminary report of typhoid can be issued to a clinician as soon as a
presumptive identification of S. Typhi is obtained. Methods for the isolation of
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S. Typhi from normally sterile sites (e.g., blood, bone marrow, and urine) are
presented in Appendix 3; isolation of S. Typhi from fecal specimens is presented in
Appendix 10. Blood, bone marrow, or urine specimens collected from a patient
with suspect typhoid fever or a diagnosis of fever of unknown origin and sent to a
laboratory should be cultured on blood or chocolate agar; in addition, if resources
permit the use of more than one medium, MacConkey agar (MAC) should be
inoculated. Fecal specimens should be cultured on selective agar media (e.g.,
bismuth sulfite agar [BS] or desoxycholate citrate agar [DCA]). Isolates from
blood, bone marrow or urine should be Gram stained, whereas isolates obtained
from stool specimens should not. In most situations, presumptive identification is
based on the reaction of the isolate on Kligler iron agar (KIA) / triple sugar iron
Agar (TSI) and a positive serologic reaction in Salmonella Vi or D antisera.
If gram-negative rods are cultured from specimens obtained from normally sterile
sites and/or their culture yields colorless colonies on MAC, the laboratorian should
inoculate KIA/TSI. Isolates that have a reaction typical of S. Typhi on KIA/TSI
should then be tested with Vi and D antisera. The results of the serologic testing
should be promptly reported to health authorities, and Mueller-Hinton agar
should be inoculated for antimicrobial susceptibility testing. For any blood isolate,
antimicrobial susceptibility testing should not be delayed pending biochemical or
serologic identification.
Although clinicians will not necessarily be waiting for the results of antimicrobial
susceptibility tests or even the verification of identification, the reference laboratory
should confirm the pathogen’s identification via biochemical and serologic
characterization and record these and the antimicrobial susceptibility results along
with the patient’s demographic information for epidemiologic purposes. A
flowchart of tests for the identification of an agent as S. Typhi is presented in 
Figure 29, and Figure 30 illustrates a worksheet to record laboratory data.
Kligler iron agar and triple sugar iron agar
Suspicious colonies should be carefully picked from plating media to a screening
medium such as Kligler iron agar (KIA) or triple sugar iron agar (TSI) or to any
nonselective agar medium and then incubated overnight. Select at least one of each
colony type of the well-isolated colonies on each plate. Using an inoculating
needle, lightly touch only the center of the colony. Do not take the whole colony
or go through the colony and touch the surface of the plate because this practice
could result in picking up contaminants that may be present on the surface of the
agar. If the ability to select an isolated, pure colony is questionable, the suspicious
colony should be purified by streaking for isolation on another agar plate before
inoculating the colony to a TSI/KIA slant.
TSI and KIA are inoculated by stabbing the butt and streaking the surface of the
slant. The caps should be loosened before incubation. After incubation for 24
KIA or TSI agar 
biochemical tests
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Positive with
D antiserum
= suspected S. Typhi*
FIGURE 29: Flowchart for the isolation and identification of Salmonella ser.Typhi
Macroscopic examination of growth on 
blood agar shows grayish, transparent
to opaque, glistening colonies, usually
>1 mm in diameter. On MAC, colorless
colonies are 2–3 mm.
Typical appearance of colonies on:
BS: Black, surrounded by a black or brownish
zone with a metallic sheen; 1 – 3 mm.
DCA: Colorless; 1 – 2 mm.
SS agar: Colorless; 1 – 2 mm.
HE: Blue-green (with or without black centers)
or yellow with black centers; 1 – 2 mm.
XLD: Red (with or without black centers), or 
yellow with black centers; 1 – 2 mm.
MAC: Transparent or colorless opaque; 2 – 3 mm
Fecal specimens Sterile site specimens
(e.g., blood, bone marrow)
Antimicrobial susceptibility testing by 
disk diffusion on Mueller-Hinton agar
KIA*: K/A (+), no gas
TSI*: K/A (+), no gas
Not positive with
Vi or D antisera 
= negative
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Vi and D slide serology
* K= alkaline (purple) reaction, LIA
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group D antiserum 
(e.g., S. Enteritidis).
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hours at 35˚–37˚C, the TSI or KIA slants are observed for reactions typical of
Salmonella. On TSI or KIA slants, S. Typhi characteristically produces an alkaline
slant (red, “K”), an acid butt (yellow, “A”), and a small amount of blackening of
the agar (H2S, +) at the site of the stab on the slant and in the stab line (Figure
31); no gas (G) is produced. It is worth noting that occasionally S. Typhi isolates
do not produce H2S. S. Paratyphi A isolates on TSI/KIA are usually K/AG and do
not produce H2S. Most other Salmonella serotypes produce a K/AG+ reaction,
indicating that glucose is fermented with gas and H2S production. Table 12
summarizes the reactions of Salmonella on screening biochemicals.
Additional screening biochemicals for the identification of S. Typhi
Isolates can be identified biochemically as Salmonella by traditional tubed media
or commercial biochemical systems. Table 12 lists biochemical reactions of the
tests that are helpful screening tests for S. Typhi. After performing the tests, read
and record the results, then compare them to results for presumptive S. Typhi. If
they match, then proceed by confirming with serologic testing if it has not already
been performed.
Lysine iron agar
Lysine iron agar (LIA) is a useful screening medium because most Salmonella
isolates decarboxylate lysine and produce H2S, whereas gas production varies by
serotype. Preparation and quality control (QC) of this medium are described in
Appendix 2. Inoculate LIA by stabbing the butt and streaking the surface of the
slant; read and interpret the reactions after incubation for 24 hours at 35˚–37˚C for
24 hours.
On LIA, Salmonella typically give an alkaline (purple) reaction on the slant and
butt and may produce gas and H2S (blackening of medium) as well, as indicated in
Table 12. When the reaction in the butt of the tube is alkaline, the lysine is
decarboxylated and the isolate is termed “lysine-positive.” Unlike most other
Salmonella, S. Paratyphi A isolates are lysine-negative and appear yellow on LIA.
If a diagnosis of infection with S. Typhi is suspected and prompt diagnosis is
required to identify appropriate treatment, suspect isolates should be screened with
antisera prior to biochemical identification. However, in the setting of a public
health study, because slide serology can be performed using growth from KIA, TSI,
or LIA, performing serology after those tests and saving antiserum for only those
isolates showing biochemical characteristics typical of S. Typhi is more cost-
effective.
Motility agar
Motility agar should be inoculated with a straight inoculating needle, making a
single stab about 1–2 cm down into the medium. The surface of the motility agar
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FIGURE 31: Salmonella ser. Typhi colonies on triple sugar iron (TSI) Agar
On triple sugar iron agar (TSI) or Kligler iron agar (KIA) slants, S. Typhi
characteristically produces an alkaline slant (red,“K”), an acid butt
(yellow,“A”), and a small amount of blackening of the agar (H2S, +)
at the site of the stab on the slant and in the stab line;
no gas (G) is produced.
should be dry when used: moisture can cause a non-motile organism to grow
down the sides of the agar creating a haze of growth and appearing to be motile.
Motility agar may be inoculated with growth from a KIA or TSI that shows a
reaction typical of S. Typhi. Alternatively, motility agar can be inoculated at the
same time as the KIA or TSI slant by using the same inoculating needle without
touching the colony again. (When motility agar is to be inoculated at the same
time as KIA or TSI, use the same colony to first inoculate the motility agar and
then to inoculate the KIA or TSI by stabbing the butt and then streaking the
surface of the slant. Do not select a second colony to inoculate the KIA or TSI
after the motility agar has been inoculated because it may represent a different
organism.
Examine after overnight incubation at 35°–37°C. Motility is indicated by the
presence of diffuse growth (appearing as clouding of the medium) away from the
line of inoculation (Figure 39). Non-motile organisms do not grow out from the
line of inoculation. Motility reactions may be difficult for inexperienced
laboratorians to read; therefore, reactions should be compared with positive and
negative control strains. S. Typhi is usually motile (+ 97%).
Sulfide-indole-motility medium is a combination medium that is commercially
available in dehydrated form (see Appendix 2, “Media, Reagents, and Quality
Control”). It can be used in place of motility medium.
Urea medium
Urea medium screens out urease-producing organisms (e.g., Klebsiella and
Proteus). Urea agar is inoculated heavily over the entire surface of the slant. Loosen
caps before incubating overnight at 35°–37°C. Urease-positive cultures produce
an alkaline reaction in the medium, evidenced by a pinkish-red color (Figure
40). Urease-negative organisms do not change the color of the medium, which is a
pale yellowish-pink. S. Typhi is always urease negative.
Slide serology for S. Typhi identification
TSI/KIA cultures that are suspicious for S. Typhi should be screened serologically
with Salmonella Vi and group D “O” antisera. Because Vi is a capsular antigen, if it
is present, it may mask the somatic “O” group reaction. Therefore, S. Typhi isolates
will usually either be positive in the Vi or the D antisera (though it is possible they
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TABLE 12. Typical reactions of Salmonella spp. in screening biochemicals
Nontyphoidal Salmonella or
Screening medium Salmonella Typhi Salmonella Paratyphi A Salmonella Paratyphi B or C
Triple sugar iron agar (TSI) K/A(+)a K/AG-a K/AG+a
Kligler iron agar (KIA) K/A(+)a K/AG-a K/AG+a
Lysine iron agar (LIA) K/K(+)b K/AG-b K/K+b
Hydrogen sulfide (H2S) (weak)c negative positive
Urea negative negative negative
Motility positivec positive positive
Indole negative negative negative
a for KIA / TSI: K = alkaline (red); A = acid (yellow); G = gas production; + = black H2S produced (weak); – = no H2S 
b for LIA: K= alkaline (purple); A= acid (yellow); G = gas production; + = black H2S produced (weak); – = no H2S 
~  An alkaline reaction (purple) in the butt of the medium indicates that lysine was decarboxylated.
~ An acid reaction (yellow) in the butt of the medium indicates that lysine was not decarboxylated.
c this reaction occurs 97% of the time.
will be weakly positive in both). Occasionally, S. Paratyphi C will also be positive in
Vi antiserum, but because it produces gas from glucose and is H2S positive,
reactions on KIA/TSI allow for the differentiation of S. Paratyphi C from S. Typhi.
Serologic agglutination tests may be performed in a petri dish or on a clean glass
slide.
a) Use an inoculating loop or needle, sterile applicator stick, or toothpick to
remove a portion of the growth from the surface of KIA, TSI, LIA, or other
nonselective agar medium. Serologic testing should not be done on growth
from selective media (e.g., MAC, DCA, BS, or XLD) because selective media
may yield false-negative serologic results.
b) Emulsify the growth in three small drops of physiological saline and mix
thoroughly.
c) Add a small drop of O group D antiserum to one of the suspensions and a small
drop of Vi antiserum to a second. The third suspension is used as a control for
autoagglutination (roughness). Usually approximately equal volumes of
antiserum and growth suspension are mixed, but the volume of suspension may
be as much as double the volume of the antiserum. To conserve antiserum,
volumes as small as 10 ml can be used. A bent inoculating loop may be used to
dispense small amounts of antisera if micropipettors are not available (Figure
32).
d) Mix the suspension and antiserum thoroughly and then tilt the slide back and
forth to observe for agglutination. It will be easier to see the agglutination if the
slide is observed under a bright light and over a black background; if the
reaction is positive, clumping will appear within 30 seconds to 1 minute (Figure
42). Examine the saline suspension carefully to ensure that it is even and does
not show clumping caused by autoagglutination. If autoagglutination occurs,
the culture is termed “rough” and cannot be serotyped. Strong agglutination
reactions are read as positive.
Cultures that have a TSI/KIA reaction typical of S. Typhi and that react serologically
in either the Vi or the D antisera can be presumptively identified as S. Typhi. The
tube agglutination for the “d” flagellar antigen or further biochemical tests may be
conducted by reference laboratories to confirm the identification as S. Typhi.
Antimicrobial susceptibility testing of S. Typhi
Treatment with an appropriate antimicrobial agent is crucial for patients with
typhoid. Because recent reports have noted an increasing level of resistance to one
or more antimicrobial agents in S. Typhi strains, isolates should undergo
antimicrobial susceptibility testing as soon as possible. The disk diffusion method
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presented in this chapter is a modification of the Kirby-Bauer technique that has
been carefully standardized by NCCLS (an international, interdisciplinary,
nonprofit, educational organization that develops updated consensus standards
and guidelines for the healthcare community on an annual basis),31 and, if
performed precisely according to the protocol below, will provide data that can
reliably predict the in vivo effectiveness of the drug in question. However, any
deviation from the method can invalidate the results. For this reason, if
laboratories lack the resources to perform the disk diffusion test exactly as
described, they should forward isolates to other laboratories for antimicrobial
susceptibility testing. Antimicrobial agents suggested for use in antimicrobial
susceptibility testing of S. Typhi are listed in Table 13.
Special considerations for antimicrobial susceptibility testing of S. Typhi 
As previously mentioned, testing some bacteria against certain antimicrobial
agents may yield misleading results because these in vitro results do not necessarily
correlate with in vivo activity. Salmonella (including ser. Typhi) isolates, for
instance, are usually susceptible to aminoglycosides (e.g., gentamicin, kanamycin)
and first- and second-generation cephalosporins using the disk diffusion test, but
treatment with these drugs is often not effective [NCCLS 2002].
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FIGURE 32: Use of a bent loop to dispense small amounts of antiserum for slide agglutination tests
31 Formerly known as the “National Committee for Clinical Laboratory Standards,” NCCLS is now known
solely by its acronym.
Salmonella serotype Typhi | 113
TABLE 13: Antimicrobial agents suggested for use in antimicrobial susceptibility testing of Salmonella ser. Typhi 





*If resistant to nalidixic acid, the isolate should be tested for susceptibility to ciprofloxacin,
and will probably exhibit reduced susceptibility to ciprofloxacin.
It is also worth noting that sometimes the result of one antimicrobial
susceptibility test will indicate the need for additional tests to confirm an
expected result. For example, when an isolate of S. Typhi is resistant to nalidixic
acid, it will usually exhibit reduced susceptibility to ciprofloxacin; this scenario
may translate in the clinical setting to need for a longer course of treatment.
Isolates exhibiting resistance to nalidixic acid should be tested for susceptibility to
ciprofloxacin.
Agar disk diffusion testing of S. Typhi
Mueller-Hinton agar medium is the only antimicrobial susceptibility test medium
that has been validated by NCCLS. Mueller-Hinton agar should always be used for
disk diffusion susceptibility testing according to NCCLS and international
guidelines. Because the way in which Mueller-Hinton is prepared can affect disk
diffusion test results, this medium should be prepared strictly according to the
methods and quality control instructions presented in Appendix 2. A summary of
the disk diffusion method of antimicrobial susceptibility testing is presented in
Figure 33.
A 0.5 McFarland turbidity standard should be prepared and quality controlled prior
to beginning antimicrobial susceptibility testing (see Appendix 2, Figure 50). If
tightly sealed to prevent evaporation and stored in the dark, the turbidity standard
can be stored for up to 6 months. The 0.5 McFarland turbidity standard is used to
adjust the turbidity of the inoculum for the antimicrobial susceptibility test.
Preparation of inoculum
Each culture to be tested should be streaked onto a non-inhibitory agar medium
(e.g., blood agar, brain heart infusion agar, or tryptone soy agar [TSA]) to obtain
isolated colonies. After incubation at 35˚C overnight, select four or five well-
isolated colonies with an inoculating needle or loop, and transfer the growth to a
tube of sterile saline or nonselective broth (e.g., Mueller-Hinton broth, heart
infusion broth, or tryptone soy broth [TSB]) and vortex thoroughly. The bacterial
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FIGURE 33: Flowchart of the general procedure for antimicrobial susceptibility testing by disk diffusion 
Confirm identification of isolates.
Subculture on non-selective agar.
Optional growth method 
Inoculate Mueller-Hinton broth 
with several well-isolated colonies;
incubate at 35˚C until turbid.
Typical preparation of suspension 
Prepare suspension of the bacteria to 
be tested in sterile saline or 
non-selective broth.
Prepare inoculum
Compare suspension to the 0.5
McFarland standard and adjust turbidity
as needed with sterile saline or pure 
culture until proper density is achieved.
Adjust turbidity
Inoculate Mueller-Hinton agar plate
with swab for confluent growth.
Allow to dry.
Place disks on plate with sterile forceps
or tweezers.*  Do not move the disks
once they have touched the agar
Measure zone diameters with ruler.
Interpret according to NCCLS standards,
as appropriate. Record and report 
findings.
Perform quality 






strain zones of 
inhibition first. If within 
limits, read test strain.
*Do not use a disk ring; zone diameters
may overlap and will therefore not be valid.
Incubate
suspension should then be compared to the 0.5 McFarland turbidity standard. This
comparison can be made more easily if the tubes are viewed against a sheet of
white paper on which sharp black lines are drawn (see Appendix 2, Figures 51 and
52). The turbidity standard should be agitated on a vortex mixer immediately prior
to use. If the bacterial suspension does not appear to be the same density as the 0.5
McFarland turbidity standard, the turbidity can be reduced by adding sterile saline
or broth or increased by adding more bacterial growth.
Alternatively, the growth method may be used to prepare the inoculum. Pick four
or five colonies from overnight growth on agar and inoculate them into broth
(Mueller-Hinton broth, heart infusion broth, or TSB). Incubate the broth at 35˚C
until turbid (usually 16–24 hours), and then adjust the turbidity to the proper
density.
Inoculation procedure
Within 15 minutes after adjusting the turbidity of the inoculum suspension, dip a
sterile cotton swab into the suspension. Pressing firmly against the inside wall of
the tube just above the fluid level, rotate the swab to remove excess liquid. Streak
the swab over the entire surface of the medium three times, rotating the plate
approximately 60 degrees after each application to ensure an even distribution of
the inoculum (Figure 34). Finally, swab around the entire edge of the agar surface.
If the bacterial colonies used to prepare the suspension are picked off a plate
containing mixed growth (i.e., if isolated colonies are picked from a plate that does
not contain pure culture, as may occur when working with cultures from stool
specimens), laboratorians may choose to prepare a purity plate to ensure the
suspension used for antimicrobial susceptibility testing is pure. To prepare the
purity plate, after inoculating the Mueller-Hinton agar plate for confluent growth,
label (a portion of) a separate TSA plate (or other non-selective medium) and use
the same swab of suspension with which the Mueller-Hinton was inoculated to
streak for isolation; do not place the swab back into the suspension. Several
inocula can be streaked on different sections of a properly labeled purity plate,
but the streaks must not overlap.
Quality control 
To verify that antimicrobial susceptibility test results are accurate, at least one
control organism should be included with each test. (ATCC 25922 is the E. coli
control strain used when testing S. Typhi and other Enterobacteriaceae.) Zone
diameters obtained for ATCC 25922 should be compared with NCCLS published
limits; Table 14 includes the diameters of the zones of inhibition for ATCC 25922.
If zones produced by the control strain are out of the expected ranges, the
laboratorian should consider possible sources of error.
Antimicrobial susceptibility tests are affected by variations in media, inoculum
size, incubation time, temperature, and other factors. The medium used may be a
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FIGURE 34: Inoculation of Mueller-Hinton medium for antimicrobial susceptibility tests
Inoculate a Mueller-Hinton plate by dipping a sterile swab into the standardized inoculum one time and then swabbing
the entire surface of the medium three times, rotating the plate after each application to ensure an even inoculum for
confluent growth.
source of error if it fails to conform to NCCLS recommended guidelines. For
example, agar containing excessive amounts of thymidine or thymine can reverse
the inhibitory effects of sulfonamides and trimethoprim, causing the zones of
growth inhibition to be smaller or less distinct. Organisms may appear to be
resistant to these drugs when in fact they are not. If the depth of the agar in the
plate is not 3–4 mm, the rate of diffusion of the antimicrobial agents or the
activity of the drugs may be affected.
If the inoculum is not a pure culture or does not contain a concentration of
bacteria that approximates the 0.5 McFarland turbidity standard, the antimicrobial
susceptibility test results will be affected. For instance, a resistant organism could
appear to be susceptible if the inoculum is too light. Also, if colonies from blood
agar medium are used to prepare a suspension by the direct inoculum method,
trimethoprim or sulfonamide antagonists may be carried over and produce 
a haze of growth inside the zones of inhibition surrounding trimethoprim-
sulfamethoxazole disks, even when the isolates being tested are susceptible.
If antimicrobial disks are not stored properly or are used beyond the stated
expiration date, their potency may decrease; this will usually be indicated by a
decrease in the size of the inhibition zone around the control strain.
Antimicrobial disks
The working supply of antimicrobial disks should be stored in a refrigerator (4˚C).
Upon removal of the disks from the refrigerator, the package containing the
cartridges should be left unopened at room temperature for approximately 1 hour
to allow the temperature to equilibrate; this reduces the amount of condensation
on the disks. If a disk-dispensing apparatus is used, it should have a tight-fitting
cover, be stored in the refrigerator, and be allowed to warm to room temperature
before use.
Apply the antimicrobial disks to the plates as soon as possible, but no longer than
15 minutes after inoculation. The plate surface should be dry, with no liquid
remaining. Place the disks individually with sterile forceps or with mechanical
dispensing apparatus, and then gently press down onto the agar. In general, no
more than 12 disks should be placed on a 150-mm plate and no more than four
disks should be placed on a 100-mm plate to prevent overlapping of the zones of
inhibition and possible resultant error in measurement. Diffusion of the drug in
the disk begins immediately; therefore, once a disk contacts the agar surface, the
disk should not be moved.
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TABLE 14: Inhibition zone diameter size interpretive standards for Enterobacteriaceae (for selected antimicrobial disks 
appropriate for Salmonella ser. Typhi)
Diameter of zone of inhibition (mm) and
Antimicrobial Disk equivalent MIC breakpoint (µg/ml) NCCLS QC strain
agent potency Susceptible Intermediate Resistant E. coli ATCC 25922
Ampicillin 10 µg ≥ 17 mm 14 – 16 mm ≤ 13 mm 16 – 22 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8  µg/ml)
Chloramphenicol 30 µg ≥ 18 mm 13 – 17 mm ≤ 12 mm 21 – 27 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8  µg/ml)
Trimethoprim- 1.25 / 23.75 µg ≥ 16 mm 11 – 15 mm ≤ 10 mm 23 – 29 mm
sulfamethoxazole (≤ 2/38 µg/ml) (4/76 µg/ml) (≥ 8/152 µg/ml) (≤ 0.5/9.5 µg/ml)
(cotrimoxazole)
Nalidixic acid 30 µg ≥ 19 mm 14 – 18 mm ≤ 13 mm 22 – 28 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (1–4 µg/ml)
Ciprofloxacin 5 µg ≥ 21 mm 16 – 20 mm ≤ 15 mm 30 – 40 mm
(≤ 1 µg/ml) (2 µg/ml) (≥ 4 mg/ml) (0.004–0.016 µg/ml)
Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement.
NCCLS document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087 USA.
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Recording and interpreting results
After the disks are placed on the plate, invert the plate and incubate at 35˚C for
16–18 hours; if a purity plate was prepared, incubate it under the same conditions.
After incubation, measure the diameter of the zones of complete inhibition
(including the diameter of the disk) (Figure 28) and record it in millimeters. (A
sample worksheet is included in Figure 35.) The measurements can be made with
calipers or a ruler on the undersurface of the plate without opening the lid. With
sulfonamides and trimethoprim-sulfamethoxazole, a slight amount of growth may
occur within the inhibition zone; in this instance, slight growth (approximately
80% inhibition) should be ignored and the zone diameter should be measured to
the margin of heavy growth. For S. Typhi, zones of growth inhibition should be
compared with the zone-size interpretative table for Enterobacteriaceae (Table 14),
and recorded as susceptible, intermediate, or resistant to each drug tested.
Colonies growing within the clear zone of inhibition may represent resistant
variants or a mixed inoculum. Measure the distance from the inner-most colonies
(i.e., those closest to the disk) to the center of the antimicrobial disk, and double
this measurement to obtain the diameter; record the measurement and
interpretation of antimicrobial susceptibility (Figure 35). If there is both an inner-
and outer zone of inhibition of growth around the antimicrobial disk:
a) If a purity plate was prepared, check the streak to confirm the culture was pure.
(Step a is optional.)
b) Record the diameter and interpretation of antimicrobial susceptibility of those
colonies in the outer zone (i.e., in addition to those in the inner zone).
c) Pick the colonies inside the zone, streak for isolation on a new plate, confirm
their identification, and perform the disk diffusion test again to confirm the
previous results.
The presence of colonies within a zone of inhibition may predict eventual
resistance to that antimicrobial agent.
Data for decision-making
Once the laboratory has assessed the identity and antimicrobial susceptibility
patterns of S. Typhi isolates, the information should be reported promptly to
public health officials. Factors to consider in the development of a treatment policy
include:
• The antimicrobial agent should be affordable.
• The antimicrobial agent chosen should be available locally (or be able to be
obtained quickly).




 for recording antim
icrobial susceptibility test results for Salm
onella
ser.Typhi 
Note:After 16-18 hours incubation,check the results for the NCCLS-recom
m
ended quality control (QC) strain E.coli ATCC 25922 against the acceptable range of inhibition zone diam
eters and then record
disk diffusion results (m
m
).(Inhibition zone ranges and breakpoints for interpretation of results m
ay be found in Table 14.)
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• Immunization with available typhoid fever vaccines should be considered only
for high-risk populations where epidemic or high endemic rates of multi-drug
resistant S. Typhi infections are a major cause of morbidity and mortality, and
where vaccine effectiveness can be formally evaluated.
Consideration of such factors when making decisions based on data will help
public health officials meet needs in a manner appropriate to the local situation
and antimicrobial susceptibility profile.
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The genus Shigella is divided into four subgroups: Shigella dysenteriae(Subgroup A), Shigella flexneri (Subgroup B), Shigella boydii (Subgroup C),and Shigella sonnei (Subgroup D). Each of these subgroups, with the exception
of S. sonnei, has several serotypes (Table 15). In general, S. sonnei is more common
in developed countries and S. flexneri and S. dysenteriae serotype 1 occur more
frequently in developing countries. The proportions of each subgroup varies from
country to country, though epidemic dysentery in developing countries is usually
caused by S. dysenteriae 1, an unusually virulent pathogen. The hallmark of
infection with Shigella is diarrhea with blood, often termed “dysentery.” However,
in almost half of cases, Shigella causes acute non-bloody diarrheas that cannot be
distinguished clinically from diarrhea caused by other enteric pathogens. Severity
of symptoms appears to be dose-related.
Shigella dysenteriae serotype 1 differs from other Shigella in several ways:
• Only S. dysenteriae 1 causes large and prolonged epidemics of dysentery.
• Infection with S. dysenteriae 1 causes more severe, more prolonged, and more
frequently fatal illness than does infection with other Shigella.
• Antimicrobial resistance develops more quickly and occurs more frequently in
S. dysenteriae 1 than in other Shigella groups.
This section of the laboratory manual focuses on the isolation, identification, and
antimicrobial susceptibility testing of Shigella.
Identification of Shigella
Methods for the collection and transport of fecal specimens and the primary
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Appendices 9 and 10. Suspect Shigella isolates should be subcultured to a
nonselective medium (e.g., Kligler iron agar [KIA] or triple sugar iron agar [TSI])
in preparation for identification by slide serology and biochemical tests. Figure 36
presents a flowchart for the isolation and identification of an isolate as Shigella,
and Figure 37 provides a sample worksheet which can be used to record test
results.
Biochemical screening tests
Identification of Shigella subgroups involves both biochemical and serologic
testing. The use of biochemical screening media is usually advisable to avoid
wasting antisera. For most laboratories, KIA or TSI will be the single most helpful
medium for screening suspected Shigella isolates. If an additional test is desired,
motility medium can be used to screen isolates before serologic testing is
performed.
Kligler iron agar and triple sugar iron agar
To obtain true reactions in KIA, TSI, or other biochemical tests, a pure culture
must be used to inoculate the medium. Carefully select at least one of each type of
well-isolated colony on each type of plate that was streaked for isolation (i.e., if
suspect lactose-nonfermenting colonies that differ in macroscopic appearance are
present, a separate test should be run for each.) Using an inoculating needle, lightly
touch only the center of the colony. Do not take the whole colony or go through
the colony and touch the surface of the plate because doing so can pick up
contaminants that may be on the surface of the agar. If there is doubt that a
particular colony is sufficiently isolated from surrounding colonies, purify the
suspicious colony by streaking on another agar plate; afterwards, the KIA slant or
TSI slant may be inoculated. Only one colony should be inoculated into each test
medium.
KIA and TSI tubes are inoculated by stabbing the butt and streaking the surface of
the slant. After incubation for 18–24 hours at 35°–37°C, the slants are observed for
reactions typical of Shigella. When incubating most biochemicals, caps should be
loosened before placement in the incubator. This is particularly important when
using KIA and TSI. If the caps are too tight and anaerobic conditions exist in
KIA or TSI, the characteristic reactions of Shigella may not occur and a
misleading result could be exhibited. In addition, the KIA and TSI tubes must be
prepared so that the tubes have a deep butt (i.e., approximately 3.5 cm) and a long
slant (i.e., approximately 2.5 cm). Shigella characteristically produces an alkaline
(red) slant and an acid (yellow) butt, little or no gas, and no H2S (see Table 15 and
Figure 38). A few strains of S. flexneri serotype 6 and very rare strains of S. boydii
produce gas in KIA or TSI.
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Polyvalent B antiserum
(if + agglutination = 
S. flexneri)
FIGURE 36: Flowchart for the isolation and identification of Shigella 
Stool specimens should be plated on two different
selective media (MAC and XLD) as soon as possible
after arrival at the laboratory. (If XLD is not available,
use DCA or HE agar.) Plate a single drop of liquid 
stool suspension, or use a rectal/fecal swab.
Antimicrobial susceptibility testing
(standardized disk diffusion method 
on Mueller-Hinton agar)
KIA: K/A, no gas, no H2S
TSI: K/A, no gas, no H2S
Different appearance of colonies on the 
selective agars (lactose-fermenting or 
xylose-fermenting colonies)  
= negative
MAC: convex colorless colonies, 2–3* mm
XLD: red or colorless colonies 1–2* mm
(DCA: colorless colonies, 2–3* mm)
(HE: green colonies, 2–3* mm)
Do not use SS agar for suspect S. dysenteriae 1.
Optional screening biochemicals
* K= alkaline slant (red);
A= acid butt (yellow)
Motility: negative
Urea: negative
LIA: K/A (purple slant / yellow butt)
no gas, no H2S
= suspect Shigella 
(Use growth from 
KIA, TSI, or LIA 
for slide serology)
* S. dysenteriae serotype 1 colonies may be smaller.




Once one colony is identified
serologically, testing other




(If + agglutination = S. dysenteriae 1)
Polyvalent D antiserum
(If + agglutination = 
S. sonnei)
(If negative in A1 antiserum)
(If negative in B antiserum)































































































































































































































































































Motility agar should be inoculated with a straight inoculating needle, making a
single stab about 1–2 cm down into the medium. The surface of the motility agar
should be dry when used: moisture can cause a non-motile organism to grow
down the sides of the agar, creating a haze of growth and appearing to be motile.
Motility agar may be inoculated with growth from a KIA or TSI that shows a
reaction typical of Shigella. Alternatively, motility agar can be inoculated at the
same time as the KIA or TSI slant by using the same inoculating needle without
touching the colony again. (When motility agar is to be inoculated at the same
time as KIA or TSI, use the same colony to first inoculate the motility agar and
then to inoculate the KIA or TSI by stabbing the butt and then streaking the
surface of the slant. Do not select a second colony to inoculate the KIA or TSI
after the motility agar has been inoculated because it may represent a different
organism.
Examine after overnight incubation at 35°–37°C. Motility is indicated by the
presence of diffuse growth (appearing as clouding of the medium) away from the
line of inoculation (Figure 39). Non-motile organisms do not grow out from the
line of inoculation. Motility reactions may be difficult for inexperienced
laboratorians to read; therefore, reactions should be compared with positive and
negative control strains. Shigella are always non-motile (Table 15).
Sulfide-indole-motility medium is a combination medium that is commercially
available in dehydrated form (see Appendix 2, “Media, Reagents, and Quality
Control”). It can be used in place of motility medium.
Additional biochemical screening tests
Other biochemical tests (e.g., urea medium and lysine iron agar [LIA]) may be
used for additional screening of isolates before testing with antisera (Table 15).
TABLE 15: Reactions of Shigella in screening biochemicals
Screening medium Shigella reaction Figure number
Kligler iron agar (KIA) K/A, no gas produced (red slant/yellow butt) a Figure 38
Triple sugar iron agar (TSI) K/A, no gas produced (red slant/yellow butt) a ~
H2S (on KIA or TSI) Negative (positive reaction would be blackened medium) ~
Motility Negative Figure 39
Urea Negative Figure 40
Indole Positive or Negative ~
Lysine iron agar (LIA) K/A (purple slant/yellow butt) b Figure 41
a K = alkaline (red); A = acid (yellow). Some strains of S. flexneri serotype 6 and S. boydii produce gas from glucose.
b K = alkaline (purple); A = acid (yellow). An alkaline reaction in the butt of the medium indicates that lysine was
decarboxylated; an acid reaction in the butt indicates that lysine was not decarboxylated.
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FIGURE 38: Reaction typical of Shigella in Kligler iron agar (KIA): alkaline slant and acid butt
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The value of these other tests should be assessed before they are used routinely;
rationale for performing each test is included along with the following methods.
These media, their preparation, and suggested quality control strains are described
in Appendix 2.
Urea medium
Urea medium screens out urease-producing organisms (e.g., Klebsiella and
Proteus). Urea agar is inoculated heavily over the entire surface of the slant. Loosen
caps before incubating overnight at 35°–37°C. Urease-positive cultures produce
an alkaline reaction in the medium, evidenced by a pinkish-red color (Figure
40). Urease-negative organisms do not change the color of the medium, which is a
pale yellowish-pink. Shigella are always urease-negative.
Lysine iron agar
LIA is helpful for screening out Hafnia spp. and certain E. coli, Proteus, and
Providencia strains. LIA should be inoculated by stabbing the butt and streaking
the slant. After incubation for 18–24 hours at 35°–37°C, organisms that produce
lysine decarboxylase in LIA cause an alkaline reaction (purple color) in the butt of
the medium and also on the slant (Figure 41). A blackening of the medium
FIGURE 39: Motility medium showing a non-motile organism in the
left tube and a motile organism (seen as clouding) in the right tube.
FIGURE 40: Reactions in urea medium
A pink color develops in a positive urease reaction
(tube on left)
Non-motile Motile
indicates H2S production. Organisms lacking lysine decarboxylase produce an
alkaline slant (purple) and an acid butt (yellow), no gas, and no H2S. Proteus and
Providencia species will often produce a red slant caused by deamination of the
lysine. Lysine iron agar must be prepared so that the tubes have a deep butt (i.e.,
approximately 3.5 cm). Shigella are lysine-negative and characteristically produce
an alkaline (purple) slant, an acid (yellow) butt, no gas, and no H2S in LIA.
Serologic identification of Shigella
Serologic testing is needed for the identification of Shigella isolates. Serologic
identification of Shigella is performed typically by slide agglutination with
polyvalent somatic (O) antigen grouping sera, followed, in some cases, by testing
with monovalent antisera for specific serotype identification. Monovalent
antiserum to S. dysenteriae 1 is required to identify this serotype, which is the most
frequent cause of severe epidemic dysentery (Table 16). Once one colony from a
plate has been identified as Shigella, no further colonies from the same specimen
need to be tested.
Laboratorians should be aware that some Shigella commercial antiserum is
labeled or packaged differently; that is, two packages with different names may
contain the same antisera. For example, Shigella polyvalent A, which includes
antisera to serotypes 1 through 7, may also be labeled polyvalent A1. Further,
monovalent antiserum may be labeled such that it could be confused with
polyvalent antiserum; for example, monovalent antiserum to S. dysenteriae 1 may
be labeled “Shigella A1” instead of “S. dysenteriae serotype 1”. (Table 16 can serve as
a useful guide for referencing which subgroups and serotypes are associated with
what Shigella nomenclature designation.) When using newly purchased antisera,
the laboratorian should read the package insert or check with the manufacturer if
the label is not self-explanatory. All lots of antisera should undergo quality control
testing before use (Appendix 2).
Slide agglutination
Because S. dysenteriae 1 is the most common agent of epidemic dysentery
(followed by S. flexneri and S. sonnei), isolates that react typically in the screening
biochemicals should be screened first with monovalent A1 antiserum, then with
polyvalent B antiserum, and finally in polyvalent D antiserum. When a positive
agglutination reaction is obtained in one of the antisera, the Shigella subgroup is
identified, and no further testing with antisera needs to be conducted. (Because
subgroup C, S. boydii, is so rare it is not cost-effective to perform routine screens
for it.)
a) Agglutination tests may be performed in a Petri dish or on a clean glass slide.
Divide the slide into test sections with a wax pencil and place one small drop of
physiological saline in each test section on the slide.
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FIGURE 41: Reactions in lysine iron agar (LIA) medium 
Organisms positive for lysine decarboxylase produce a purple color throughout the LIA medium 
(tube on the right). Lysine-negative organisms produce a yellow color (acid) in the butt portion of the 
tube (tube on left).
b) Use an inoculating loop or needle, sterile applicator stick, or toothpick to
remove a portion of the growth from the surface of KIA, TSI, heart-infusion
agar (HIA), or other non-selective agar medium. (Serologic testing should not
be done on growth from selective media such as MacConkey or XLD agar
because selective media may yield false-negative serologic results.) Emulsify the
growth in each drop of physiological saline on the slide and mix thoroughly to
create a moderately milky suspension.
c) Add a small drop of antiserum to one of the suspensions; the second
suspension serves as the control. To conserve antiserum, volumes as small as 
10 µl can be used; a bent inoculating loop may be used to dispense small
amounts of antisera if micropipettors are not available (Figure 32). Usually
approximately equal volumes of antiserum and growth suspension are mixed,
although the volume of suspension may be as much as double the volume of
the antiserum.
d) Mix the suspension and antiserum well and then tilt the slide back and forth to
observe for autoagglutination (Figure 2). The agglutination is more visible if the
slide is observed under a bright light and over a black background. If the
reaction is positive, clumping will appear within 30 seconds to 1 minute (Figure
42). Examine the saline suspension carefully to ensure that it is even and does
not show clumping resulting from autoagglutination. If autoagglutination
occurs, the culture is termed “rough” and cannot be serotyped.
Cultures that react serologically and show no conflicting results in the biochemical
screening tests are reported as positive for Shigella.
Antimicrobial susceptibility testing of Shigella
As antimicrobial resistance increases in many parts of the world, monitoring the
antimicrobial susceptibility of Shigella becomes increasingly important. The disk
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TABLE 16: Subgroup and serotype designations of Shigella
Shigella Subgroup designation Serotypes (Label on commercial
(common name) (polyvalent antisera) (monovalent antisera) antiserum may also say)
S. dysenteriae Group A 1 – 15 a,b (A1, A2, A3, …, A13)
S. flexneri Group B 1 – 6, X,Y (B1, B2, B3, B4, B5, B6)
S. boydii c Group C 1 – 19 b (C1, C2, C3, … , C18)
S. sonnei Group D 1 (D1)
a Detection of S. dysenteriae 1 is of particular importance since it is unusually virulent and causes endemic or epidemic dysentery
with high death rates. Monovalent antiserum (absorbed) is required to identify S. dysenteriae 1.
b Additional provisional serotypes have been reported, but antisera to these new serotypes were not commercially available at the
time this manual was printed.
c Because S. boydii is so rare it is not cost-effective to perform routine screens for it.
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FIGURE 42: Serologic identification: agglutination reactions of Shigella
Shigella antiserum will agglutinate strains of the same subgroup or serotype (right); in contrast, the Shigella suspension on
the left did not agglutinate when mixed with saline.
diffusion method presented in this chapter is a modification of the Kirby-Bauer
technique that has been carefully standardized by NCCLS (an international,
interdisciplinary, nonprofit, educational organization that develops updated
consensus standards and guidelines for the healthcare community on an annual
basis),32 and if performed precisely according to the protocol below, will provide
data that can reliably predict the in vivo effectiveness of the drug in question.
However, any deviation from the method may invalidate the antimicrobial
susceptibility test results. For this reason, if laboratories lack the resources to
perform the disk diffusion test exactly as described, they should forward isolates to
other laboratories for antimicrobial susceptibility testing.
Specific methods for determination of antimicrobial susceptibility of Shigella are
presented in this chapter; however, there are some general guidelines that must
first be considered before proceeding: test isolates from the beginning of an
outbreak; test appropriate antimicrobial agents; provide timely feedback to public
health officials; and, periodically monitor the epidemic for shifts in antimicrobial
susceptibility patterns.
32 Formerly known as the “National Committee for Clinical Laboratory Standards,” NCCLS is now known 
solely by its acronym.
• Test the isolates from the beginning of an outbreak
Antimicrobial susceptibilities should be determined for the first 30 to 50
isolates identified by the laboratory at the beginning of an epidemic. That
number will provide sufficient information to develop an antimicrobial
treatment policy for the organism. After that, the laboratory should conduct
periodic surveys to detect any changes in antimicrobial susceptibility patterns.
(World Health Organization [WHO] surveillance manuals can be useful guides
for survey design.)
• Test appropriate antimicrobial agents
The laboratory should routinely test only those antimicrobial agents that are
available in the country or antimicrobial agents that are recommended by
WHO as efficacious in the treatment of shigellosis (Table 17). In addition, if
all isolates are resistant to a particular antimicrobial agent (e.g., to ampicillin)
during the first round of testing, testing against those agents during future
surveys of the outbreak strain is probably not warranted (although testing of
isolates may still be performed once or twice a year to confirm resistance).
Sending 10 to 20 of the initial isolates to an international reference laboratory
can be useful for confirmatory identification of the strain and antimicrobial
susceptibility pattern. Guidelines for the packing and shipping of etiologic
agents are included in Appendix 12.
• Provide timely feedback to public health officials
Once the organisms are isolated and the antimicrobial susceptibility patterns
determined, these results should be transmitted as quickly as possible to the
national epidemiologist and to other public health officials. The data can then
be used to make rational choices for antimicrobial treatment policy.
• Monitor for changes in antimicrobial susceptibility
As a dysentery epidemic progresses, periodic surveys of 30 to 50 isolates of
the epidemic organism should be carried out to detect any changes in the
antimicrobial susceptibility pattern of the organism causing the epidemic.
These surveys should be conducted every 2–6 months, depending on conditions
and resources. Any changes should be reported to the national epidemiologist
and to other public health officials so that the antimicrobial treatment policy
can be modified, if necessary. If any major changes are noted, it is useful to send
isolates to an international reference laboratory for confirmation.
Antimicrobial agents for treatment and testing of Shigella
The following antimicrobial agents are recommended by the WHO for treatment
of Shigella infections: ampicillin, ciprofloxacin, norfloxacin, enoxacin, nalidixic
acid, pivmecillinam, and trimethoprim-sulfamethoxazole (often referred to as
cotrimoxazole).
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Antimicrobial agents suggested for use in susceptibility testing of Shigella are listed
in Table 17; these WHO recommendations are current as of the date of publication
of this document.
Testing Shigella against certain drugs may yield misleading results when in vitro
results do not correlate with in vivo activity. Shigella isolates, for instance, are
usually susceptible to aminoglycosides (e.g., gentamicin, kanamycin) and first- and
second-generation cephalosporins in the disk diffusion test, but treatment with
these drugs is often not effective [NCCLS 2002].
The selection of antimicrobial treatment should be based on the results of recent
antimicrobial susceptibility testing of Shigella strains obtained from the same
region (or from nearby areas if Shigella is new to the area). Unfortunately,
resistance of Shigella to ampicillin and trimethoprim-sulfamethoxazole has
become widespread. Nalidixic acid, formerly used as a “backup” drug to treat
resistant shigellosis, is now the drug of choice in most areas, but resistance to it has
appeared in many places. When resistant to nalidixic acid, Shigella should be tested
with ciprofloxacin; strains resistant to nalidixic acid often exhibit reduced
susceptibility to ciprofloxacin. Pivmecillinam (i.e., amdinocillin pivoxil) is still
effective for most strains of Shigella but may not be readily available.
Fluoroquinolones (e.g., ciprofloxacin, norfloxacin, and enoxacin) are often costly
and may not be readily available; fluoroquinolones should be considered only if
Shigella isolates are resistant to nalidixic acid.
As of the publication of this document (2002), Shigella strains are often resistant to
ampicillin, trimethoprim-sulfamethoxazole, metronidazole, streptomycin,
tetracycline, chloramphenicol, and sulfonamides. In addition, although Shigella
may be susceptible to some antimicrobial agents in vitro, the drug may have no
documented efficacy in vivo. Examples of such agents are nitrofurans (e.g.,
nitrofurantoin, furazolidone), aminoglycosides (e.g., gentamicin, kanamycin), first-
and second-generation cephalosporins (e.g., cephalexin, cefamandol), and
amoxicillin.
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TABLE 17: Antimicrobial agents suggested for use in antimicrobial susceptibility testing of Shigella





*If resistant to nalidixic acid, the isolate should be tested for susceptibility to ciprofloxacin,
and will probably exhibit reduced susceptibility to ciprofloxacin.
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Procedure for agar disk diffusion antimicrobial susceptibility testing of Shigella
The disk diffusion method of antimicrobial susceptibility testing is similar to that
described in the S. Typhi chapter, and is summarized in Figure 33. Laboratory
diagnostic supplies required for Shigella disk diffusion testing are listed in
Appendix 9. This section provides seven steps for antimicrobial susceptibility
testing of Shigella by the disk diffusion method.
1. Mueller-Hinton antimicrobial susceptibility test agar 
Mueller-Hinton agar medium is the only antimicrobial susceptibility test
medium that has been validated by NCCLS. Mueller-Hinton agar, poured to a
uniform depth of 3–4mm, should always be used for disk diffusion
antimicrobial susceptibility testing, according to NCCLS and international
guidelines. Because the way in which Mueller-Hinton is prepared can affect disk
diffusion test results, this medium should be prepared strictly according to the
methods and quality control instructions presented in Appendix 2.
2. McFarland turbidity standard
A 0.5 McFarland turbidity standard should be prepared and quality controlled
prior to beginning antimicrobial susceptibility testing (Appendix 2, Figure 50).
If tightly sealed to prevent evaporation and stored in the dark, the turbidity
standard can be stored for up to 6 months. The 0.5 McFarland turbidity
standard is used to adjust the turbidity of the inoculum for the antimicrobial
susceptibility test.
3. Preparation of inoculum
Each culture to be tested should be streaked onto a non-inhibitory agar medium
(e.g., blood agar, brain heart infusion agar, or tryptone soy agar [TSA]) to obtain
isolated colonies. After incubation at 35°C overnight, select 4 or 5 well-isolated
colonies with an inoculating needle or loop, and transfer the growth to a tube of
sterile saline or nonselective broth (e.g., Mueller-Hinton broth, heart infusion
broth, or tryptone soy broth [TSB]) and vortex thoroughly. The bacterial
suspension should then be compared to the 0.5 McFarland turbidity standard.
This comparison can be made more easily if the tubes are viewed against a sheet
of white paper on which sharp black lines are drawn (Figures 51 and 52 in the
McFarland turbidity standard section of Appendix 2). The turbidity standard
should be agitated on a vortex mixer immediately prior to use. If the bacterial
suspension does not appear to be the same density as the 0.5 McFarland
turbidity standard, the turbidity can be reduced by adding sterile saline or broth,
or increased by adding more bacterial growth.
Alternatively, the growth method may be used to prepare the inoculum. Pick
four or five colonies from overnight growth on agar and inoculate them into
broth (Mueller-Hinton broth, heart infusion broth, or TSB). Incubate the broth
at 35˚C until turbid (usually 16–24 hours), and then adjust the turbidity to the
proper density.
4. Inoculation procedure
Within 15 minutes after adjusting the turbidity of the inoculum suspension, dip
a sterile cotton swab into the suspension. Pressing firmly against the inside wall
of the tube just above the fluid level, rotate the swab to remove excess liquid.
Streak the swab over the entire surface of the medium three times, rotating the
plate approximately 60 degrees after each application to ensure an even
distribution of the inoculum (Figure 34). Finally, swab around the entire edge
of the agar surface.
5. Antimicrobial disks
The working supply of antimicrobial disks should be stored in the refrigerator
(at 4°C). Upon removal of the disks from the refrigerator, the package
containing the cartridges should be left unopened at room temperature for
approximately 1 hour to allow the temperature to equilibrate; this reduces the
amount of condensation on the disks. If a disk-dispensing apparatus is used, it
should have a tight-fitting cover, be stored in the refrigerator, and be allowed to
warm to room temperature before using.
Apply the antimicrobial disks to the plates as soon as possible after the plate is
dry, but no longer than 15 minutes after inoculation. Place the disks
individually with sterile forceps or with a mechanical dispensing apparatus,
equidistant from each other, and then gently press down onto the agar. In
general, no more than 12 disks are placed on a 150-mm plate and no more
than four disks are placed on a 100-mm plate to prevent overlapping of the
zones of inhibition and possible resultant error in measurement. Diffusion of
the drug in the disk begins immediately; therefore, once a disk contacts the
agar surface, the disk should not be moved. After the disks are placed on the
plate, invert the plate and incubate at 35°C for 16–18 hours.
6. Recording and interpreting results
After incubation, measure the diameter of the zones of complete inhibition
(including the diameter of the disk) (Figure 43) and record it in millimeters.
(A sample worksheet is provided in Figure 44.) The measurements can be made
with calipers or a ruler on the undersurface of the plate without opening the
lid. With sulfonamides and trimethoprim-sulfamethoxazole, a slight amount of
growth may occur within the inhibition zone. In this instance, slight growth
(approximately 80% inhibition) should be ignored and the zone diameter
should be measured to the margin of heavy growth. The zones of growth
inhibition should be compared with the zone-size interpretative table (Table
18), and recorded as susceptible, intermediate, or resistant to each drug tested.
Colonies growing within the clear zone of inhibition may represent resistant
variants or a mixed inoculum. Measure the distance from the inner-most
colonies (i.e., those closest to the disk) to the center of the antimicrobial disk,
and double this measurement to obtain the diameter; record the measurement
and interpretation of antimicrobial susceptibility (Figure 44). If there is 
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both an inner- and outer zone of inhibition of growth around the
antimicrobial disk:
a) If a purity plate was prepared, check the streak to confirm the culture was
pure. (Step a is optional.)
b) Record the diameter and interpretation of antimicrobial susceptibility of
those colonies in the outer zone (i.e., in addition to those in the inner zone).
c) Pick the colonies inside the zone, streak for isolation on a new plate, confirm
their identification, and perform the disk diffusion test again to confirm the
previous results.
The presence of colonies within a zone of inhibition may predict eventual
resistance to that antimicrobial agent.
7. Quality control 
To verify that antimicrobial susceptibility test results are accurate, at least one
control organism should be included with each test. (ATCC 25922 is the E. coli
control strain used when testing Enterobacteriaceae [e.g., Shigella, Salmonella,
Escherichia, Klebsiella] and V. cholerae.) Zone diameters obtained for ATCC
25922 should be compared with NCCLS published limits; Table 18 includes the
diameters of the zones of inhibition for ATCC 25922. If zones produced by the
control strain are out of the expected ranges, the laboratorian should consider
possible sources of error.
TABLE 18: Zone size interpretive standards for Enterobacteriaceae for selected antimicrobial disks appropriate for the testing of
Shigella
Diameter of zone of inhibition (mm)
Antimicrobial Disk and equivalent MIC breakpoint(µg/ml) NCCLS QC strain
agent potency Susceptible Intermediate Resistant E. coli ATCC 25922
Ampicillin 10 µg ≥ 17 mm 14 – 16 mm ≤ 13 mm 16 – 22 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8 µg/ml)
Chloramphenicol 30 µg ≥ 18 mm 13 – 17 mm ≤ 12 mm 21 – 27 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8 µg/ml)
Trimethoprim- 1.25 / ≥ 16 mm 11 – 15 mm ≤ 10 mm 23 – 29 mm
sulfamethoxazole 23.75 µg (≤ 2/38 µg/ml) (4/76 µg/ml) (≥ 8/152 µg/ml) (≤ 0.5/9.5 µg/ml)
(cotrimoxazole)
Nalidixic acid 30 µg ≥ 19 mm 14 – 18 mm ≤ 13 mm 22 – 28 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (1–4 µg/ml)
Ciprofloxacin 5 µg ≥ 21 mm 16 – 20 mm ≤ 15 mm 30 – 40 mm
(≤ 1 µg/ml) (2 µg/ml) [≥ 4 µg/ml) (0.004–0.016 µg/ml)
Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement.
NCCLS document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087 USA.
Antimicrobial susceptibility tests are affected by variations in media,
inoculum size, incubation time, temperature, and other factors. The medium
used may be a source of error if it fails to conform to NCCLS recommended
guidelines. For example, agar containing excessive amounts of thymidine or
thymine can reverse the inhibitory effects of sulfonamides and trimethoprim,
causing the zones of growth inhibition to be smaller or less distinct. Organisms
may appear to be resistant to these drugs when in fact they are not. If the depth
of the agar in the plate is not 3–4 mm, the rate of diffusion of the antimicrobial
agents or the activity of the drugs may be affected.
If the inoculum is not a pure culture or does not contain a concentration of
bacteria that approximates the 0.5 McFarland turbidity standard, the
antimicrobial susceptibility test results will be affected. For instance, a
resistant organism could appear to be susceptible if the inoculum is too light.
Shigella | 137
FIGURE 43: Sample results of the disk diffusion assay
This Shigella isolate is resistant to trimethoprim-sulfamethoxazole (cotrimoxazole) and is growing up to the disk
(SXT), the zone of which is recorded as 6 mm. In addition to the zones of inhibited growth, note how evenly 
distributed the growth is on the plate.
























































































































































































Also, if colonies from blood agar medium are used to prepare a suspension 
by the direct inoculum method, trimethoprim or sulfonamide antagonists may
be carried over and produce a haze of growth inside the zones of inhibition
surrounding trimethoprim-sulfamethoxazole disks even when the isolates 
being tested are susceptible.
If antimicrobial disks are not stored properly or are used beyond the stated
expiration date, their potency may decrease; this will usually be indicated by 
a decrease in the size of the inhibition zone around the control strain.
Data for decision-making: informed epidemic response
Once the laboratory has assessed the identity and antimicrobial susceptibility
patterns of the Shigella isolates, the information should be reported to public
health officials in a timely manner. Factors to consider in the development of a
treatment policy include:
• The antimicrobial agent chosen should be effective against at least 80% of
local Shigella strains.
• The antimicrobial agent chosen should be able to be given by mouth.
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be available locally (or be able to be
obtained quickly).
Consideration of such factors when making data-based decisions will help public
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Most Vibrio cholerae isolated during cholera outbreaks will be toxigenicserogroup O1 or O139. Because the cultural and biochemical characteristicsof these two serogroups are identical, the isolation and identification
methods described below apply to both O1 and O139. Both serogroups must be
identified using O-group-specific antisera.
Isolates of V. cholerae serogroup O1 are classified into two biotypes, El Tor and
classical, on the basis of several phenotypic characteristics. Currently, the El Tor
biotype is responsible for virtually all of the cholera cases throughout the world,
and classical isolates are not encountered outside of India or Bangladesh. In
addition, V. cholerae O1 is classified into two serotypes (Inaba and Ogawa) on the
basis of agglutination in antiserum. A possible third serotype, Hikojima, has been
described, but it occurs only rarely. During an outbreak or epidemic, it is worth
documenting the biotype and serotype of the isolate; however, it is not necessary 
to know this information to respond appropriately to the epidemic.
V. cholerae serogroup O139 appeared in India in late 1992. It quickly spread to
Bangladesh and other Asian countries, although the rate of spread has slowed after
the initial outbreaks. Through 1998, 11 countries have officially reported
transmission of V. cholerae O139 to the World Health Organization (WHO).
Imported cases have been reported from the United States and other countries.
At this time, endemic V. cholerae O139 appears to be confined to Asia.
Fluid replacement is the cornerstone of cholera treatment, and rehydration therapy
is a necessity. Antimicrobial therapy is helpful, although not essential, in treating
cholera patients. Antimicrobial agents reduce the duration of illness, the volume of
stool, and the duration of shedding of vibrios in the feces. When antimicrobial
agents are used, it is essential to choose one to which the organism is susceptible.
Antimicrobial agents recommended by WHO for treating cholera patients as of the
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furazolidone, trimethoprim-sulfamethoxazole, erythromycin, or chloramphenicol.
Ciprofloxacin and norfloxacin are also effective. Because antimicrobial resistance
has been a growing problem in many parts of the world, the susceptibility of V.
cholerae O1 strains to antimicrobial agents should be determined at the beginning
of an epidemic and be monitored periodically. Methods for antimicrobial
susceptibility testing of V. cholerae are addressed in this chapter of the manual,
after identification. Isolation and presumptive identification of V. cholerae from
fecal specimens are included in Appendix 10.
Public health authorities in regions that experience outbreaks of cholera may find
that the manual Laboratory Methods for the Diagnosis of Epidemic Dysentery and
Cholera [CDC 1999] provides additional helpful discussions about cholera
epidemiology and laboratory decision-making in resource-limited regions. The
document is available from WHO in English and French; details for ordering are
included in Appendix 15.
Identification of V. cholerae
Methods for the collection and transport of fecal specimens and the primary
isolation and presumptive identification on selective agar are included in
Appendices 9 and 10. Suspect V. cholerae isolates should be subcultured to a non-
selective medium (e.g., heart infusion agar [HIA] or tryptone soy agar [TSA]) in
preparation for identification by slide serology and biochemical tests. V. cholerae
requires 0.5% NaCl (i.e., salt) for optimal growth on agar media; some
commercially available formulations of nutrient agar do not contain salt and
should not be used for culture of V. cholerae. In general, screening with
biochemical tests prior to testing with O1 and O139 antisera is not necessary for
suspected V. cholerae isolates from fecal specimens. However, if the supply of O-
antigen antisera is limited, biochemical tests may be useful for additional
screening of isolates before testing them with antisera. Screening tests and slide
serology must be performed with growth from nonselective media. Figure 45
presents a flowchart for isolation and identification of an isolate as V. cholerae, and
Figure 46 provides a sample worksheet that can be used to record screening test
results.
Oxidase test 
The oxidase test uses Kovac’s reagent (a 1% [wt/vol] solution of N, N, N’, N’
–tetramethyl-ρ-phenylenediamine dihydrochloride) to detect the presence of
cytochrome c in a bacterial organism’s respiratory chain; if the oxidase reagent is
catalyzed, it turns purple. The oxidase test can be performed on filter paper or 
on a swab.
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If O139 positive:
Send isolate to international 
reference laboratory for 
confirmation and toxin testing
FIGURE 45: Flowchart for isolation and identification of Vibrio cholerae
Antimicrobial susceptibility testing by
disk diffusion method on 
Mueller-Hinton agar
Use growth from TSA / HIA
(non-selective agars) for 
serology & optional biochemical tests
Stool specimens should be plated on 
selective media (TCBS) as soon as possible
after arrival at the laboratory. Plate a sin-
gle drop of liquid stool or fecal suspension
or use a rectal/fecal swab.
* Suspect Hikojima isolates should
be sent to international reference
laboratory
Fecal specimen
if APW cannot be streaked after 6-8 hours 
of incubation, subculture at 18 hours 
to a fresh tube of APW; incubate 
for 6-8 hours and streak to TCBS.
Optional: Enrich in APW for 6–8 hours * 
at 35˚–37˚C
Other appearance upon macroscopic 
examination of TCBS = negative
Macroscopic examination of growth on
TCBS agar shows yellow, shiny colonies
that are 2-4 mm in diameter. May be
flat with elevated center.
Optional Confirmatory Screening Tests:
KIA: K/A a, no gas, no H2S (red slant /yellow butt)
TSI: A/A a, no gas, no H2S (yellow slant/yellow butt)
LIA: K/K a, no gas, no H2S (purple slant/purple butt)
String test: positive
Oxidase testb: positive
Gram stain: small, curved rods
a K= alkaline reaction, A= acid reaction
b Oxidase test must be performed on growth 
from a non-carbohydrate medium (e.g., HIA).
Saline control and 
polyvalent O1 antiserum
Saline control plus Inaba and
Ogawa antisera
V. cholerae O1 serotype Inaba
or Ogawa *
Positive in O1 antiserum Negative for O1 Ÿ test in O139 antiserum




Inoculate to non-selective agar (e.g., HIA, TSI)
Positive
Serogroup identification (slide agglutination)
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Perform the oxidase test with fresh growth from an HIA or TSA slant or any non-
selective, non-carbohydrate-containing medium; do not use growth from
thiosulfate citrate bile-salts sucrose [TCBS] agar because it may yield either false-
negative or false-positive results. Do not perform this test with a Nichrome loop,
as it may produce a false-positive reaction. Positive and negative controls should be
tested at the same time as the test isolate for quality control purposes. Preparation
of the oxidase reagent is described in Appendix 2.
Moistened filter paper method
a) Add two to three drops of Kovac’s oxidase reagent to a piece of filter paper in a
petri dish and allow it to absorb; the filter paper should be moist (but not wet)
after the reagent has been absorbed.
b) Using a platinum loop, a plastic loop, a sterile swab, or a sterile wooden
applicator stick or toothpick, pick a portion of the colony to be tested from
non-selective media and rub it onto the moistened filter paper. (Do not use a
Nichrome loop.) 
c) If the isolate is V. cholerae, a positive (purple) reaction should occur in the
region where the growth has been smeared within 10 seconds (Figure 10).
Swab method
a) Pick up suspect colonies from a non-selective culture plate or growth from a
non-selective agar slant with the swab.
b) Use a Pasteur pipette to add one drop of Kovac’s oxidase reagent to the swab.
c) If the isolate is V. cholerae, a positive (purple) reaction should occur within 10
seconds. (See Figure 20).
If an isolate has not turned purple within 10 seconds of adding the Kovac’s oxidase
reagent, it is not considered oxidase-positive. Organisms of the genera Vibrio
(Table 19), Neisseria, Campylobacter, Aeromonas, Plesiomonas, Pseudomonas, and
Alcaligenes are all oxidase-positive; all Enterobacteriaceae are oxidase-negative.
Additional biochemical screening tests
The string reaction, Kligler iron agar (KIA) or triple sugar iron agar (TSI), lysine
iron agar (LIA), Gram stain, and wet mount for motility are other possible tests
that may be used for additional screening of isolates before testing with antisera
(Table 19). The value of these other tests should be assessed before they are used
routinely; rationale for performing each test (e.g., use of the string test to rule out
Aeromonas) is included along with the following methods. These media, their
preparation, and suggested quality control strains are described in Appendix 2.
String test
The string test uses fresh growth from nonselective agar and is useful for ruling out
non-Vibrio species, particularly Aeromonas species. The string test may be
performed on a glass microscope slide or plastic petri dish by suspending 18- to
24-hour growth from heart infusion agar (or other noninhibitory medium) in a
drop of 0.5% aqueous solution of sodium deoxycholate. If the result is positive, the
bacterial cells will be lysed by the sodium deoxycholate, the suspension will lose
turbidity, and DNA will be released from the lysed cells, causing the mixture to
become viscous. A mucoid “string” is formed when an inoculating loop is drawn
slowly away from the suspension (Figure 47). V. cholerae strains are positive,
whereas Aeromonas strains are usually negative (Table 19). Other Vibrio species
may give a positive or weak string test reaction.
Kligler iron agar and triple sugar iron agar 
KIA and TSI can be used to rule out Pseudomonas species and certain
Enterobacteriaceae. It is important that Kligler iron agar and triple sugar iron
agar be prepared so the tubes have a deep butt and a long slant; if the butt is not
deep enough, misleading reactions may occur in these media (Appendix 2). A
tube prepared so that the butt is approximately 3.5-cm deep and the slant is
approximately 2.5-cm is acceptable.
KIA or TSI agar slants are inoculated by stabbing the butt and streaking the surface
of the medium. Incubate the slants at 35°–37°C and examine after 18–24 hours.
Caps on all tubes of biochemical media should be loosened before incubation,
but this is particularly important for KIA or TSI slants. If the caps are too tight
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TABLE 19: Reactions of Vibrio cholerae in screening tests




String test Positive Figure 47
Kligler iron agar (KIA) K/A (red slant/yellow butt)a, no gas produced,
no H2S [18–24 hours] Figure 48
Triple sugar iron agar (TSI) A/A (yellow slant/yellow butt)a, no gas produced,
no H2S [18–24 hours] Figure 48
Lysine iron agar (LIA) K/K (purple slant / purple butt)a,b, no gas produced,
no H2S [18–24 hours] –
Gram stain Small, gram-negative curved rods –
Wet mount Small, curved rods with darting motility –
a K= alkaline; A= acid
b An alkaline reaction (purple) in the butt of the medium indicates that lysine was decarboxylated.
An acid reaction (yellow) in the butt indicates that lysine was not decarboxylated.
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and anaerobic conditions exist in the tube, an inappropriate reaction will occur
and the characteristic reactions of V. cholerae may not be exhibited.
The reactions of V. cholerae on KIA, which contains glucose and lactose, are similar
to those of lactose-nonfermenting Enterobacteriaceae (i.e., alkaline [red] slant, acid
[yellow] butt, no gas, and no H2S). However, on TSI, V. cholerae strains produce an
acid (yellow) slant, acid (yellow) butt, no gas, and no H2S (Table 19 and Figure 48).
Lysine iron agar
LIA is helpful for screening out Aeromonas and certain Vibrio species, which,
unlike V. cholerae, do not decarboxylate lysine. LIA must be prepared so that the
tubes have a deep butt (approximately 3.5 cm) and a long slant (approximately 2.5
cm). As with KIA and TSI, if the butt is not deep enough, misleading reactions
may occur in this medium. In LIA, the decarboxylation of lysine occurs only in
anaerobic conditions and a false-negative reaction may result from insufficient
medium in the tube (Appendix 2). Inoculate LIA by stabbing the butt and then
FIGURE 47: A positive string test with Vibrio cholerae
streaking the slant; after incubation for 18–24 hours at 35°–37°C, examine the LIA
slants for reactions typical of V. cholerae. Organisms that produce lysine
decarboxylase in LIA cause an alkaline reaction (purple color) in the butt of the
tube (Figure 41); organisms without the enzyme produce an acid reaction (yellow
color) in the butt portion of the tube. H2S production is indicated by a blackening
of the medium. The LIA reaction for V. cholerae is typically an alkaline slant
(purple), alkaline butt (purple), no gas, and no H2S (Table 19). Proteus and
Providencia spp. will often produce a red slant caused by deamination of the lysine.
Gram stain 
Examining overnight growth of Vibrio cholerae from a heart infusion agar slant by
Gram stain will demonstrate typical small, curved gram-negative rods (Table 19).
Staining with crystal violet only is a more rapid technique that will also
demonstrate the cell morphology typical of Vibrio species.
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V. cholerae in 
TSI agar
(A/A = acid slant,
acid butt, no gas*)
Yellow (acid) butt
* Red color indicates an alkaline reaction, and yellow indicates acid. V. cholerae
does not produce gas or H2S in either KIA or TSI agar. If gas were present, the
agar would appear to be fractured, or cracked. Production of H2S would be 




V. cholerae in 
KIA agar
(K/A = alkaline slant,
acid butt, no gas*)
Yellow (acid) butt
KIA slant TSI slant
Wet mount
Dark-field and phase-contrast microscopy have been used for screening suspected
isolates of V. cholerae. With these techniques, saline suspensions are microscopically
examined for the presence of organisms with typical small, curved rods and darting
(i.e., “shooting star”) motility (Table 19).
Serologic identification of V. cholerae O1 and O139
Following presumptive biochemical identification of the agent as V. cholerae, it is
appropriate to confirm identification with serology. If an epidemic of cholera is
suspected, the most common cause is V. cholerae O1. If V. cholerae O1 is not
isolated, the laboratory should test for V. cholerae O139. If neither of these
organisms is isolated, arrangements should be made to send stool specimens to a
reference laboratory. Local and regional laboratories should send isolates requiring
testing with O139 antiserum to the national reference laboratory; if the national
reference laboratory is still unable to confirm the identification of a V. cholerae
isolate as O1 or O139, an international reference laboratory can provide guidance.
To conserve resources, the laboratory can first test V. cholerae for somatic O1
antigens, and then test with O139 antiserum only if the isolate does not yield a
positive agglutination reaction in the O1 antiserum.
Presumptive identification using O1 and O139 antisera
For slide agglutination testing with polyvalent O1 or O139 antisera, fresh growth
of suspected V. cholerae from a nonselective agar medium should be used. (Using
growth from thiosulfate citrate bile salts sucrose (TCBS) agar may result in
false-negative reactions.) After 5–6 hours of incubation, growth on the surface of
the slant is usually sufficient to perform slide agglutination with antisera; if not,
incubate for a longer period. If the isolate does not agglutinate in O1 antiserum,
test in O139 antiserum. If it is positive in the polyvalent O1 or in the O139
antiserum, the isolate may be reported as presumptive V. cholerae O1 or O139.
Presumptive V. cholerae O1 isolates should be tested in monovalent Ogawa and
Inaba antisera (methods follow this section). Once one colony from a plate has
been identified as V. cholerae O1 or O139, no further colonies from the same plate
need to be tested. [Refer to Appendix 2 for a discussion on quality control of
antisera.]
Confirmation of V. cholerae O1 using Inaba and Ogawa antisera
The O1 serogroup of V. cholerae has been further divided into three serotypes:
Inaba, Ogawa, and Hikojima (which is very rare). Serotype identification is based
on agglutination in monovalent antisera to type-specific O antigens (Table 20). A
positive reaction in either Inaba or Ogawa antiserum is sufficient to confirm the
identification of a V. cholerae O1 isolate. Isolates that agglutinate weakly or slowly
with serogroup O1 antiserum but do not agglutinate with either Inaba or Ogawa
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antiserum are not considered to be serogroup O1. Identifying these antigens is
valid only with serogroup O1 isolates. For this reason, Inaba and Ogawa antisera
should never be used with strains that are negative with polyvalent O1 antiserum.
Strains of one serotype frequently produce slow or weak agglutination in
antiserum to the other serotype, depending on how well the serotype-specific
antisera have been absorbed. For this reason, agglutination reactions with Inaba
and Ogawa antisera should be examined simultaneously, and the strongest and
most rapid reaction should be used to identify the serotype. With adequately
absorbed antisera, strains that agglutinate very strongly and equally with both the
Ogawa and Inaba antisera are rarely, if ever, encountered. If such reactions are
suspected, the strains should be referred to a reference laboratory for further
examination and may be referred to as “possible serotype Hikojima.”
Slide agglutination procedure
Agglutination tests for V. cholerae somatic O antigens may be conducted in a Petri
dish or on a clean glass slide.
a) Divide the slide into test sections with a wax pencil and place one small drop of
physiological saline in each test section on the slide.
b) Use an inoculating loop or needle, sterile applicator stick, or toothpick to
remove a portion of the growth from the surface of KIA, TSI, HIA, or other
non-selective agar medium. (Serologic testing should not be done on growth
from selective media such as MacConkey or XLD agar because selective media
may yield false-negative serologic results.) Emulsify the growth in each drop of
physiological saline on the slide and mix thoroughly to create a moderately
milky suspension.
c) Add a small drop of antiserum to one of the suspensions; the second suspension
serves as the control. To conserve antiserum, volumes as small as 10 µl can be
used; a bent inoculating loop may be used to dispense small amounts of antisera
if micropipettors are not available (Figure 32). Usually approximately equal
volumes of antiserum and growth suspension are mixed, although the volume of
suspension may be as much as double the volume of the antiserum.
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TABLE 20: Agglutination reactions in absorbed antiserum of serotypes of Vibrio cholerae serogroup O1
V. cholerae O1 serotype Ogawa antiserum Inaba antiserum
Ogawa + a – b
Inaba – +
Hikojima c + +
a + indicates a positive agglutination reaction in the absorbed antiserum.
b  –  indicates a negative agglutination reaction in the absorbed antiserum.
c If there is a positive reaction in both Ogawa and Inaba antisera and the Hikojima serotype is suspected, send the isolate to an 
international reference laboratory, following packing regulations as presented in Appendix 12.
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d) Mix the suspension and antiserum well and then tilt the slide back and forth to
observe for autoagglutination (Figure 2). The agglutination is more visible if the
slide is observed under a bright light and over a black background. If the
reaction is positive, clumping will appear within 30 seconds to 1 minute (Figure
42). Examine the saline suspension carefully to ensure that it is even and does
not show clumping resulting from autoagglutination. If autoagglutination
occurs, the culture is termed “rough” and cannot be serotyped.
Confirmation of V. cholerae O139 
A suspected V. cholerae isolate that reacts in O139 antiserum but not in polyvalent
O1 antiserum should be sent to a reference laboratory. Confirmation of V. cholerae
O139 includes testing for production of cholera enterotoxin and verification of
the O139 antigen by slide agglutination with O139 antiserum. No serotypes have
been identified in the O139 serogroup. Enterotoxin assays (e.g., PCR, EIA, DNA
probing) are complex and beyond the scope of this manual. Few laboratories are
capable of doing these tests, and they are performed mainly by international
reference laboratories. (See Appendix 12 for packing and shipping regulations 
and Appendix 14 for a list of international reference laboratories.)
Following identification of the agent, it is appropriate for the laboratorian to
commence testing for antimicrobial susceptibility patterns if antimicrobial agents
are to be used to treat the cholera outbreak.
Antimicrobial susceptibility testing of V. cholerae
As antimicrobial resistance increases in many parts of the world, monitoring the
antimicrobial susceptibility of Vibrio cholerae O1 and O139 has become increasingly
important. The disk diffusion method presented in this chapter is a modification of
the Kirby-Bauer technique that has been carefully standardized by NCCLS (an
international, interdisciplinary, nonprofit, educational organization that develops
updated consensus standards and guidelines for the healthcare community on an
annual basis),33 and if performed precisely according to the protocol below, will
provide data that can reliably predict the in vivo effectiveness of the drug in
question. However, any deviation from the testing method may invalidate the
antimicrobial susceptibility test results. For this reason, if laboratories lack the
resources to perform the disk diffusion test exactly as described, they should
forward isolates to other laboratories for antimicrobial susceptibility testing.
Specific methods for determination of antimicrobial susceptibility patterns of
V. cholerae are presented in this manual; however, there are some general guidelines
that must first be considered before proceeding: test isolates from the beginning of
33 Formerly known as the “National Committee for Clinical Laboratory Standards,” NCCLS is now known solely by its
acronym.
an outbreak; test appropriate antimicrobial agents; provide timely feedback to
public health officials; and, periodically monitor the epidemic for shifts in
antimicrobial susceptibility patterns.
• Test the isolates from the beginning of the outbreak 
Antimicrobial susceptibilities should be determined for the first 30 to 50
isolates identified by the laboratory at the beginning of an epidemic. That
number will provide sufficient information to develop an antimicrobial
treatment policy for the organism. After that, the laboratory should conduct
periodic surveys to detect any changes in antimicrobial susceptibility patterns.
WHO surveillance manuals can provide guidance in the development of such
surveys.
• Test appropriate antimicrobial agents
The laboratory should not routinely test antimicrobial agents that are not
available in the country or antimicrobial agents that are not recommended by
WHO as efficacious in the treatment of cholera (Table 21). In addition, if all
isolates are resistant to a particular antimicrobial agent (e.g., to ampicillin)
during the first round of testing, testing against those agents during future
surveys of the outbreak strain is probably not warranted (although testing of
isolates may still be performed once or twice a year to confirm resistance).
Sending 10 to 20 of the initial isolates to an international reference laboratory
(Appendix 14) can be useful for confirmatory identification of the strain and
antimicrobial susceptibility pattern. Guidelines for the packing and shipping of
etiologic agents are included in Appendix 12.
• Provide timely feedback to public health officials
Once the organisms are isolated and the antimicrobial susceptibility patterns
determined, these results should be transmitted as quickly as possible to the
national epidemiologist and to other public health officials. The data can then
be used to make rational choices for antimicrobial treatment policy.
• Monitor for changes in antimicrobial susceptibility
As a cholera epidemic progresses, periodic surveys of 30 to 50 isolates of the
epidemic organism should be carried out to detect any changes in the
antimicrobial susceptibility pattern of the organism causing the epidemic.
These surveys should be conducted every 2–6 months, depending on conditions
and resources. Any changes should be reported to the national epidemiologist
and to other public health officials so that the antimicrobial treatment policy
can be modified, if necessary. If any major changes are noted, it is useful to send
isolates to an international reference laboratory for confirmation.
The antimicrobial agents recommended by the WHO for testing of V. cholerae are
included in Table 21; these recommendations are current as of 2002.
In addition to the general principles of antimicrobial susceptibility testing
presented in the previous section, there are several special considerations to be
heeded when performing disk diffusion testing of Vibrio cholerae:
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• Although the disk diffusion technique is the most commonly used method 
for antimicrobial susceptibility testing, zone size interpretive criteria for 
V. cholerae O1 and O139 have been established by NCCLS only for ampicillin,
chloramphenicol, sulfonamides, tetracycline, and trimethoprim-
sulfamethoxazole. The interpretations of susceptible, intermediate and resistant
for isolates tested against these drugs by disk diffusion correlate well with the
minimum inhibitory concentration (MIC) results determined by broth
microdilution.
• Disk diffusion tests should not be used for doxycycline and erythromycin
because the results for these drugs are frequently inaccurate for V. cholerae O1
and O139 strains. Therefore, these agents should not be tested using this
method.
• The results from the tetracycline disk should be used to predict susceptibility to
doxycycline. If a strain is susceptible to tetracycline, it will also be susceptible to
doxycycline.
• At this time there is no in vitro method to accurately determine susceptibility to
erythromycin.
• The reliability of disk diffusion results for other antimicrobial agents, including
ciprofloxacin, furazolidone, and nalidixic acid, has not been validated.
3 Until interpretive criteria have been established for V. cholerae, disk diffusion
may be used to screen V. cholerae for resistance to ciprofloxacin, using
NCCLS interpretive criteria for the Enterobacteriaceae (Table 22).
3 Tentative breakpoints have been proposed for testing furazolidone and
nalidixic acid with V. cholerae based on multi-laboratory studies using NCCLS
testing methodologies. When screening with the disk diffusion method for
these agents, results should be interpreted with caution (Table 22).
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TABLE 21: Antimicrobial agents suggested for use in susceptibility testing of Vibrio cholerae O1 and O139





a The results from the tetracycline disk are also used to predict susceptibility to doxycycline.
b If resistant to nalidixic acid, the isolate should be tested for susceptibility to ciprofloxacin,
and will probably exhibit reduced susceptibility to ciprofloxacin.
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Procedure for agar disk diffusion antimicrobial susceptibility testing of V. cholerae
Laboratory diagnostic supplies required for V. cholerae disk diffusion testing are
listed in Appendix 9. Figure 33 summarizes the disk diffusion method of
antimicrobial susceptibility testing for enteric bacterial pathogens. The following
section provides seven steps for antimicrobial susceptibility testing of Vibrio
cholerae by the disk diffusion method.
1. Mueller-Hinton antimicrobial susceptibility test agar
Mueller-Hinton agar medium is the only antimicrobial susceptibility test
medium that has been validated by NCCLS. Mueller-Hinton agar, poured to 
a uniform depth of 3–4 mm, should always be used for disk diffusion
antimicrobial susceptibility testing, according to NCCLS and international
guidelines. Because the way in which Mueller-Hinton is prepared can affect disk
diffusion test results, this medium should be prepared strictly according to the
methods and quality control instructions presented in Appendix 2.
2. McFarland turbidity standard
A 0.5 McFarland turbidity standard should be prepared and quality controlled
prior to beginning antimicrobial susceptibility testing (Appendix 2, Figure 50).
If tightly sealed to prevent evaporation and stored in the dark, the turbidity
standard can be stored for up to 6 months. The 0.5 McFarland turbidity
standard is used to adjust the turbidity of the inoculum for the antimicrobial
susceptibility test.
3. Preparation of inoculum
Each culture to be tested should be streaked onto a non-inhibitory agar
medium (e.g., blood agar, brain heart infusion agar, or tryptone soy agar [TSA])
to obtain isolated colonies. After incubation at 35°C overnight, select 4 or 5
well-isolated colonies with an inoculating needle or loop, and transfer the
growth to a tube of sterile saline or nonselective broth (e.g., Mueller-Hinton
broth, heart infusion broth, or tryptone soy broth [TSB]) and vortex
thoroughly. The bacterial suspension should then be compared to the 0.5
McFarland turbidity standard. This comparison can be made more easily if
the tubes are viewed against a sheet of white paper on which sharp black lines
are drawn (Figures 51 and 52 in the McFarland turbidity standard section of
Appendix 2). The turbidity standard should be agitated on a vortex mixer
immediately prior to use. If the bacterial suspension does not appear to be the
same density as the 0.5 McFarland turbidity standard, the turbidity can be
reduced by adding sterile saline or broth, or increased by adding more bacterial
growth.
Alternatively, the growth method may be used to prepare the inoculum. Pick
four or five colonies from overnight growth on agar and inoculate them into
broth (Mueller-Hinton broth, heart infusion broth, or TSB). Incubate the broth
at 35˚C until turbid (usually 16–24 hours), and then adjust the turbidity to the
proper density.
4. Inoculation procedure
Within 15 minutes after adjusting the turbidity of the inoculum suspension, dip
a sterile cotton swab into the suspension. Pressing firmly against the inside wall
of the tube just above the fluid level, rotate the swab to remove excess liquid.
Streak the swab over the entire surface of the medium three times, rotating the
plate approximately 60 degrees after each application to ensure an even
distribution of the inoculum (Figure 34). Finally, swab around the entire edge
of the agar surface.
If the bacterial colonies used to prepare the suspension are picked off a plate
containing mixed growth (i.e., if isolated colonies are picked from a plate that
does not contain pure culture), laboratorians may choose to prepare a purity
plate to ensure the suspension used for antimicrobial susceptibility testing is
pure. To prepare the purity plate, after inoculating the Mueller-Hinton agar
plate for confluent growth, label (a portion of) a separate TSA plate (or other
non-selective medium) and use the same swab of suspension with which the
Mueller-Hinton was inoculated to streak for isolation; do not place the swab
back into the suspension. Several inocula can be streaked on different sections
of a properly labeled purity plate, but the streaks must not overlap.
5. Antimicrobial disks
The working supply of antimicrobial disks should be stored in the refrigerator
(at 4˚C). Upon removal of the disks from the refrigerator, the package
containing the cartridges should be left unopened at room temperature for
approximately 1 hour to allow the temperature to equilibrate. This reduces the
amount of condensation on the disks. If a disk-dispensing apparatus is used, it
should have a tight-fitting cover, be stored in the refrigerator, and be allowed to
warm to room temperature before use.
Apply the antimicrobial disks to the plates as soon as possible after they are dry,
but no longer than 15 minutes after inoculation. Place each disk individually
with sterile forceps or with a mechanical dispensing apparatus, and then gently
press down onto the agar. In general, no more than 12 disks are placed on a
150-mm plate and no more than four disks are placed on a 100-mm plate to
prevent overlapping of the zones of inhibition and possible resultant error in
measurement. Diffusion of the drug in the disk begins immediately; therefore,
once a disk contacts the agar surface, the disk should not be moved. After the
disks are placed on the plate, invert the plate and incubate at 35°C for 16–18
hours; if a purity plate was prepared, incubate it under the same conditions.
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6. Recording and interpreting results
After incubation, measure and the diameter of the zones of complete inhibition
(including the diameter of the disk) in millimeters. (Figure 43 shows growth,
Figure 6 and Figure 28 show how to measure the zones, and Figure 49 presents
a sample worksheet in which to record data.) The measurements can be made
with calipers or a ruler on the under-surface of the plate without opening the
lid. With sulfonamides and trimethoprim-sulfamethoxazole, a slight amount of
growth may occur within the inhibition zone. In this instance, slight growth
(approximately 80% inhibition) should be ignored and the zone diameter
should be measured to the margin of heavy growth. The zones of growth
inhibition should be compared with the zone-size interpretative table (Table
22), and recorded as susceptible, intermediate, or resistant to each drug tested.
Colonies growing within the clear zone of inhibition may represent resistant
variants or a mixed inoculum. Measure the distance from the inner-most
colonies (i.e., those closest to the disk) to the center of the antimicrobial disk,
and double this measurement to obtain the diameter; record the measurement
and interpretation of antimicrobial susceptibility (Figure 49). If there is both an
inner- and outer zone of inhibition of growth around the antimicrobial disk:
a) If a purity plate was prepared, check the streak to confirm the culture was
pure. (Step a is optional.)
b) Record the diameter and interpretation of antimicrobial susceptibility of
those colonies in the outer zone (i.e., in addition to those in the inner zone).
c) Pick the colonies inside the zone, streak for isolation on a new plate, confirm
their identification, and perform the disk diffusion test again to confirm the
previous results.
The presence of colonies within a zone of inhibition may predict eventual
resistance to that antimicrobial agent.
7. Quality control of agar disk diffusion antimicrobial susceptibility testing 
To verify that antimicrobial susceptibility test results are accurate, at least one
control organism should be included with each test. (ATCC 25922 is the E. coli
control strain used when testing Enterobacteriaceae [e.g., Shigella, Salmonella,
Escherichia, Klebsiella] and V. cholerae.) Zone diameters obtained for ATCC
25922 should be compared with NCCLS published limits; Table 22 includes the
diameters of the zones of inhibition for ATCC 25922. If zones produced by the
control strain are out of the expected ranges, the laboratorian should consider
possible sources of error.
Antimicrobial susceptibility tests are affected by variations in media, inoculum
size, incubation time, temperature, and other factors. The medium used may be a
source of error if it fails to conform to NCCLS recommended guidelines. For




 for recording antim
icrobial susceptibility results for Vibrio cholerae
Note:After 16–18 hours incubation,check the results for the NCCLS-recom
m
ended quality control (QC) strain E.coli ATCC 25922 against the acceptable range of inhibition zone diam
eters
and then record disk diffusion results (m
m
).(Inhibition zone ranges and breakpoints for interpretation of results m
ay be found in Table 22.)
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example, agar containing excessive amounts of thymidine or thymine can reverse
the inhibitory effects of sulfonamides and trimethoprim, causing the zones of
growth inhibition to be smaller or less distinct. Organisms may appear to be
resistant to these drugs when in fact they are not. If the depth of the agar in the
plate is not 3–4 mm, the rate of diffusion of the antimicrobial agents or the activity
of the drugs may be affected.
If the inoculum is not a pure culture or does not contain a concentration of
bacteria that approximates the 0.5 McFarland turbidity standard, the
antimicrobial susceptibility test results will be affected. For instance, a resistant
organism could appear to be susceptible if the inoculum is too light. Also, if
colonies from blood agar medium are used to prepare a suspension by the direct
inoculum method, trimethoprim or sulfonamide antagonists may be carried over
and produce a haze of growth inside the zones of inhibition surrounding
trimethoprim-sulfamethoxazole disks even the isolates being tested are susceptible.
Again, as mentioned above, erythromycin tested against V. cholerae will give
TABLE 22: Interpretive standards for antimicrobial susceptibility testing of Vibrio cholerae with selected antimicrobial disks
Diameter of zone of inhibition (mm) and
Antimicrobial Disk equivalent MIC breakpoint (µg/ml) (NCCLS QC strain
agent potency Susceptible Intermediate Resistant E. coli ATCC 25922
Ampicillin a 10 µg ≥ 17 mm 14 – 16 mm ≤ 13 mm 16 – 22 mm
(≤ 8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8 µg/ml)
Chloramphenicol a,b 30 µg ≥ 18 mm 13 – 17 mm ≤ 12 mm 21 – 27 mm
(≤8 µg/ml) (16 µg/ml) (≥ 32 µg/ml) (2–8 µg/ml)
Furazolidone c 100 µg ≥ 18 mm - < 18 mm 22 – 26 mm d
-
Nalidixic acid c 30 µg ≥ 19 mm - < 19 mm 22 – 28 mm
(1–4 µg/ml)
Ciprofloxacin e 5 µg ≥ 21 mm 16 – 20 mm ≤ 15 mm 30 – 40 mm
(≤1 µg/ml) (2 µg/ml) (≥ 4 µg/ml) (0.004–0.016 µg/ml)
Tetracycline a 30 µg ≥ 19 mm 15 – 18 mm ≤ 14 mm 18 – 25 mm
(≤ 4 µg/ml) (8 µg/ml) (> 16 µg/ml) ( 0.5–2 µg/ml)
Trimethoprim- 1.25 / ≥ 16 mm 11 – 15 mm ≤ 10 mm 23 – 29 mm
sulfamethoxazole a 23.75 µg (≤ 2/38 µg/ml) (4/76 µg/ml) (≥ 8/152 µg/ml) (≤ 0.5/9.5 µg/ml)
(cotrimoxazole)
a Source: NCCLS (2002) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement.
NCCLS document M100-S12 [ISBN 1-56238-454-6]. NCCLS 940 West Valley Road, Suite 1400,Wayne, PA 19087 USA.
b Use these interpretive standards for chloramphenicol with caution because the disk diffusion test may misclassify many 
organisms (high minor error rate) [NCCLS 2002].
c Proposed interpretative criteria based on multi-laboratory studies; criteria have not been established for V. cholerae by NCCLS.
d Quality control inhibition zone diameter ranges for furazolidone have not been validated by NCCLS; the ranges presented in this
table are based on those suggested by the manufacturer of the antimicrobial disks.
e Criteria for interpretation of susceptibility of V. cholerae to ciprofloxacin have not been developed; this table presents tentative
interpretive criteria based on NCCLS interpretive criteria for Enterobacteriaceae.
misleading results because these in vitro results do not necessarily correlate with in
vivo activity.
If antimicrobial disks are not stored properly or are used beyond the stated
expiration date, their potency may decrease; this will usually be indicated by a
decrease in the size of the inhibition zone around the control strain.
Data for decision-making: informed epidemic response
Once the laboratory has assessed the identity and antimicrobial susceptibility
patterns of the V. cholerae O1 or O139 isolates, the information should be reported
back to public health officials in a timely manner. Factors to consider in the
development of a treatment policy include:
• The antimicrobial agent chosen should be effective against at least 80% of local
V. cholerae O1/O139 strains. Evidence of clinical efficacy is the most important
criterion, especially for a drug such as erythromycin, which cannot be tested
in vitro.
• The antimicrobial agent chosen should be able to be given by mouth.
• The antimicrobial agent chosen should be affordable.
• The antimicrobial agent chosen should be available locally (or be able to be
obtained quickly).
Consideration of such factors when making data-based decisions will help public
health officials meet needs in manner appropriate to the local situation and
antimicrobial susceptibility profile.
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The techniques and media described in this manual adhere to internationallyrecognized clinical standards. The procedures provide laboratorians fromregions with limited resources with the methodological tools needed for the
quality-controlled detection of antimicrobial resistance in seven pathogens causing
acute bacterial infections of public health importance. Application of these
methods will enable laboratorians to make valid comparisons and interpretations
of their findings within countries and across borders.
This manual addresses the identification and antimicrobial susceptibility testing of
bacterial pathogens that cause acute respiratory infections, meningitis, febrile
illness, diarrheal disease, and sexually transmitted infections of public health
concern. Haemophilus influenzae, Neisseria meningitidis, and Streptococcus
pneumoniae are three pathogens contributing to a substantial proportion of
bacterial pneumonia and meningitis morbidity and mortality; commonly used
antimicrobial agents (e.g., penicillin and trimethoprim-sulfamethoxazole) are
becoming decreasingly effective for treatment of these pathogens. Laboratory data
on antimicrobial susceptibility and serotype (or serogroup) distributions can help
determine not only if antibiotic treatment or prophylaxis is appropriate, but also if
vaccination would be efficacious. Antimicrobial resistance in Neisseria gonorrhoeae
is a growing concern not only because of its direct health effects on the
reproductive tract, but also because epidemiological evidence indicates that
gonorrhea infection facilitates transmission of HIV/AIDS. Typhoid fever, a disease
caused by Salmonella serotype Typhi, is endemic in many developing countries,
and outbreaks of multi-drug resistant strains have been reported worldwide.
Shigella is frequently the agent of epidemic bloody diarrhea and has become
progressively more resistant to commonly available and affordable treatment
regimens. Cholera, an internationally reportable disease caused by Vibrio cholerae
O1 and O139 that is clinically recognized by the presentation of abundant watery
diarrhea, must be treated primarily with rehydration therapy, but antimicrobial
Conclusion
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agents contribute to the reduction of stool volume. As antimicrobial resistant
strains of disease spread throughout communities and more people become
infected with less-treatable bacteria, the burden on public health and on social 
and economic development will continue to grow.
A goal of this manual has been to provide public health reference laboratories with
a tool to produce standardized antimicrobial susceptibility test results that can be
used for public health decision-making. Individual results of antimicrobial
susceptibility tests are important for clinical treatment plans; adequate information
must be provided to health-care providers. Laboratorians have the power and
responsibility to contribute to the shaping of local policy for prevention, control,
and treatment of disease by communicating patterns of a pathogen’s antimicrobial
susceptibility to public health officials. Concerted public health efforts are needed
to reduce the frequency and spectrum of antimicrobial resistant disease in both
hospital and community settings.
